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CHAPTER 1
GENERAL INTRODUCTION
Based on:
Improving Prognosis in Primary Biliary Cholangitis – therapeutic 
options and a treatment strategy
Risk stratification and Prognostication in Primary 
Biliary Cholangitis
Surrogate Endpoints for Optimal Therapeutic Response to 
UDCA in Primary Biliary Cholangitis
10 CHAPTER 1
Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, was first 
described by Addison & Gull in 18511. PBC is a chronic liver disease that is characterized by a 
non-suppurative destructive cholangitis, and its autoimmune features. The disease can lead 
to severe ductopenia, accompanied by progressing fibrosis, ultimately leading to cirrhosis, 
liver failure, and death. 
DIAGNOSIS
A clinician should consider PBC in case of persistent, unexplained cholestatic abnormalities - 
in particular alkaline phosphatase - in serum liver tests. The diagnosis of PBC can be finalized 
when anti-mitochondrial antibodies (AMA) at a titre of >1:40 are also present in serum. 
Up to 95% of patients with PBC have detectable anti-mitochondrial autoantibodies against 
pyruvate dehydrogenase complex E2 in serum, making this a hallmark in the diagnosis2. 
Given the high specificity of the combination of these serological markers for PBC, there is 
no need for a liver biopsy when both are present3. In case of AMA-negativity together with 
unexplained increased serum alkaline phosphatase, or in case of suspicion of an autoimmune 
overlap syndrome, a liver biopsy can be helpful. Histologically, PBC is characterized by chronic, 
non-suppurative inflammation, destroyed interlobular and septal bile ducts, and florid duct 
lesions. The latter can often be identified at early stages of the disease. When there is more 
progression of disease, fibrosis and bile duct loss can be found4, 5.
NOMENCLATURE
Until recently, primary biliary cholangitis was known as primary biliary cirrhosis. The latter 
name was first proposed in 1950, as most patients at that time presented with advanced 
liver disease6. However, over the years, this name became an anachronism, as the majority 
of patients nowadays are diagnosed in an early stage of disease, in which cirrhosis is not 
present7-9. Many patients struggled with the stigmatization that came with the denomination 
cirrhosis, as in society it is often associated with excessive use of alcohol. These arguments 
regarding the misnomer of cirrhosis have led to an extensive re-evaluation of the suitability 
of the former disease name. “Chronic non-suppurative destructive cholangitis” was often 
proposed, but although this name was highly accurate, most professionals and patients 
agreed that it would be desirable to stick to the well-known abbreviation PBC. Eventually, 
consensus was found in “primary biliary cholangitis”, despite the pleonasm that is secluded 
in this new name10. 
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EPIDEMIOLOGY
PBC is the most common of the autoimmune diseases of the liver. A systematic review of 
epidemiological studies on PBC across North America, Europe, Australia, and Asia showed an 
estimated incidence of 0.9-5.8 per 100,000 people per year11, 12. The prevalence is estimated 
at 2-58 patients per 1000 people, but in many countries, a trend of rising incidence and 
prevalence is observed. There are, however, large geographical differences in both incidence 
and prevalence, for which an explanation is lacking to date. The disease predominantly 
affects women, with a reported male to female ratio of 1:10, although recent studies show 
a trend over time towards a higher percentage of males13. Patients are typically diagnosed in 
their fifties, but the disease can affect patients as young as twenty, as well as elderly.
AETIOLOGY AND PATHOPHYSIOLOGY
PBC is considered to be an autoimmune disease, in light of its strong association with other 
autoimmune diseases such as CREST, Sjögren’s disease and rheumatoid arthritis14, the strong 
female preponderance, and the presence of anti-mitochondrial antibodies in approximately 
95% of patients15. Studies suggest an etiological cohesion between genetic predisposition15, 
16 and environmental factors, given the geographical clustering of PBC and associations 
between PBC and exposure to hair dyes, nail polish and cigarette smoking, as well as 
infectious agents such as Escherichia coli, Mycobacterium gordonae, and retroviruses17-19. 
However, these associations were neither strong, nor was a causative relation ever 
confirmed. The pathogenesis seems to evolve through interacting immunological and biliary 
pathways, leading to cell injury and chronic cholestasis20. Although much is still unknown, 
some of these pathways have been unraveled and have led to several pharmacological 
targets that are being discussed here. Firstly, it is well-established that patients with PBC 
encounter immunological intolerance to biliary epithelial cells, which relates to the small 
duct cholangitis, progressive bile duct destruction and cholestasis21. Loss of tolerance to 
mitochondrial antigens, most often the pyruvate dehydrogenase complex-E2, is characteristic 
of PBC and is reflected by elevated serum levels of anti-mitochondrial antibodies in ~95% of 
patients. The reason for this loss of tolerance, however, is yet unclarified. 
Secondly, the ‘biliary umbrella’ theory has been an important step in better understanding 
of the biliary pathways in this disease22. It explains that under physiological conditions, an 
intact exchange of Cl- and HCO3- and an intact biliary glycocalyx – together forming a biliary 
‘umbrella’- are vital to prevent invasion of the toxic hydrophobic bile acid monomers that 
are present in human bile. In PBC, this bicarbonate umbrella is malfunctioning. Reduced 
expression of the anion exchanger 2 (AE2), which is responsible for Cl-/HCO3- exchange, on 
biliary epithelial cells is observed, leading to less bicarbonate excretion and subsequently 
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a more toxic composition of the bile. Cholangiocytes are consequently exposed to higher 
concentrations of toxic bile salts, which endangers the structure of cell membranes and 
mitochondria, and thereby stimulates apoptosis of the cholangiocytes. In turn, AE2 
expression in biliary epithelial cells can be further suppressed by hydrophobic bile acids 
through inducement of biliary epithelial cell senescence, which subsequently leads to 
production of different interleukins and thereby to bile duct inflammation. 
Another step in identifying pharmacological targets has been made through further 
comprehension of the mechanisms involved in the gut-liver axis. More specifically, the 
discovery that nuclear hormone receptors directly regulate genes that are involved in the 
homeostasis of bile acids made an impact23. The farnesoid X receptor (FXR) is a nuclear 
receptor which acts as a key transcriptional sensor of bile homeostasis, and is predominantly 
expressed in the liver and small intestine. Chenodeoxycholic acid and cholic acid are 
endogenous ligands for FXR in humans. Through suppression of CYP7A1 and upregulation 
of FGF19, FXR ligation inhibits bile acid uptake, bile acid synthesis, hepatic inflammation, 
and development of tissue fibrosis, and upregulates pathways associated with bile acid 
export, hepatic regeneration, and tumour suppression24. Alterations in nuclear receptor 
signaling may contribute to the pathogenesis of PBC. Although evidence for dysfunction 
of the aforementioned nuclear receptors in PBC is not established, activation was found 
be protective in animal models mimicking PBC. Other nuclear receptors found to be 
important in the regulation of bile acid metabolism include the peroxisome proliferator-
activated receptor (PPAR), that regulates pathways inhibiting both inflammation and bile 
acid synthesis and enhancing phospholipids secretion, and the pregnane X receptor (PXR), 
mainly involved in detoxifying pathways and inhibition of biliary secretion. 
Both the results of sibling studies in PBC, and the fact that first-degree relatives of PBC 
patients carry an increased risk of developing the same disease, indicate that genetic factors 
contribute to the development of the disease25. Genome-wide association studies (GWAS) 
and smaller genetic studies have identified several genetic risk loci for PBC, but more specific 
studies are needed for further implementation of these findings26-28. Personalized genomics 
will likely identify more nuclear receptor polymorphisms that link the pathogenesis of PBC to 
an altered bile metabolism, and might uncover other therapeutic targets. 
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SYMPTOMS
The initial clinical presentation of patients with PBC ranges from incidentally detected 
abnormal liver chemistry on routine testing to a first presentation of end-stage liver disease 
complications such as variceal bleeding. However, cirrhosis-unrelated symptoms also 
represent an important clinical problem for patients with PBC. The most common symptoms 
are  pruritus and fatigue, but a range of other symptoms can occur including arthralgia, dry eyes 
and mouth (‘’sicca complex’’), nonspecific abdominal pain, and unsightly xanthelasma. It has 
been well established that also  cognitive symptoms, sleep disturbance, and  social isolation 
may affect patients’ quality of life29. As debilitating PBC-related symptoms largely dictate the 
burden of disease, improving patient’s quality of life by ameliorating these symptoms is one 
of the key goals of ongoing studies. Aforementioned limitations in the understanding of the 
pathogenesis of the disease is reflected by the current limited therapeutic options to relieve 
symptoms satisfactorily in a large subset of symptomatic patients.
NATURAL HISTORY
Timely diagnosis of PBC can be challenging as patients may remain asymptomatic for many 
years30, all the while the disease may silently progress31. Histologically, chronic destructive 
non-suppurative cholangitis is typical for PBC4, but liver biopsy no longer has a place in 
the standard diagnostic work-up20, 32. In contrast with the situation several decades ago, 
the majority of patients are nowadays diagnosed in an early stage of disease33, 34. When 
left untreated, patients with PBC are likely to develop cirrhosis, potentially resulting in 
cirrhosis-related complications, liver failure and death. In the follow up of one of the first 
clinical trials, liver biopsies were performed on a regular basis. This study showed that 31% 
of the patients with histological stage 1 and 50% of the patients with stage 2 progressed 
toward cirrhosis within 4 years35. Few studies have assessed the incidence of cirrhosis-
associated complications in untreated patients with PBC. A Chinese study, in which 26 
patients were included that were not or inconsistently treated, showed that the median 
time until decompensation was approximately 5 years. Unsurprisingly, decompensating 
events are associated with poor subsequent survival. The median survival after such events 
was reported to be approximately two years, which is comparable with the natural history of 
other liver diseases36, 37. An English long-term observational study of 770 untreated patients 
with PBC reported a median survival after PBC diagnosis of 9.3 years, and a standardized 
mortality ratio of 2.9 (95% confidence interval 2.6-3.2)38. In multivariate Cox regression 
analysis, several factors were reported to be predictive of subsequent patient survival. 
This model included age at diagnosis, albumin, bilirubin, and alkaline phosphatase. Earlier 
studies have reported that survival of patients who are symptomatic at time of diagnosis is 
much shorter than of those who present asymptomatic, with a median survival of 7.5 and 
14 CHAPTER 1
16 years respectively30, but a larger cohort described by Mahl et al. found that although the 
absence of symptoms at time of diagnosis represented an earlier stage of disease, it was 
not associated with better prognosis39. Other long-term follow up studies also showed that 
initially asymptomatic patients are likely to eventually develop pruritus and fatigue and that 
their survival is impaired as compared to the general population40. In 1989, Dickson et al. 
developed the Mayo Risk Score, a model including the clinical parameters bilirubin, albumin, 
prothrombin time, age, and severity of oedema, which predicted short-term survival in 
untreated PBC based on the data of 312 patients of which 125 died during a median follow-
up of 4.1 years41. The outcome of this continuous score allows estimation of survival up to 
seven years. Patients stratified into low, medium and high risk groups by this model had 
median 5-year survival rates of approximately 90%, 60% and 10% respectively. The Mayo 
Risk Score has long been considered very instrumental in predicting prognosis in PBC and 
has in fact been frequently used in the evaluation of treatment efficacy by comparing the 
Mayo-predicted survival to the actual observed survival with treatment.
THERAPIES 
In the mid 1970’s, little was known about the pathophysiology of PBC and copper 
deposition was thought to play an important pathophysiological role. Hence, the first 
randomized controlled trial (RCT) in PBC studied the effectivity of the copper-chelating 
agent D-penicillamine42. Treatment benefit was not confirmed in large multicenter studies, 
and the drug came with serious adverse effects43,44. Since then, the understanding of PBC 
has improved considerably, but today the etiology of the disease still remains largely 
unknown. Consequently, specific etiology-based curative therapies are currently not 
available and the search for new and better therapeutic options is ongoing. A number of 
non-specific therapies, however, have shown significant potential to modify the course of 
the disease and have substantially changed perspectives for patients with PBC. Although 
ultimate therapeutic benefit is measured by a reduction of the risk of mortality or liver 
transplantation (LT) in randomized controlled trials (RCTs), earlier measures of outcome 
in PBC can include biochemical and histological parameters, non-invasive markers of liver 
fibrosis, and incidence of relevant clinical events.
First-line treatment
Beneficial effects of treatment with bear bile were already recognized in ancient China. In the 
previous century, following the identification of ursodeoxycholic acid (UDCA) as the primary 
bile acid in bear bile and its biochemical structure and properties, UDCA was extensively 
used for treating (dissolution) of cholesterol bile stones. Early anecdotal reports of Japanese 
researchers on treatment effects of UDCA on liver biochemistry in the sixties and seventies 
remained virtually unnoticed. The first reports of Ulrich and Maria Leuschner, showing 
GENERAL INTRODUCTION AND OUTLINE OF THIS THESIS 15
1
beneficial effects of UDCA on laboratory parameters, published in 1985, marked the real 
beginning of the UDCA era in PBC45. Today, UDCA is the most extensively studied therapeutic 
agent in PBC. It is a choleretic and hydrophilic endogenous bile acid that has multiple sites 
and mechanisms of action. Firstly, it stimulates secretion of bile acids from hepatocytes, 
preventing hepatocyte injury, apoptosis, and necrosis and subsequent inflammation and 
fibrosis. Secondly, through the activation of AE2 transporters, treatment results in UDCA 
enrichment and expansion of the bile acid pool and thereby induces a less toxic bile 
composition. Subsequently, the bile is less harmful to its environment of cholangiocytes, 
ameliorating the degree of cholangiocellular injury, inflammation, and proliferation. Thirdly, 
immunomodulatory effects have been observed, possibly influenced by UDCA-induced 
activation of the glucocorticoid receptor21. Based on the extensive experience obtained 
with this drug over the past decades, 13-15 mg per kilogram of UDCA daily is currently 
recommended as the standard treatment for PBC by international guidelines20, 32. A multi-
center RCT with 2 years of follow up (n=146) reported a 57% reduction of ALP in UDCA-
treated patients, as opposed to a 5% increase in the placebo arm. Bilirubin decreased 
slightly with 9% in UDCA-treated patients, while there was a marked worsening of 68% in 
the placebo-arm (both p<0.001)46. Numerous other placebo-controlled trials also showed 
that UDCA induced significant reductions of bilirubin, ALP and transaminases. Although 
regression of histological stage has not been reported, most studies observed significant 
differences in portal inflammation, bile duct paucity and piecemeal necrosis in favor of 
UDCA-treated patients47-50. Although there were some conflicting results48-50, several studies 
concluded that UDCA delays progression of fibrosis and histological stage47, 51. In a cohort 
study of over 4000 patients, no difference in cumulative HCC incidence between UDCA-
treated and untreated patients (p=0.972) was established. However, it should be noted that 
HCC is a rare event in PBC with an overall incidence rate of 3.4 per 1000 patient years52. 
Despite these overall promising results, however, RCTs failed to show a therapeutic benefit 
on transplant-free survival, as did most meta-analyses46, 50, 51, 53-60. In one combined analysis 
(without predefined inclusion criteria) of three specific RCTs, Poupon et al. reported a 
reduced risk of LT or death (RR 1.9, p<0.001) in patients treated with UDCA, but only in case 
of advanced disease61. However, as PBC is a slowly progressing disease, the follow-up of 
most of the trials has not been adequate to reliably evaluate treatment effect on survival, 
especially in patients with an early stage of disease who nowadays represent the majority 
of patients. As the feasibility of new studies that could adequately assess treatment effect 
on LT and death is hugely complicated by the low prevalence and the slowly progressive 
nature of the disease, a quest for valid and accurate surrogate markers for clinical outcomes 
was inevitable in PBC. It has been long established that bilirubin is an important prognostic 
marker for clinical outcome in PBC62, 63. However, elevation of bilirubin is often not observed 
in early stages of disease, and is thereby a relatively late marker of disease progression. In 
2006, Pares et al. reported that 61% of patients of an observational cohort of 192 UDCA-
treated patients showed either normalization or a decrease of at least 40% of their serum 
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ALP after one year of treatment. The study demonstrated that achievement of this newly 
proposed response criteria was associated with a better LT-free survival compared to the 
survival of so-called ‘non-responders’ to UDCA (RR 5.5, p=0.004)64. In the following years, 
several other criteria for biochemical response to UDCA were constructed, based on 
observational studies of UDCA-treated patients. These studies all reported that achievement 
of biochemical response (according to their specified criteria after one or two years of 
treatment) was significantly associated with an improved LT-free survival as compared to 
patients with inadequate response, as well as compared to their expected survival without 
UDCA based on the Mayo Risk Score, thereby suggesting a therapeutic benefit of UDCA65-69.
Being an endogenous substance, UDCA is very well tolerated and real intolerance is a rare 
event. Severe adverse effects are not known. An occasional patient may experience some 
abdominal discomfort, flatulence, or diarrhea upon initiation of treatment, but these 
symptoms are usually transient. In case of persistent discomfort, switching to a different 
brand of UDCA or lowering the dosage might be considered. There is no evidence or other 
ground to assume that the effect of apportioning the total dosage of 13-15 mg/kg UDCA as 
a multiple dosage regimen is better than a single dosage once daily70.
Second-line treatments
For the majority of patients, treatment with UDCA is effective and the life expectancy 
of patients with a complete biochemical response is comparable to that of sex and age 
matched counterparts in the general population71. However, Trivedi et al. reported in a recent 
cohort of mainly UDCA-treated patients that approximately 40% of patients had developed 
cirrhosis after 10 years, with the subsequent risk of cirrhosis-associated complications8. 
Approximately one third of patients has an inadequate biochemical response to treatment 
with UDCA71. For these patients, there is a need for additional treatment to reduce the risk 
of premature mortality and LT. Several therapies have recently been proposed as second-
line therapy, most often in addition to treatment with UDCA. Since most of these therapies 
are relatively new, long-term data is scarce. Therefore, most of the evidence for these 
treatments available today is based on the assumption of surrogacy of ALP and bilirubin for 
long-term outcome. 
Budesonide
Budesonide is a highly potent glucocorticoid that has a 90% first-pass effect through the liver 
in healthy individuals, with a receptor binding activity 15-20 times greater than prednisolone. 
Because only 10% of the substance reaches the systemic circulation, the potential risk of 
systemic side effects is much lower than in classical steroids72. This is of importance, especially 
giving the intrinsically higher risk of bone density problems in women with PBC73. Notably, 
it has been demonstrated in vitro that budesonide and UDCA are synergistic in upregulating 
AE2 expression. Budesonide was the first potential second-line therapeutic drug in PBC to 
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show promising, but also conflicting results in trials. In 1999, the first placebo-controlled 
trial of 39 patients assessed budesonide as add-on therapy to UDCA at 9 mg/day in patients 
with early PBC, and reported significant reductions of ALP and histological improvements 
in the treatment arm. The UDCA monotherapy group (n=19) had a 30% reduction of ALP 
after two years, as opposed to 50% in the budesonide add-on arm (n=20)74. However, in 
a subsequent open label study (n=22) of patients with a persistently elevated ALP despite 
UDCA treatment, only a marginal improvement of ALP was reported after one year of add-on 
budesonide (9 mg/day), and this was accompanied by worsening of osteoporosis, and not 
by improvement of bilirubin or prognosis as reflected by the Mayo Risk Score75. Rautiainen 
et al. later reported encouraging results of statistically significant improvement of fibrosis 
(25%) and histological stage (22%) in a 3-year non-blinded controlled study in non-cirrhotic 
patients with PBC (n=77) However, this finding might have been influenced by a markedly 
high rate of progression in the UDCA monotherapy arm (20% histological stage deterioration 
and 70% increased fibrosis). There was no significant difference regarding the change in 
grade of inflammation and ALP between UDCA monotherapy the intervention arm, and 
bone density was not assessed76. A 3-year phase III double-blind RCT was terminated early 
because of slow recruitment and as a result, insufficient power to detect a significant 
histological difference between treatment groups, although normalization occurred in 35% 
of the treated arm77. Side effects of budesonide mostly include steroid-related effects such 
as bruises, acne, thinning of skin and weight gain. Importantly, the pharmacokinetics of 
budesonide are different in patients with advanced disease. Aside from potential bone 
density issues, serious adverse advents such as portal vein thrombosis have been described 
after administration of budesonide to cirrhotic patients with PBC78. Therefore, treatment 
with budesonide is regarded contraindicated in late stage disease. 
Fibrates
Fibrates are carboxylic acids and are primarily known for their ability to reduce serum 
lipid levels. In 1993, fibrates were first suggested as a potential therapy for patients with 
cholestatic liver disease after an improvement in ALP was observed in patients that were 
treated for hyperlipidaemia79. Later, fibrates were shown to act as ligand for the nuclear 
receptor PPAR. PPAR is known to exist in three isoforms (alpha (α), beta (β)/gamma (γ), 
and delta (δ)). These isoforms are encoded by distinct genes and have different patterns of 
distribution. The available types of fibrates have different specificities for the PPAR isoforms, 
and thereby induce different effects. 
Fenofibrate is a selective PPARα-agonist. PPARα is involved in several pathways influencing 
lipid metabolism, pathways regulating synthesis and detoxification of bile acids, and pathways 
regulating inflammatory responses. Over the past 15 years, several pilot studies have 
assessed the effect of 80-200mg fenofibrate treatment in PBC as add-on to UDCA in patients 
with an incomplete biochemical response to UDCA alone80-85. All reported an improvement 
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of up to 50% in ALP, but these studies were of small sample size and mostly with short 
follow up. Two more recent observational studies also reported results regarding the effect 
of fibrates on the (estimated) prognosis86, 87. Although Cheung et al. described a favourable 
adjusted decompensation-free survival (HR 0.15, p=0.03) among those treated with add-
on fenofibrate (n=46) as opposed to those treated with UDCA alone (n=74), it should be 
noted that the number of clinical events in this study was limited and ongoing biochemical 
deterioration was observed in both study arms. Hegade et al. (n=23) found no significant 
improvement in estimated LT-free survival based on the UK-PBC score (a continuous score 
estimating transplant-free survival, based on biochemistry), despite a significant decrease 
in ALP after one, two and three years of follow-up86. A placebo-controlled phase-III trial is 
currently ongoing in China. 
Bezafibrate is a non-selective PPAR-agonist, targeting the three isoforms in equivalent molar 
concentrations. Although many pilot studies, mainly from Japan, have suggested beneficial 
effects on biochemistry associated with bezafibrate as add-on treatment to UDCA88-95, the 
strongest evidence in favor of efficacy of any add-on fibrate treatment originates from the 
recently presented results of BEZURSO. This 1:1 placebo-controlled trial (n=100) assessed 
the add-on effect of 400mg/day bezafibrate to UDCA in patients with an incomplete 
response to UDCA, which was defined as ALP >1.5x the upper limit of normal (ULN), or 
AST >1.5x ULN, or bilirubin>ULN, after one year of UDCA (Paris II response criteria58). In 
total, 67% of bezafibrate-treated patients achieved normalization of ALP, and 30% even 
showed a complete biochemical normalization of bilirubin, ALP, aminotransferases, albumin 
and other parameters after two years. Treated patients also showed improvement of liver 
stiffness measurements (p<0.01). Notably, there was a remarkable decrease in pruritus in 
the treatment arm as opposed to no change in the placebo group96. Beneficial effects of 
bezafibrate were also observed in a prospectively followed Spanish cohort with 48 patients 
over a median period of 38 months. Important observations were a major effect on pruritus 
and absence of a clear favorable response in more advanced disease93. 
Other fibrates that are currently being studied include MBX-8025 (seladelpar, a selective 
PPARδ-agonist) and GFT-505 (elafibranor, a dual PPARα/δ-agonist). Unlike PPARα that is 
predominantly expressed in hepatocytes, PPARδ is also expressed in cholangiocytes, Kupffer, 
and stellate cells. Consequently, it may regulate additional pathways involved in bile acid 
absorption and secretion, function of cholangiocytes and may induce anti-fibrotic and anti-
inflammatory effects on Kupffer and stellate cells. A recent 12-week phase II RCT in which 
seladelpar was dosed in patients with an incomplete response to UDCA (n=41) showed that 
both 50mg and 200mg daily induced >50% reduction in ALP. This study was terminated, 
however, after occurrence of significant transaminase increases in patients treated with 
the active drug97. None of the other aforementioned studies found evidence for serious 
adverse events related to fibrate treatment. Flares of both transaminases and creatinine 
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have been reported, but were transient after discontinuation of treatment. The flares in 
creatinine imply that the use of fibrates should be avoided in case of renal impairment. One 
study reported an accelerated increase in bilirubin in cirrhotic fenofibrate-treated patients, 
suggesting that caution with the use of fenofibrates might be warranted in these patients87. 
In clinical practice, the choice for a specific fibrate is often limited by the fact that subtypes 
are not uniformly available in most countries. 
Farnesoid X receptor agonists 
FXRs have a key role in the regulation of the synthesis, secretion, detoxification and 
transportation of bile acids. Chenodeoxycholic acid is the most potent endogenous bile acid 
for FXR. Obeticholic acid (OCA) is a synthetic derivative of chenodeoxycholic acid and is >100-
fold more potent, and thus a strong FXR-agonist. Besides activating FXR, OCA also induces 
expression of fibroblast growth factor (FGF)-19, possibly explaining the anti-inflammatory 
effects that have been observed in murine models. OCA was granted FDA approval in 
2016, based on the results of an international multi-centre phase III RCT of 216 patients. 
In this study, OCA was assessed as add-on treatment to UDCA in patients with persistent 
abnormalities in their liver biochemistry under treatment with UDCA monotherapy98. The 
approval of OCA represented a major breakthrough in the treatment of PBC, with OCA being 
the first FDA-approved drug for PBC since the introduction of UDCA nearly three decades 
earlier. Subjects in the 5mg and 10mg treatment arms showed significant improvement 
of ALP (-113U/L and –130U/L vs. -14U/L in the placebo arm, p<0.001) and total bilirubin 
(-0.3μmol/L and -0.5μmol/L vs. +2.0μmol/L in the placebo arm, p<0.001). As mentioned, 
survival benefit of add-on OCA has yet to be confirmed, for which a long-term follow-up 
is currently ongoing. Importantly, OCAs most common side effect in patients with PBC is 
pruritus, a symptom that already is prevalent in PBC and can be debilitating. However, when 
the dosage was titrated up to a maximum of 10 mg/day, treatment discontinuation due to 
pruritus was rare. Another potentially worrisome effect of OCA includes alteration of the 
lipid metabolism, resulting in a significant decrease of high-density lipoprotein cholesterol 
and an increase of low-density lipoprotein, of which long-term implications are unclear99. 
Recently, the Food and Drug Administration (FDA) has warned that dosing of OCA should be 
altered in patients with moderate to severe decreases in liver function. In case of Child-Pugh 
B or C, patients should be started on 5 mg once weekly, rather than daily as advised in other 
PBC patients. 
Other strategies 
Immunosuppressive and immunomodulatory agents 
PBC is considered to be an autoimmune disease100. Logically, the effects of several 
immunosuppressive and immunomodulatory agents besides budesonide have been 
assessed over the past decades. Immunosuppressive and immunomodulatory drugs that 
were evaluated in RCTs include azathioprine93, methotrexate101, thalidomide102, colchicine103, 
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corticosteroids104-106, cyclosporine107, malotilate108, and mycophenolate mofetil109, and were 
mostly studied as add-on treatment to UDCA. Unfortunately, the results of these studies have 
been largely disappointing, with a lack of improvement of patients’ biochemistry, histology, 
and overall survival, and/or reporting unacceptable risk of adverse events. These trials have 
resulted in the recommendation not to use any of the aforementioned agents as standard 
therapy for PBC. However, low dose prednisone might be considered in case of (features 
of) an autoimmune overlap syndrome20. Considering the assumption that PBC is primarily 
an autoimmune mediated disease, these overall disappointing results are remarkable and 
may suggest that autoimmune features only partially reflect the true nature of the disease. 
Biologicals and other experimental studies 
In other fields such as inflammatory bowel disease, the use of biologic agents that target 
cytokines and other pathways of immune responses, have caused a major breakthrough in 
treatment. In PBC, the possibilities and potential of biological therapies are currently being 
studied extensively, with promising results in preclinical studies. Several studies are currently 
assessing safety and clinical effect in humans, but patience is likely required for potential 
implementation into clinical practice. Antiretroviral drugs have also been evaluated for the 
treatment of PBC, but results have been conflicting110. 
Liver transplantation
When pharmacological interventions fail to adequately delay disease progression, PBC can 
eventually lead to end-stage liver disease and liver failure, at which point LT is the only 
therapeutic intervention that can prevent death. Refractory pruritus and hepatocellular 
carcinoma are other much more rare indications for LT in PBC. In the first decades following 
the first human LT in 1963, primary biliary cholangitis was the leading indication for LT 
in Europe, accounting for 30-50% of all LTs111. The gradual introduction of UDCA as the 
standard of care is thought to have made a substantial impact. Nevertheless, a minority of 
patients with PBC does still require LT to prevent premature mortality today. Also, a recent 
study showed that waitlist mortality is higher in PBC as compared to most other etiologies 
except chronic hepatitis C and alcoholic liver disease112. Graft and patient survival after LT 
for PBC are generally good. The European Liver Transplantation Registry reported a 1, 5 
and 10 year patient survival of 86%, 80%, and 71% respectively, and results reported by 
the United Network for Organ Sharing in the United States were highly comparable112, 113. 
Disease recurrence after LT occurs in 11-42% of all transplanted patients114. 
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RISK STRATIFICATION
In the setting of risk stratification the aim is to estimate the likelihood of a clinical event 
taking place. Assessment of the risks and risk parameters allow identification of patients 
or patient groups with mild or a more progressive disease pathway, and thereby allow the 
targeting of care. Below the association and impact of various biochemical and clinical 
factors with clinical events is reviewed. Shapiro et al. (1979) were the first to start a long 
history of studying factors associated with disease progression in PBC, recognizing the 
association between serum bilirubin levels and survival (Table 1)62. They found that patients 
with bilirubin levels >2 mg/dl in two subsequent measurements within 6 months had an 
average survival of 4.1 years, whereas the average survival was 2.1 and 1.4 years when 
two subsequent measurements were above 6 or 10 mg/dl, respectively. Furthermore, they 
showed that the behavioural pattern of bilirubin is characterized by two distinct phases: a 
phase in which bilirubin remains stable for many years followed by an ‘acceleration’ phase 
with rapidly increasing values cumulating in death within a few years62. Similar patterns are 
observed in other end-stage liver diseases115. Confirming these phases, Harms et al. (2016) 
showed (n=3529) that the curve breaking point of bilirubin was found at a bilirubin 1.6 times 
the upper limit of normal (ULN). From this breaking point onward there were a median 
of 19 months before a clinical endpoint occurred116. This suggests that bilirubin is a “late” 
biomarker, i.e. increasing only shortly before a clinical event, and thereby less applicable for 
early detection of progression of disease. 
Alkaline phosphatase (ALP) and gamma-glutamyl transpeptidase (GGT) are considered to 
be early markers of disease20. In meta-analyses of 4845 patients Lammers et al. showed 
that both alkaline phosphatase (>2.0 x ULN) and bilirubin (> 1.0xULN) are independent 
predictors of liver transplantation and death34. Although outcomes were best predicted by 
biochemistry measured one year after initiation of UDCA, ALP and bilirubin measured at 
other time points remained strongly associated with clinical outcomes. Importantly, ALP 
levels held additive prognostic value to bilirubin and this effect was independent of sex, 
follow-up time, presenting age, UDCA treatment and disease stage. Thus, this landmark 
paper showed that ALP and bilirubin levels are strongly associated with long-term outcomes 
in PBC. Both are considered the most robustly validated markers of disease activity (ALP 
and bilirubin) and disease stage (bilirubin) in PBC. ALP and bilirubin are accepted to be 
‘reasonably likely to predict clinical benefit’ in PBC and are used as an endpoint in clinical 
trials117. 
The concept of biochemical response 
Angulo et al. were the first to recognize that changes in biochemical parameters during 
UDCA treatment were associated with clinical outcome 118.In a cohort of 180 UDCA-treated 
patients, they showed that patients with serum ALP >2 times the upper limit of normal 
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(ULN) after six months of therapy were more likely to encounter severe disease progression 
(11% vs. 33%, p<0.04). In 2006, a Spanish study found (n=192) that a 40% reduction of 
ALP after one year of treatment was associated with a similar survival as that of matched 
controls from a general population (Barcelona criteria). In contrast, the prognosis of those 
who did not meet these criteria was worse than that of a general population (relative risk 
for liver transplantation or death 7.47 (95% CI 1.87-29.78)). Since then, several response 
criteria have been proposed, all with different combinations of biochemical variables to 
capture incomplete response to UDCA and thereby identifying patients that are at risk of 
events64-68, 119, 120 (Table 2). Most criteria evaluate biochemical response after one year of 
UDCA. However, the optimal time point for biochemical evaluation has yet to be determined 
and it may already be possible to assess response to therapy after 6 months121. Leuschner 
et al. showed that approximately 80% of decrease of alkaline under UDCA treatment occurs 
within 6 months of UDCA therapy, suggesting that most criteria are best applied after at least 
6 months of therapy74. The Paris-I criteria are the most accurate and thoroughly validated 
dichotomous criteria and are considered superior in discriminating patients into low- and 
high-risk categories for events66, 122-124. However, the optimal response criteria may differ 
between patients and study populations. For example, Paris II criteria were designed for 
early stage disease patients68. Combined analyses of various proposed criteria showed they 
have independent prognostic significance, suggesting that none of these criteria is optimal 
measure of response125. Furthermore, some criteria are mainly focused at the assessment 
of response to treatment and do not incorporate markers of disease severity or stage (e.g. 
albumin and/or bilirubin). These criteria may not sufficiently capture the baseline difference 
in survival that is associated with difference stages of disease126. Nonetheless, biochemical 
response criteria provide a readily available way to identify patients that are likely to benefit 
from additional therapies or clinical trials.  
Serum markers of fibrosis 
Serum markers of fibrosis provide an outcome on a continuous outcome scale, potentially 
providing more information than the categorized histological disease stages. Although 
several markers, including serum hyaluronate, the ELF (enhaced liver fibrosis) score, and 
AST/ALT ratio have been studied127-131, the most promising serum marker of fibrosis is the 
aspartate aminotransferase-to platelet ratio (APRI). An APRI of >0.54, as a surrogate for liver 
fibrosis and portal hypertension, is an important non-invasive marker and prognostic factor 
associated with cirrhotic complications, death and liver transplantation in PBC patients122, 132. 
APRI is associated with outcome independent of response to treatment with UDCA and thus 
imparts additional prognostic value to existing biochemical response criteria122. An APRI of 
>0.54 after one year of UDCA an therapy is associated with an almost 3-fold increase in risk 
of death or liver transplantation. 
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Liver stiffness measurement 
Liver stiffness measurement (LSM) with vibration-controlled transient elastography provides 
a simple measure of liver fibrosis stage, especially in severe fibrosis and cirrhosis130, 133, 134. 
In an Italian cohort study (n=120), LSM by transient elastography was better in identifying 
any grade of fibrosis and cirrhosis (AUROC 0.89, 0.92 and 0.99 for fibrosis stage II, III and IV, 
respectively) than non-invasive surrogate markers of fibrosis such as APRI (AUROC 0.66,0.67 
and 0.84 for fibrosis stage II, III and IV, respectively) and the AST/ALT ratio (AUROC 0.53,0.57 
and 0.58 for fibrosis stage II, III and IV, respectively). Subsequently, Corpechot et al. showed 
LSM values above 9.6 kPA carry a hazard of 5 for adverse outcomes (decompensation, liver 
transplantation or death)133. In addition, progression of liver stiffness at a cut-off of 2.1 kPa/
year is associated with an increased risk of adverse outcomes133. Recent studies suggest that 
poor biochemical response is associated with higher rates of LSM progression and that LSM 
progression is able to predict clinical outcomes in PBC independently of UDCA response133, 135. 
Preliminary data suggests that LSM significantly improves risk stratification of newly 
established prognostic scores136. However, transient elastography is not uniformly available 
in all clinics, requires experience and may be unreliable in obese patients. Moreover, 
cholestasis can falsely increase LSM values resulting in inaccurate estimates of fibrosis 
severity137. These factors currently limit the possibilities of including LSM into prognostic 
tools for the general clinician. 
Continuous models predicting transplant-free survival
Early risk prediction models were mostly developed for end-stage PBC, primarily focus on 
short-term survival, and do not incorporate biochemical response or disease activity (e.g. 
ALP). Therefore, in this era with mostly UDCA-treated and early-disease stage presenting 
patients, these models may not be sufficient. Recently, two new models were proposed 
that overcome these shortcomings. In  2015, the GLOBE score was introduced (www.
globalpbc.com). This model was constructed using a derivation cohort of 2488- and a 
validation cohort of 1634 UDCA-treated patients, and comprises age, bilirubin, albumin, 
alkaline phosphatase, and platelet count after 1 year of UDCA treatment as independent 
predictors of liver transplantation or death in UDCA-treated patients123. Also introduced 
in 2015, the UK-PBC risk score (www.uk-pbc.com) was developed in a nation-wide cohort 
of 1916 patients (derivation cohort) and validated in a cohort of 1249 UDCA-treated PBC 
patients, this score predicts the risk of liver-related death or liver transplantation with a 
model comprising baseline albumin and platelet count, as well as bilirubin, transaminases, 
and alkaline phosphatase after 1 year of UDCA therapy131. With C-statistics of >0.8, both 
these models have superior predictive performances for incomplete response to UDCA 
compared to previously proposed dichotomous criteria123, 131. The scores use variables on 
a continuous scale resulting in more conservation of predictive information. The outcomes 
of the scores have a continuous scale too and thus provide gradual individualized estimates 
of survival, rather than crude differentiation into high- and low-risk groups. Importantly, 
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they take into account biochemical response to UDCA by incorporating biochemistry after 
one year of therapy, thus combining predictive information of both disease severity and 
response to treatment. Therefore, these models are better able to accurately predict 
survival than previously introduced models and biochemical response criteria. The GLOBE 
score was initially constructed to estimate the risk of death or liver transplantation after 1 
year of UDCA therapy. However, recent analyses indicate that the score can also be used to 
risk stratify UDCA-treated patients at later points in time138-140. An advantage of the GLOBE 
score is its use of age-specific thresholds beyond which survival significantly deviates from 
a sex and age-matched general population. The score presents the median survival of this 
matched population at 3, 5, 10, and 15 years. 
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SCOPE AND AIMS OF THIS THESIS
 
This thesis focuses on the natural history, risk stratification, and treatment of patients with 
primary biliary cholangitis. The aims of this thesis were to assess: 
1.  the predictive value of bilirubin within the normal range on transplant-free survival 
among patients with PBC
2.  the incidence of and risk factors for cirrhosis-related complications among ursodeoxycholic-
acid treated patients with PBC
3.  the association between ursodeoxycholic acid and transplant-free survival in patients 
with PBC, both in relative and absolute measures
4.  biochemical response and clinical outcome of PBC patients treated with fenofibrate and 
bezafibrate
5.  the estimated survival benefit induced by treatment with obeticholic acid in patients with 
PBC  
6. ti me trends in liver transplantation for patients with PBC. 
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ABSTRACT 
Objective In primary biliary cholangitis (PBC), bilirubin and alkaline phosphatase (ALP) are 
widely established as independent predictors of prognosis. Current treatment goals do not 
aim for normalization of surrogate markers, as their association with survival has not been 
defined. 
Methods Patients from the GLOBAL PBC Study Group cohort were utilized, comprising of 
long-term follow-up data from European and North American centers. Ursodeoxycholic acid 
(UDCA)-treated and untreated patients with bilirubin levels ≤1×ULN at baseline or 1 year 
were included. The association of normal ALP with transplant-free survival was assessed in 
a sub-group with ALP≤1.67×ULN at 1 year. Optimal thresholds of bilirubin and ALP to predict 
liver transplantation (LT) or death were evaluated.
Results There were 2281 patients included in the time zero cohort and 2555 patients in the 
1-year cohort. The bilirubin threshold with the highest ability to predict LT or death at 1 
year was 0.6×ULN (HR 2.12, 95% CI 1.69-2.66, P<.001). The 10-year survival rates of patients 
with bilirubin ≤0.6×ULN and >0.6×ULN were 91.3% and 79.2%, respectively (P<.001). The 
risk for LT or death was stable below bilirubin levels of 0.6×ULN yet increased beyond this 
threshold. UDCA-induced reduction in bilirubin below this threshold was associated with 
an 11% improvement in 10-year survival. Further, ALP normalization was optimal, with 10-
year survival rates of 93.2% in patients with ALP≤1×ULN and 86.1% in those with ALP 1.0-
1.67×ULN. 
Conclusion Attaining bilirubin levels ≤0.6×ULN or normal ALP are associated with the lowest 
risk for LT or death in patients with PBC. This has important implications for treatment targets.
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INTRODUCTION
Primary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease that is 
characterized by chronic non-suppurative inflammation of the small intrahepatic bile ducts1. 
The disease usually has a slow progressive course, which may eventually lead to cirrhosis 
and ultimately liver failure or premature death in the absence of liver transplantation (LT). 
However, the prolonged number of years it may take for patients to develop such clinical 
outcomes poses a significant obstacle in randomized controlled trials that aim to evaluate 
the clinical benefit of therapeutic interventions. Due to these feasibility concerns, various 
surrogate markers have been evaluated for their prognostic value on clinical outcomes2. 
Such surrogate markers can allow the risk stratification of patients without the need for an 
extended follow-up period and can be implemented by health care providers or in clinical 
trials to promptly assess the need and benefit of a therapeutic agent.
It is widely established that bilirubin is an independent predictor of prognosis in both 
ursodeoxycholic acid (UDCA)-treated and untreated patients with PBC2–4.The normalization 
of bilirubin prompted by UDCA has been associated with improved transplant-free survival4.
Furthermore, bilirubin has been established as a surrogate endpoint that is “reasonably likely 
to predict clinical benefit” and the threshold that best predicted liver transplant-free survival 
was reported to be the upper limit of normal (ULN)2. Normal bilirubin is also a component of 
multiple response criteria, such as the Rotterdam, Paris-I, and Paris-II criteria5–7.
Abnormal bilirubin levels are observed during later stages of PBC and are indicative of 
impaired liver function8. Over the past decades, however, there has been an increase in the 
proportion of patients that present with normal bilirubin levels over the years and this group 
now represents the majority of patients with PBC9.Since bilirubin is usually not elevated 
above the ULN until later stages of the disease, it is considered to be an inadequate marker 
for risk stratification in early stage PBC. The prognostic value of bilirubin below the ULN has 
not been previously assessed. Thus, the aim of this study was to evaluate whether bilirubin 
levels within the normal range (≤1×ULN) are associated with survival in patients with PBC. 
44 CHAPTER 2 
MATERIALS AND METHODS 
Population and study design 
This is a retrospective study on the predictive value of normal bilirubin for survival in 
patients with PBC. We utilized the Global PBC Study Group database, which includes long-
term follow-up data of PBC patients from 16 centers across Europe and North America. 
To evaluate the association between normal bilirubin and survival, we included UDCA-
treated and untreated patients diagnosed with PBC according to internationally accepted 
guidelines and whose bilirubin levels were normal (≤1×ULN as defined by each local center) 
at time zero or 1 year after study entry 8,10,11. Those with short follow-up (<6 months), short-
term treatment with UDCA (discontinued), absent laboratory values, unknown dates of 
important clinical events, overt overlapping features of autoimmune hepatitis (AIH), or other 
concomitant liver diseases were excluded from the study. Patients were allocated to two 
independent cohorts based on the time point(s) at which their bilirubin levels were normal 
(time zero and 1 year). The inclusion of patients into each cohort is not mutually exclusive, as 
patients may have had normal bilirubin levels at both time points. This study was conducted 
in accordance with the 1975 Declaration of Helsinki. The protocol was approved by the 
institutional research board at all participating centers as per local regulations.
Data collection
In the Global PBC Study Group database, time zero (study entry) is defined as the date 
UDCA was initiated in treated patients and the date of the first visit in untreated patients. 
At study entry, the following data were available: sex, age at diagnosis, anti-mitochondrial 
(AMA) antibody serological status, liver histology, biochemical disease stage (according 
to Rotterdam criteria5), and UDCA therapy. The following laboratory parameters were 
collected every 6-12 months: total bilirubin, alkaline phosphatase (ALP), albumin, aspartate 
aminotransferase (ALT), alanine aminotransferase (AST), and platelet count. Histological 
data obtained from liver biopsies conducted within 12 months of study entry were staged 
according to Ludwig et al. and Scheuer’s criteria12,13. The completeness and accuracy of the 
data was established by visits to participating centers.
Statistical analyses 
The primary endpoint was a composite of LT and all-cause mortality. Survival was defined 
as an absence in LT and all-cause mortality. Patients without an event at the end of follow-
up and those who were lost to follow-up were censored at their last visit. The predictive 
value of normal bilirubin on the primary endpoint was initially analyzed based on the 
bilirubin quartiles corresponding to each cohort. The survival rates across quartiles were 
estimated with a Kaplan-Meier curve and compared with a log-rank test. Multivariable Cox 
proportional hazards’ regression (hazard ratio [HR] with 95% CI) analyses were performed to 
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adjust for potential confounding variables: age at study entry, sex, year of diagnosis, UDCA 
therapy, ALP, and geographical region.
To test the hypothesis of a threshold and to determine the optimal threshold for bilirubin 
within the normal range two approaches were followed: 1) bilirubin levels at baseline and 1 
year of follow-up were dichotomized according to various thresholds ranging from 0.3 to 0.9 
×ULN in 0.01 increments. Multivariable Cox proportional hazards’ regression analyses were 
employed to estimate the risk for LT or death associated with each threshold. The C-statistic 
was calculated to evaluate the performance of each threshold in predicting survival and 
the threshold with the best performance was determined by the highest C-statistic. 2) To 
assess bilirubin on a continuous spectrum and test the hypothesis that the predetermined 
bilirubin threshold is the point at which the risk for LT or death increases, bilirubin was 
inserted into the Cox regression as a restricted cubic spline function with four knots. This 
analysis included patients with bilirubin levels above the ULN to illustrate how their risk for 
a poor prognosis differs relative to those with bilirubin below the ULN. The restricted spline 
function was repeated with crude bilirubin levels (mg/dL). 
All analyses were adjusted for age at study entry, sex, year of diagnosis, UDCA therapy, ALP, 
and geographical region. Laboratory data included in the multivariable model that were 
not normally distributed were log transformed. Sensitivity analyses of the predetermined 
bilirubin threshold by multivariable Cox regression were performed in additional sub-
groups stratified by the ULN of bilirubin (<1.2mg/dL and ≥1.2mg/dL [75th percentile of ULN 
of bilirubin across centers]), age at study entry (≤55 years and >55 years), sex, treatment 
(UDCA-treated and UDCA-untreated), histological stage (I-II and III-IV), and ALP (≤1.67×ULN 
and >1.67×ULN). Furthermore, sensitivity analyses were performed for bilirubin at 2-5 years 
after the start of follow-up.
For illustrative purposes, Kaplan-Meier analyses were conducted to describe the survival 
rates associated with bilirubin levels at baseline and 1 year (normal bilirubin [≤/> the 
threshold] and abnormal bilirubin). Patients with abnormal bilirubin were included for 
reference purposes. The distribution of the clinical events (LT, liver-related death, or liver-
unrelated death) at 10 years within each bilirubin group was also evaluated. 
An additional analysis was conducted in UDCA-treated patients whose baseline bilirubin 
levels were above the predetermined threshold and stratified based on their bilirubin levels 
at 1 year. In case of missing bilirubin at baseline or 1 year, the imputed laboratory data 
was used. Multiple imputation with by the Markov chain Monte Carlo method for missing 
data and Rubin’s rules were used to estimate bilirubin and its standard error14. Ten imputed 
datasets based on the assumption that data were missing at random were created from 
iterations to reduce sampling variability. 
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The pattern of bilirubin (mean and 95% CI) over the first 5 years was evaluated in patients 
with normal bilirubin at time zero and stratified based on whether they experienced a late 
clinical event (LT or death from 5-10 years) or no clinical event in the first 10 years of follow-
up. All patients included in the latter group had 10 years of follow-up. The imputed dataset 
was used for this analysis. A P-value less than 0.05 was considered statistically significant. All 
analyses were two-sided and were performed using IBM SPSS Statistics for Windows, version 
25.0 (IBM Corp., Armonk, NY, USA) and SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Study population characteristics
A total of 3060 patients with normal bilirubin at baseline or one year after study entry 
were included. Two normal bilirubin cohorts were constructed based on the time point(s) 
at which their bilirubin levels were normal: time-zero cohort (n=2281) and 1-year cohort 
(n=2555). An overlap of 1821 patients exists between these cohorts. There were 297 and 
344 primary endpoints according to each respective cohort. Patient characteristics per 
cohort are presented in Table 1. 
Normal bilirubin quartiles are associated with survival 
The quartiles in each individual cohort were formulated according to the following 
bilirubin levels (median [IQR], ×ULN): 0.53 (0.40-0.70) and 0.50 (0.38-0.67), 
respectively. In Kaplan-Meier analysis of patients that had normal bilirubin at time 
zero, the cumulative 10-year survival rate decreased with higher bilirubin quartiles 
and was 93.3%, 89.9%, 87.7%, 81.3% from quartiles 1-4 (Q1-Q4), respectively 
(Figure 1). In pairwise comparisons, Q4 was significantly different from Q1-Q3 (all 
P < 0.005).  Additionally, Q1 was significantly different from Q3 (P = 0.041). Similar results 
were obtained in the Kaplan-Meier analysis of the 1-year cohort, in which the 10-year 
survival rates with increasing bilirubin quartiles were 92.0%, 92.3%, 86.1%, and 78.2%. 
Q3 and Q4 were significantly different from one another and from the remaining quartiles 
(all P < 0.01). In multivariable Cox regression analyses, normal bilirubin quartiles were a 
significant predictor for survival. In the time zero cohort, the risk for LT or death increased 
with higher bilirubin quartiles: Q1 (reference), Q2 (HR 1.12, 95% CI 0.73-1.72, P = 0.61), Q3 
(HR 1.34, 95% CI 0.89-2.01, P = 0.16), Q4 (HR 1.83, 95% CI 1.24-2.71, P = 0.003). A similar 
trend was observed in the 1-year cohort: Q1 (reference), Q2 (HR 0.97, 95% CI 0.65-1.45, P = 
0.88), Q3 (HR 1.46, 95% CI 1.02-2.10, P = 0.04), Q4 (HR 2.20, 95% CI 1.56-3.10, P < 0.0001).
  
Bilirubin threshold within the normal range to predict survival
Upon exploration of the optimal threshold of bilirubin within the normal range at 1 year, all 
bilirubin thresholds (0.3-0.9×ULN) were significant predictors of survival in that patients with 
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Table 1. Characteristics of PBC patients in each normal bilirubin cohort
Time zero cohort
 (n=2281) 1-year cohort (n=2555)
Follow-up time, y, median (IQR) 7.9 (4.3-12.7) 7.3 (3.7-11.5)
Age at study entry, mean ± SD 55.3 ± 12.0 54.6 ± 11.8
Female, no. (%) 2086 (91.5) 2354 (92.1)
AMA-positive, no. (%) 2036/2222 (91.6) 2273/2485 (91.5)
Year of diagnosis, median (range) 1998 (1961-2014) 1997 (1961-2013)
UDCA-treated, no. (%) 1979/2223 (89.0) 2345/2523 (92.9)
Laboratory parameters, median (IQR)
 Total bilirubin, ×ULN 0.53 (0.40-0.70) 0.50 (0.38-0.67)
 ALP, ×ULN 1.99 (1.27-3.32) 1.26 (0.88-1.96)
 Albumin, ×LLN 1.17 (1.09-1.26) 1.17 (1.09-1.26)
 AST, ×ULN 1.30 (0.93-1.93) 0.87 (0.65-1.20)
 ALT, ×ULN 1.51 (0.98-2.35) 0.83 (0.58-1.33)
 Platelet count, 109/L 255 (207-308) 250 (202-304)
Bilirubin ULN (mg/dl), median (IQR) 1.1 (1.0-1.2) 1.17 (1.0-1.2)
Abbreviations: No., number; AMA, anti-mitochondrial antibodies; UDCA, ursodeoxycholic acid; ULN, upper limit 
of normal; ALP, alkaline phosphatase; LLN, lower limit of normal; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; IQR, interquartile range.
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Figure 1. Survival estimates of bilirubin quartiles in patients with normal bilirubin at A) time zero and B) 1 year. 
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Table 2. Multivariable Cox regression analyses of various normal bilirubin thresholds at 1 year for the prediction 
of liver transplantation and death
Bilirubin at 1 year (n=2382)
Threshold 
(×ULN) C-statistic (95%CI) HR (95% CI) P value
No. of patients 
≤/> threshold
0.30 0.7223 (0.6930-0.7515) 1.63 (1.04-2.58) 0.035 302/2080
0.40 0.7240 (0.6948-0.7531) 1.51 (1.12-2.06) 0.008 712/1670
0.50 0.7366 (0.7081-0.7651) 1.85 (1.46-2.36) <0.0001 1243/1139
0.55 0.7357 (0.7073-0.7642) 1.90 (1.51-2.40) <0.0001 1416/966
0.59 0.7400 (0.7114-0.7686) 2.02 (1.61-2.54) <0.0001 1573/809
0.60 0.7429 (0.7144-0.7713) 2.12 (1.69-2.66) <0.0001 1619/763
0.61 0.7423 (0.7137-0.7710) 2.09 (1.67-2.62) <0.0001 1630/752
0.62 0.7385 (0.7095-0.7676) 2.00 (1.60-2.50) <0.0001 1676/706
0.63 0.7385 (0.7095-0.7675) 2.02 (1.61-2.52) <0.0001 1687/695
0.65 0.7351 (0.7061-0.7642) 1.89 (1.51-2.37) <0.0001 1751/631
0.66 0.7354 (0.7063-0.7645) 1.90 (1.52-2.38) <0.0001 1755/627
0.67 0.7361 (0.7070-0.7652) 1.92 (1.53-2.40) <0.0001 1821/561
0.68 0.7354 (0.7064-0.7644) 1.89 (1.51-2.37) <0.0001 1824/558
0.69 0.7341 (0.7051-0.7631) 1.88 (1.50-2.36) <0.0001 1854/528
0.70 0.7344 (0.7055-0.7633) 1.91 (1.52-2.40) <0.0001 1889/493
0.75 0.7346 (0.7052-0.7640) 1.96 (1.54-2.49) <0.0001 1999/383
0.80 0.7336 (0.7045-0.7626) 2.14 (1.67-2.75) <0.0001 2085/297
0.85 0.7291 (0.6997-0.7584) 1.89 (1.41-2.52) <0.0001 2175/207
0.90 0.7253 (0.6959-0.7546) 1.86 (1.34-2.59) <0.001 2242/140
bilirubin above each threshold had an increased risk for LT or death (Table 2). The bilirubin 
threshold at 1 year with the highest ability to predict LT or death was 0.6×ULN (C-statistic 
0.7429, 95% CI 0.7144-0.7713). The 10-year survival of patients with normal bilirubin 
≤0.6×ULN, normal bilirubin >0.6×ULN, and abnormal bilirubin 1 year were 91.3%, 79.2%, 
and 37.3%, respectively (P < 0.0001) (Figure 2A). At baseline, the 10-year survival rates were 
91.7%, 85.6%, and 49.5% (P < 0.0001). We evaluated the distribution of clinical events from 
the 10-year survival rates associated with each bilirubin group. Clinical events in patients 
with bilirubin from 0.6-1.0×ULN were characterized by an increased proportion of LT and 
liver-related deaths, alongside a decreased proportion of liver-unrelated deaths compared 
to patients with bilirubin ≤0.6×ULN (Supplementary Figure 1). In an analysis of UDCA-
treated patients with normal bilirubin levels >0.6×ULN at baseline (n=1170), a reduction in 
bilirubin ≤0.6×ULN at 1 year was associated with prolonged survival as compared to stable 
bilirubin that remained above the threshold and abnormal bilirubin after 1 year (both P 
<0.0001) (Figure 2B). The 10-year survival rate of these patients was 93%.
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Figure 2. Survival estimates in patients with normal bilirubin (stratified by 0.6×ULN threshold) and abnormal 
bilirubin. A) Kaplan-Meier estimates of survival rates in patients with normal bilirubin (stratified by 0.6×ULN 
threshold) and abnormal bilirubin at 1 year. B) Additional analysis of the survival rates in UDCA-treated patients 
with bilirubin levels >0.6×ULN at baseline. 
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The threshold was evaluated in various sub-groups of patients that had normal bilirubin at 1 
year, all of which confirmed that patients with bilirubin ≤0.6×ULN have a decreased risk for 
LT or death (Figure 3). Importantly, the association with a reduced risk remained when all 
patients with normal bilirubin in which the ULN was defined as ≥1.2mg/dL were excluded 
from the analyses (HR 2.10, 95% CI 1.54-2.85, P < 0.0001). Although the threshold of 0.6×ULN 
did not reach statistical significance in males and those with a histological stage III-IV, bilirubin 
levels above the threshold were also associated with an increased risk in these patients. 
 
The risk for liver transplantation or death increases at bilirubin levels of 0.6×ULN 
We assessed bilirubin on a continuous spectrum with a restricted spline function to evaluate 
whether the predetermined threshold is the point at which the hazard ratio for LT or death 
increases. The reference in each cohort was the predetermined threshold of 0.6×ULN. In 
both cohorts, the risk for LT or death remained stable below 0.6×ULN (Figure 4). However, 
beyond this threshold, a linear relationship was observed between bilirubin and the risk for 
LT or death that continued past the normal range. The test for curvature, which establishes 
whether there is a significant deviation from a linear relationship, was significantly different 
for the time zero (P = 0.03) and 1-year cohort (P = 0.05). As a sensitivity analysis, the restricted 
spline function analysis was repeated using crude bilirubin levels (mg/dL) (Supplementary 
Figure 2). The spline function analyses were also repeated with normal bilirubin levels at 
other time points (2-5 years) (Supplementary Figure 3). 
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Figure 3. Sub-group analyses based on the bilirubin threshold of 0.6×ULN in patients with normal bilirubin at 1 
year. Hazard ratio for liver transplantation or death (95% CI) obtained from multivariable Cox regression analyses 
in patients with normal bilirubin in various sub-groups. The hazard ratios correspond to bilirubin levels >0.6×ULN 
(versus bilirubin ≤0.6×ULN). 
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Figure 4. The association between bilirubin levels (×ULN) and risk for liver transplantation or death. Hazard 
ratios and 95% CI were estimated by a restricted cubic spline function in A) the time zero cohort and B) the 1-year 
cohort. The bilirubin reference in each cohort is 0.6×ULN.
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Patients who remain below 0.6×ULN over time have good long-term prognosis 
To assess how the trajectory of bilirubin over time may be related with the development 
of a clinical event (LT or death), bilirubin levels over the course of 5 years were evaluated 
in patients with normal bilirubin at time zero. The patients were stratified according to 
whether they developed a late clinical event from 5-10 years (n=103) or did not develop a 
clinical event in the first 10 years of follow-up (n=848). Patients who had no clinical event 
within 10 years of follow-up presented with a mean bilirubin level of 0.55×ULN (95% CI 0.54-
0.56) and demonstrated stable bilirubin levels (below 0.6×ULN) in the first five years (Figure 
5). In contrast, patients who reached a clinical endpoint presented with slightly higher mean 
bilirubin levels (0.61×ULN, 95% CI 0.57-0.65, P = 0.01) and exhibited a gradual increase 
within the normal range that precluded the occurrence LT or death. 
ALP levels below 1.67×ULN are associated with transplant-free survival 
In a subgroup analysis of patients with ALP ≤1.67×ULN from the normal bilirubin cohort 
at 1 year (n=1523), the optimal ALP threshold was 1.0×ULN (C-statistic, 95% CI). The HR 
for LT or death was 1.44 in those with ALP>1×ULN (95% CI 1.04-2.00, P = 0.03). Patients 
with ALP ≤1×ULN had the highest survival rate at 10 years (93.2%), compared to those with 
ALP between 1.0-1.67×ULN (86.1%), and ALP>1.67×ULN (85.4%) P < 0.005. Interestingly, the 
survival rate of the ALP 1.0-1.67×ULN group was not significantly different from that of ALP 
1.67-3.0×ULN (P = 0.64) (Supplementary Figure 5).  
Figure 5. Mean bilirubin levels over 5 years in patients with normal bilirubin at study entry and stratified by 
outcome. Trajectory of the mean bilirubin levels (×ULN) and 95% CI over the first 5 years depending on whether 
they experienced a late clinical event between 5 and 10 years (n=132) or no event within the first 10 years of 
follow-up (n=979). Clinical event is defined as liver transplantation or death. All patients without a clinical event 
had a follow-up of at least 10 years. 
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Alkaline phosphatase normalization and bilirubin levels below 0.6xULN
Implementing both ALP and bilirubin thresholds established, the prognosis of patients with
282 bilirubin >0.6xULN was dependent on ALP normalization (Supplementary Figure 5). 
Given normal ALP levels, their survival rates were similar to those with bilirubin ≤0.6xULN, 
however if ALP was 1.0-1.67xULN, their survival was diminished to 74.2% at 10 years and 
63.4% at 15 years (P<.001 compared to remaining groups). 
DISCUSSION 
This study reports that bilirubin levels within the normal range are associated with the risk 
for LT or death in patients with PBC. We demonstrated that bilirubin levels ≤0.6×ULN at 
baseline and 1 year were associated with a decreased risk for LT or death compared to 
patients with bilirubin above this threshold and that a reduction in bilirubin within the ULN 
after 1 year of UDCA therapy was associated with prolonged survival. While the risk for LT 
or death was stable when bilirubin levels were below 0.6×ULN, beyond this threshold, a 
positive linear relationship was observed between bilirubin and the risk for a clinical event. 
These results were confirmed in several sub-groups of patients. Our findings suggest that 
the interpretation of not being at risk if bilirubin is within the normal range needs to be 
revised. Additionally, ALP levels below 1.67×ULN were also associated with survival. This 
might have implications in the number of patients eligible for inclusion in clinical trials 
that assess novel second-line therapies since ALP levels >1.67×ULN/abnormal bilirubin are 
eligibility requirements that have been previously implemented. 
Although previous studies reported that the ULN of bilirubin was the most predictive for 
survival in patients with PBC and considered a reasonable threshold2, we found that the 
risk for LT or death is already increased when bilirubin levels were above 0.6×ULN. Similarly, 
the optimum bilirubin cut-off associated with survival has been previously identified to be 
lower than the ULN15. The current ULN of bilirubin represents the 97.5 percentile cut-off 
in the general population, yet this may not be the best approach to determine an optimal 
threshold since levels below this threshold are not reflective of an absence of increased 
risk16. In part, this might be explained by the high percentage of individuals with Gilbert’s 
syndrome in the general population, which ranges from 3-10%17. Additionally, the current 
ULN of bilirubin may be a suboptimal threshold for risk stratification in PBC due to the 
female predominance of the disease, while sex differences in bilirubin are present in the 
general population18. An American study based on the Third National Health and Nutrition 
Examination Survey (NHANES III) assessed serum bilirubin levels in 16,865 adults from the 
general population and reported that mean serum bilirubin levels are significantly lower 
in women (0.52 mg/dL ± 0.003) than men (0.72 mg/dL ± 0.004)16. Consequently, the 97.5 
percentile cut-off was 0.5 mg/dL higher in men. Other studies have reported similar sex 
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differences in bilirubin levels in the general population19,20. Thus, the overall ULN of bilirubin 
may be skewed to higher levels in PBC because of the inclusion of both men and women. 
These considerations suggest that the ULN for bilirubin may need to be stratified by sex, as 
has been previously implemented for aspartate aminotransferase21,22. 
We found that the predictive value of the bilirubin threshold of 0.6×ULN was irrespective of 
age, treatment with UDCA, and ALP levels. Importantly, it remained significantly predictive 
at various independent time points. Furthermore, in patients treated with UDCA that had a 
bilirubin level above 0.6×ULN but below the ULN at initiation of treatment, we found that 
a reduction below 0.6 was associated with significantly prolonged survival as compared to 
remaining within the normal range or increasing to an abnormal bilirubin level. This suggests 
that besides the predictive value of bilirubin within the normal range, a treatment-induced 
reduction of bilirubin within the current normal range is beneficial for long-term prognosis, 
which could have important implications for current patient care, but also for the design and 
interpretation of future clinical trials of potential second-line therapies in PBC. While recent 
clinical trials have often included normalization of bilirubin as a primary endpoint, it might 
be preferable to aim for lower bilirubin levels23,24. 
The pattern of bilirubin within the current normal range over time may also be relevant, as 
there was an overall increase of 0.47×ULN in mean bilirubin during the first 5 years of follow-
up in patients who eventually reached a clinical endpoint after extended follow-up. While 
rapid increases in bilirubin have been shown to preclude death in untreated patients, these 
results suggest that there is an association between the trajectory of bilirubin and clinical 
outcomes even if within the normal range3.The fact that the mean bilirubin levels of patients 
who did not experience a clinical event remained below 0.6×ULN over time further support 
an incentive to aim for bilirubin levels below our proposed threshold of 0.6×ULN. Further, 
our findings emphasize the importance of the continuous clinical evaluation of patients’ 
bilirubin levels even in those with early stage disease. 
A robust analysis of the predictive value of bilirubin within the normal range would not 
be possible without the large number of patients and extended follow-up available from 
the Global PBC Study Group cohort.  Furthermore, bilirubin was assessed at multiple 
independent time points to confirm that bilirubin levels obtained during a random follow-up 
assessment could also be utilized for risk stratification. Nonetheless, some study limitations 
should be noted. Whereas, total serum bilirubin levels in healthy patients are primarily 
composed of unconjugated bilirubin, total bilirubin in patients with PBC is predominantly 
of conjugated form that leaks into the serum when it is unable to be excreted through 
bile25. However, bilirubin was available as total bilirubin in this study due to the fact that 
independent measurement of the conjugated and unconjugated forms is not part of routine 
standard of care in the majority of laboratories. 
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Although bilirubin was analyzed based on the ULN defined by local centers, which ranged 
from 0.6-1.7mg/dL, sensitivity analyses were performed to address this. The analyses with 
crude bilirubin levels (mg/dL) as well as the one excluding patients with an ULN above 1.2mg/
dL confirmed our initial findings and exclude the possibility that patients with bilirubin levels 
above 0.6×ULN have worse survival due to the utilization of high ULNs. 
In this multi-center international follow-up study of patients with PBC, bilirubin levels below 
the current ULN were shown to be predictive of survival and 0.6×ULN was established as 
the threshold from which point on the risk for LT or death increases. Additionally, reduction 
within the current normal range to below 0.6×ULN was associated with prolonged survival. 
Our proposed threshold of 0.6× the current ULN of bilirubin may be a more sensitive 
reference to identify patients at risk for a poor outcome and represent a threshold that 
increases the number of patients included in intervention studies that may benefit from 
therapeutic agents. 
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SUPPLEMENTARY DATA
Supplementary Table 1. Survival estimates at 15 years according to bilirubin quartiles and bilirubin threshold of 
0.6×ULN
15-year survival rates (%)
Bilirubin quartiles Time zero cohort 1-year cohort 
Q1 83.4 82.3 
Q2 82.6 85.4  
Q3 77.6 74.6 
Q4 71.3 64.6 
Bilirubin threshold Time zero cohort 1-year cohort 
<0.6×ULN 82.0 82.9
0.6-1.0×ULN 73.0 65.1 
>1×ULN 33.4 30.0
Abbreviations: ULN, upper limit of normal.
Supplementary Table 2. Multivariable Cox regression analyses of various normal bilirubin thresholds at time zero 
for the prediction of liver transplantation and death.
Threshold 
(×ULN) C-statistic (95% CI) HR (95% CI) vvalue
No. of patients ≤/> 
threshold
0.30 0.734 (0.702-0.765) 1.48 (0.90-2.43) 0.13 228/1824
0.40 0.736 (0.705-0.767) 1.43 (1.00-2.05) 0.053 522/1530
0.50 0.740 (0.710-0.771) 1.56 (1.19-2.05) 0.001 979/1073
0.55 0.738 (0.707-0.769) 1.44 (1.11-1.86) 0.006 1135/917
0.60 0.740 (0.709-0.771) 1.47 (1.15-1.89) 0.002 1323/729
0.65 0.747 (0.716-0.777) 1.71 (1.33-2.19) <0.0001 1435/617
0.66 0.747 (0.717-0.778) 1.70 (1.33-2.17) <0.0001 1439/613
0.67 0.745 (0.715-0.776) 1.59 (1.24-2.03) <0.001 1492/560
0.68 0.742 (0.712-0.773) 1.52 (1.18-1.95) 0.001 1503/549
0.69 0.742 (0.712-0.773) 1.52 (1.18-1.96) 0.001 1527/525
0.70 0.743 (0.712-0.773) 1.54 (1.20-1.98) 0.001 1551/501
0.75 0.741 (0.711-0.772) 1.60 (1.22-2.08) 0.001 1681/371
0.80 0.740 (0.709-0.771) 1.57 (1.18-2.09) 0.002 1769/283
0.85 0.740 (0.709-0.771) 1.66 (1.22-2.27) 0.001 1860/192
0.90 0.743 (0.713-0.774) 2.17 (1.53-3.09) <0.0001 1929/123
Abbreviations: ULN, upper limit of normal; HR, hazard ratio; CI, confidence interval.
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Supplementary Fig. 1. Distributi on of clinical events from the 10-year survival rates associated with each 
bilirubin group. Distributi on of liver transplantati on, liver-related death, and liver-unrelated death at (A) ti me 
zero and (B) 1 year. There was a signifi cantly diff erent distributi on in the type of event according to bilirubin 
group at baseline and 1 year: P < 0.001 (Pearson Chi-square).
Supplementary Fig. 2. The associati on between bilirubin levels (mg/dL) and risk for liver transplantati on or 
death. Hazard rati os and 95% CI were esti mated by a restricted cubic spline functi on in (A) the ti me zero cohort 
and (B) the 1-year cohort. The bilirubin reference in each cohort is 0.65 mg/dL. 
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Supplementary Fig. 3. The associati on between bilirubin level and risk for liver transplantati on or death from 
2-5 years. Hazard rati os and 95% CI were esti mated by a restricted cubic spline functi on at 2-5 years. The bilirubin 
reference in each cohort is 0.6×ULN.
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Supplementary Fig. 4. Survival esti mates strati fi ed by ALP levels in pati ents with normal bilirubin at 1 year. 
Survival rates were signifi cantly diff erent between ALP≤1×ULN and 1.0-1.67×ULN (P = 0.001) and 1.67-3.0×ULN (P 
< 0.001), yet there was no signifi cant diff erence between ALP 1.0-1.67 and ALP 1.67-3.0×ULN (P = 0.64). Survival 
was compared with the log-rank test. 
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Supplementary Fig. 5. Survival esti mates according to the established thresholds for bilirubin and alkaline 
phosphatase. Pati ents with normal bilirubin (≤1×ULN) and ALP≤1.67×ULN at 1 years were included.

Harms MH, Lammers WJ, Thorburn D, Corpechot C, 
Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, 
Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, 
Dalekos GN, Bruns T, Pares A, Mason AL, Verhelst X, 
Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, 
Van Buuren HR, Global PBC Study Group. Am J Gastroenterol. 
2018 Feb;113(2):254-264.
CHAPTER 3
MAJOR HEPATIC COMPLICATIONS IN 
URSODEOXYCHOLIC ACID-TREATED 
PATIENTS WITH PRIMARY BILIARY 
CHOLANGITIS: RISK FACTORS AND TIME 
TRENDS IN INCIDENCE AND OUTCOME    
American Journal of Gastroenterology, 2018
64 CHAPTER 3
ABSTRACT
Objectives In this era of near universal ursodeoxycholic acid (UDCA) treatment for primary 
biliary cholangitis (PBC), progression to cirrhosis still occurs in an important proportion 
of patients. The aim of this study was to describe the incidence of cirrhosis-associated 
complications in patients with PBC and assess risk factors and impact on survival.
Methods Cohorts of UDCA -treated patients from 16 European and North-American liver 
centers were included. We used Cox proportional hazards assumptions and Kaplan–Meier 
estimates.
Results During 8.1 years’ median follow-up, 278 of 3,224 patients developed ascites, 
variceal bleeding, and/or encephalopathy (incidence rate of 9.7 cases/1,000 patient years). 
The overall cumulative incidence was 9.1% after 10 years of follow-up, but decreased 
over time to 5.8% after the year 2000. Earlier calendar year of diagnosis (P <0.001), high 
aspartate aminotransferase to platelets ratio index (APRI; P <0.001) and biochemical non-
response (P <0.001) were independently associated with future complications. Patients 
with both biochemical non-response and an APRI >0.54 after 12 months of UDCA had a 
10-year complication rate of 37.4%, as compared to 3.2% in biochemical responders with 
an APRI ≤0.54. The 10-year transplantation-free survival after a complication was 9% (time-
dependent hazard ratio 21.5; 20.1–22.8). Prognosis after variceal bleeding has improved 
over time.
Conclusions In this large international cohort, up to 15% of UDCA-treated PBC patients 
developed major non-neoplastic, cirrhosis-associated hepatic complications within 15 years, 
but cumulative incidence has decreased over time. Biochemical non-response to UDCA and 
APRI were independent risk factors for these complications. Subsequent long-term outcome 
after complications is generally poor, but has improved over the past decades.
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INTRODUCTION
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune disease, characterized 
by inflammatory destruction and loss of intrahepatic bile ducts. The disease usually 
progresses slowly and may eventually lead to cirrhosis and its associated complications1, 2. 
While the standard of care treatment ursodeoxycholic acid (UDCA)2-4 has been found to 
improve survival5-7, twenty to fifty percent of patients respond sub-optimally to this 
treatment8-13. Studies over the past decades suggest that nowadays only a minority of 
approximately 15% of patients have evidence of advanced disease at presentation12, 14-16 and 
that UDCA treatment is associated with a much slower histological disease progression than 
when patients are left untreated17-19. However, the cumulative incidence of cirrhosis over 
a 10-year follow-up in a recent large cohort study was approximately 40%14. This indicates 
that a substantial proportion of PBC patients might still face a risk of cirrhosis-associated 
complications at some point during their disease. 
Cirrhosis-associated complications are likely to be negatively correlated with prognosis20, 21. 
Few studies have specifically evaluated the incidence of and risk factors for major 
cirrhosis-associated complications such as ascites, encephalopathy and gastrointestinal 
bleeding in patients with PBC22-26. These studies either included small populations or a 
large majority of untreated patients, or did not provide detailed information regarding 
the spectrum of potential complications and the associated outcome.  In light of the near 
universal treatment with UDCA for PBC today, better knowledge of the risk and impact of 
major cirrhosis-associated complications in a UDCA-treated population of patients with 
PBC is important  and could be helpful for patient counselling and therapeutic decisions. 
In this study we aimed to assess the incidence and risk factors for major, non-neoplastic 
hepatic complications in a large, internationally representative cohort of UDCA-treated PBC 
patients. Secondly, we aimed to assess potential differential effects of such events on long-
term prognosis. Finally we were interested to assess potential changes over time in the 
incidence and the prognostic impact of these complications.
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PATIENTS AND METHODS
Population and study design
For the current study, patient data from 15 liver units across 10 countries in Europe and 
Northern America that are engaged in the Global PBC Study Group, were included. Individual 
patient data from long term follow-up cohorts were combined. In the individual participating 
centers, most data were collected prospectively, usually over several decades. To ensure a 
uniform database, additional data were collected retrospectively when indicated.  Only UDCA-
treated patients with an established diagnosis of PBC in accordance with internationally 
accepted guidelines2, 3 were eligible for inclusion in this study. Individuals were excluded from 
analysis in case of insufficient follow up data (<6 months follow up or <2 visits recorded), when 
dates of starting treatment or clinical events were unknown and when PBC-autoimmune 
hepatitis overlap syndrome3 or other concomitant liver disease was present. To ensure reliable 
risk factor analysis, occurrence of an hepatic complication within the first year of follow up or 
prior to the start of UDCA therapy, was also reason to omit patients from analysis.
Diligent efforts, including individual center visits to review the historical medical charts, 
were made to ensure data completeness. This study was conducted in accordance with the 
Declaration of Helsinki. The protocol was approved by the institutional research board of 
the corresponding center and at all participating centres as per local regulations.
Data collection
Baseline was set at the moment of starting UDCA therapy. The following clinical and 
biochemical data was collected: date of birth, sex, date of PBC diagnosis, liver biopsy, 
treatment (type, dosage, duration), baseline anti mitochondrial antibody (AMA) status, 
baseline and yearly biochemistry (serum alkaline phosphatase (ALP), total bilirubin, 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, γ-glutamyl 
transpeptidase (g-GT), platelets) and clinical outcomes (death, liver transplantation, 
hepatocellular carcinoma, ascites, variceal bleeding, hepatic encephalopathy). 
 Histological baseline information was taken into account when a liver biopsy was available 
within one year from baseline. Histological disease severity was classified according to the 
Ludwig and Scheuer classification27. Stage I and II were considered to be early stage disease. 
Stage III and IV were classified as advanced disease. Biochemically early versus advanced 
disease was classified according to serum bilirubin and albumin levels28.
 
Patients were followed according to the standard follow-up visit scheme of the participating 
centres. This usually included a clinic visit every 12 months for early disease stages and every 
6 months for patients with advanced disease. Only those Global PBC Study Group centres 
for which data on complications were available participated in this study. Data of the original 
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cohorts were collected to 31 December 201229. For three centres more recently joining the 
study group, data were collected up to 31 December 2015 (Supplementary Table 1). 
Hepatic complications
Data regarding the following cirrhosis-associated complications were collected: 
gastrointestinal variceal bleeding, ascites and hepatic encephalopathy, whichever came first. 
Ascites was deemed to be present when ascitic fluid was confirmed by abdominal imaging 
or in the event of prescribed diuretic treatment for clinically obvious ascites. A diagnosis of 
hepatic encephalopathy was based on expert (physician) opinion and was scored present or 
not present. Variceal bleeding was defined as hematemesis or melena due to endoscopically 
documented hemorrhage originating from gastro-esophageal varices.  
Statistical analysis
The primary outcome of this study was defined as the first occurrence of variceal bleeding, 
ascites or hepatic encephalopathy. Patients without these complications were censored 
at time of last follow-up, liver transplantation or death. For survival analyses, a combined 
endpoint of liver transplantation and death was used. The significance of biochemical response 
to UDCA was analyzed using the Barcelona, Paris, Rotterdam and Toronto biochemical criteria, 
and the recently published GLOBE and UK-PBC scores8-11, 13, 30, 31. The risk of complications 
was also analysed according to the AST to platelet ratio index (APRI) at 1 year of follow-up, 
which was also dichotomized according to the cut-point proposed by Trivedi et al16. Univariate 
and multivariable Cox proportional hazards models were fit to assess risk factors of patient 
characteristics and laboratory covariates on hepatic complications, and to assess covariates 
at time of a major hepatic complication that were associated with liver transplantation or 
death. In these analyses, we deliberately chose to not include histological disease stage as a 
variable, given there was no histological information for nearly 40% of the study population. 
A clock-reset approach was used to visualize the impact of a first hepatic complication on 
survival. The effect was assessed by time-dependent Cox regression analyses. In this approach 
patients who had a major hepatic complication were switched to a new survival curve which 
was then reset as time 0 for their further follow-up32. To identify a subgroup of patients with 
a more favourable survival after occurrence of a major non-neoplastic hepatic complication, 
we first tested the prognostic value of variables in univariate Cox regression analyses. We 
therefore also dichotomized laboratory data at different cut-offs, based on clinical relevance 
and distribution in the study cohort. Subsequently, a multivariable model was constructed. 
Multivariable analyses were stratified by center to adjust for center-specific effects. 
Data are presented as median and its interquartile range (IQR) for continuous variables when 
applicable. A value of p<0.05 was considered to be statistically significant. All analyses were 
conducted using IBM SPSS Statistics V.21.0 (Armonk, NY: IBM Corp.). Analyses to identify risk 
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factors for major hepatic complications were performed in a multiple imputed database. As 
a sensitivity analysis, a comparison with complete case analyses was provided. 
SAS version 9.4 (SAS Institute Inc., Cary, NC) was used to generated 10 imputed datasets 
(to reduce sampling variability) of laboratory results at baseline and after one, two, three, 
four and five years of follow-up (SAS Proc MI, MCMC method)33, 34. We assumed missing 
data occurred at random. Rubin’s rules were used for estimation of the parameters and 
the standard error35, 36. The imputation model variables included both those potentially 
predicting outcome and outcomes themselves. Only the continuous, biochemical values 
were imputed. The biochemical values included for imputation were: ALP, AST, ALT, total 
bilirubin, albumin and platelet count. In case of non-normality, the natural logarithm of 
these variables was used. No categorical or binary variables were imputed. 
RESULTS
Study population characteristics
Of the 4294 UDCA-treated patients in our cohort, status of major hepatic complications 
was unknown for 959 patients. The study cohort comprised 3335 UDCA-treated patients 
with PBC. 111 patients with complications prior to or within the first year of follow up 
were excluded from analysis. The final population that was used for analyses included 
3224 patients, of whom 91% were female and 73% had an early biochemical disease stage 
(Table 1). Median follow up until death, liver transplantation or censoring was 8.1 years 
(IQR 4.4-12.7) (Supplementary Table 1). During follow-up 150 patients underwent liver 
transplantation and 337 patients died (Supplementary Figure 1). 
Incidence of complications
Hepatic complications were noted in 278 patients (Figure 1). The cumulative incidence rate 
of all first complications was 9.7 cases per 1000 patient-years. At 3, 5, 10, and 15 years of 
follow up, the complication rates in the study population were 1.9%, 3.7%, 9.1% and 14.8%, 
respectively (Figure 1). In a majority of 63% (n=175 patients), the first observed complication 
was ascites, as opposed to variceal bleeding in 23% (n=65 patients) and encephalopathy 
in 8% (n=22 patients). In a minority of 6% (n=16 patients) more than one type of 
complication was noted to occur at the same time. A sensitivity analyses in which patients 
that were diagnosed with HCC before the occurrence non-neoplastic major complications 
were censored at time of their HCC diagnosis, showed a very similar complication rate 
(Supplementary Figure 2). When the cumulative incidence was stratified according to the 
time-period of inclusion, we found that the cumulative incidence decreased over time, with 
a 10-year cumulative complication rate of 13.5% for patients included in or before 1990, 
9.3% for patients included between 1990 and 2000, and 5.8% for patients included after 
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the year 2000 (p<0.01 for all) (Supplementary Figure 3). Patients included in the later time 
periods more often had an early biochemical stage of disease at time of inclusion (75.8% 
and 74.9) than before or in 1990 (63.3%). Furthermore, the majority of patients included 
≤1990 had an interval between diagnosis of PBC and initiation of UDCA therapy of at least 
two years (56.9%), as opposed to 30.4% of patients included between 1990 and 2000, and 
9.4% of patients included after 2000 (Supplementary Table 2).
Risk factors for hepatic complications
First, we used univariate Cox regression analyses to identify covariates after 12 months 
of UDCA treatment that were associated with development of hepatic complications. In 
univariate Cox regression analyses, calendar year of diagnosis, years of untreated PBC 
diagnosis before starting UDCA therapy, higher AST/ALT ratio, higher APRI and biochemical 
non-response to UDCA according to the GLOBE score, were associated with an increased 
future risk of major hepatic complications. In multivariable analyses, calendar year of PBC 
diagnosis (per 10 years) (HR 0.73, 95% CI 0.60 - 0.89), a high AST / platelets ratio index 
(APRI) (HR 5.32, 95% CI 3.82-7.41) and biochemical non-response to UDCA based on the 
GLOBE score (comprising of age, ALP, bilirubin, albumin and platelet count) (HR 2.68, 95% CI 
1.99-3.62) remained independently associated with the risk of major hepatic complications 
during follow-up (all p<0.01) (Table 2). A sensitivity analyses on complete cases showed 
similar results (Supplementary Table 3). 
Figure 1. Cumulative incidence of hepatic complications. For this analysis, only the first complication, either 
ascites, variceal bleeding or hepatic encephalopathy was taken into account. 
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Table 1. Baseline cohort characteristics 
N = 3224
Age, yearsa 53.9 (11.8)
Female, n (%) 2937 (90.6)
AMA+, n (%) 2946 (91.4)
Year of diagnosisb 1997 (1990-2003)
Year of diagnosis, range 1968-2014
Year of enrolmentb,c 1998 (1993-2004)
Year of enrolment, range 1977-2014
Histological disease stage, n (%)c
 Stage I 750 (37.8)
 Stage II 650 (32.8)
 Stage III 314 (15.8)
 Stage IV 268 (13.5)
Biochemical disease staged, n (%)
 Bilirubin≤ULN and albumin≥LLN 1239 (73.2)
  Bilirubin>ULN or albumin<LLN 381 (22.5)
Bilirubin>ULN and albumin<LLN 73 (4.3)
Serum total bilirubin ×ULNb 0.60 (0.43-0.93)
Serum ALP ×ULNb 2.17 (1.36-3.79)
Serum AST ×ULNb 1.50 (1.00-2.29)
Serum ALT ×ULNb 1.70 (1.05-2.72)
Serum albumin ×LLNa 1.16 (0.15)
Serum platelet count ×103/mm3a 254 (88)
APRIe 0.59 (0.37-0.93)
Data on histological disease stage was missing for n=1241 (38.5%), biochemical disease stage was missing for 
n=1531 (47.5%,) total bilirubin was missing for n=946 (29.3%), ALP was missing for n=943 (29.1%), AST was 
missing for n=994 (30.7%), ALT was missing for n=1035 (32.9%), albumin was missing for n=1386 (43.0%), platelet 
count was missing for n=1428 (44.3%).
a Data is expressed as mean and standard deviation;  
b Data is expressed as median and interquartile range; 
c Equals the year of initiation of UDCA treatment; 
d Histological stage according to Ludwig and Scheuer’s classification27; 
e Biochemical disease stage was classified according to the Rotterdam criteria28; 
f AST/platelets Ratio Index16, 54;
Abbreviations: AMA, anti-mitochondrial antibodies; ULN, upper limit of normal; ALP, alkaline phosphatase; ALT, 
alanine aminotransferase; AST, aspartate aminotransferase; LLN, lower limit of normal; APRI, AST/platelets Ratio 
Index. 
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Table 2. Covariates associated with future development of hepatic complications after 12 months of 
ursodeoxycholic (UDCA) therapy.
Univariate analysis Multivariable analysis
HR 95% CI p HR 95% CI p
Age (per 10 years) 1.08 0.97 - 1.21 0.176 - - -
Age < 40 years 0.74 0.50 - 1.10 0.140 - - -
Male sex 1.50 1.03 - 2.19 0.035 - - -
AMA negative 1.26 0.79 - 1.99 0.335 - - -
Year of diagnosis (per 10) 0.55 0.45 - 0.66 <0.001 0.73 0.60 - 0.89 0.002
Interval diagnosis - UDCA > 2 yrsa 2.01 1.55 - 2.61 <0.001 - - -
Advanced diseaseb 4.34 3.18 – 5.92 <0.001 - - -
Total bilirubin ×ULNc 3.70 3.11 - 4.41 <0.001 - - -
ALP ×ULNc 2.37 1.94 - 2.90 <0.001 - - -
AST ×ULNc 3.26 2.73 - 3.91 <0.001 - - -
ALT ×ULNc 2.07 1.74 - 2.46 <0.001 - - -
Albumin ×LLN 0.01 0.004 - 0.04 <0.001 - - -
Platelets (per 50x10³/mm³) 0.47 0.41 - 0.54 <0.001 - - -
AST/ALT ratioc 1.62 1.20 – 2.19 0.002 - - -
APRId, continuousc 2.85 2.59 - 2.75 <0.001 - - -
APRI> 0.54 6.97 5.11 - 9.50 <0.001 5.32 3.82 - 7.41 <0.001
UK-PBC score (per 20)e 1.53 1.40 - 1.63 <0.001 - - -
UK-PBC score ≤ mediane 2.76 2.14 - 3.69 <0.001
GLOBE-score, continuous 3.03 2.60 - 3.52 <0.001 - - -
Biochemical non-responsef 5.52 4.17 - 7.33 <0.001 2.68 1.99 - 3.62 <0.001
a Years of untreated PBC diagnosis before starting UDCA therapy;
b Abnormal serum albumin and/or bilirubin28;
c These variables were transformed with natural logarithm; 
d AST/Platelets Ratio Index16, 54;
e The median UK-PBC score in this study cohort was -103.331;
f Based on (age-dependent) GLOBE score thresholds12; 
Abbreviations: HR, hazard ratio; CI, confidence interval; AMA, anti-mitochondrial antibodies; ULN, upper limit of 
normal; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LLN, lower 
limit of normal; APRI, AST/Platelets Ratio Index.
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Biochemical non-response and APRI score as predictors of hepatic complications
Both biochemical non-response after one year of UDCA and an APRI of >0.54 were 
independent predictors of future hepatic complications. The 10-year cumulative incidence of 
first complications was 32.4% in biochemical responders, as opposed to 6.2% in biochemical 
responders. In patients with an APRI of ≤0.54, the 10 year complication rate was 3.8%, 
compared to 24.3% in patients with a higher APRI. Patients with both an APRI of ≤0.54 as 
well as biochemical response after 12 months of UDCA, had 3, 5, and 10-year complication 
rates of 0.5%, 1.1% and 3.2% respectively. In contrast, patients with both an APRI >0.54 as 
well as biochemical non-response at 12 months had 3, 5- and 10-year complication rates 
of 15.9%, 22.1%, and 37.4%. In patients with either biochemical non-response and an APRI 
of ≤0.54, or biochemical response and an APRI of >0.54, the cumulative complication rates 
were found to be comparable to the overall cohort (Figure 2). Comparable predictive values 
for biochemical non-response were found when biochemical non-response was defined by 
other criteria (Table 3).
Table 3. Predictive value of response criteria for occurrence of hepatic complications 
Response criteria HR 95% CI p value
GLOBE-score 6.046 4.773 - 7.660 <0.001
Paris-I 5.024 3.856 - 6.546 < 0.001
Paris-II 4.654 3.270 - 6.622 < 0.001
Rotterdam 4.397 3.295 - 5.866 < 0.001
Toronto 3.057 2.285 - 4.090 < 0.001
Barcelona 1.711 1.274 - 2.296 < 0.001
Biochemical response to UDCA was defined by previously reported criteria with a threshold defining response 
versus non-response, calculated by univariate Cox regression analysis. Criteria were calculated after 1 year of 
follow-up, Toronto criteria were calculated after 2 years of follow-up.
Abbreviations: HR, hazard ratio; CI, confidence interval.
Hepatic complications and subsequent survival
Overall transplantation-free survival at 1 year was 99.7%, at 3 years 97.3%, at 5 years 94.5% 
and at 10 years 85.8%. Figure 3 visualizes the transplantation-free survival rate for patients 
with and without hepatic complications, estimated using a clock-reset approach37. For 
patients remaining free of complications the 3, 5, and 10 years transplantation-free survival 
rates were 97.1%, 94.2% and 85.3%, respectively. In contrast, after occurrence of a hepatic 
complication, these survival rates dropped to 34.7%, 19.2% and 10.4%, respectively (time-
dependent HR 21.5; 20.1-22.8) (Figure 3). Transplantation-free survival after complications 
differed with respect to the nature of the first hepatic complication (p=0.004) (Figure 
4). Median survival after occurrence of variceal bleeding as a first complication was 4.0 
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Figure 2. Cumulative incidence of hepatic complications according to biochemical response and APRI score.  
The GLOBE score and the APRI score were calculated after 12 months of follow-up. T=0 represents the time after 
12 months of follow-up.
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Figure 3. Transplantation-free survival related to 
development of hepatic complications. Visualisation 
of transplant-free survival according to occurrence 
of major hepatic complications, using a clock-
reset approach. The solid line represents survival 
of all included patients (N=3241). The dotted line 
represents survival following occurrence of a hepatic 
complication (N=278).
Figure 4. Transplant-free survival following the 
first occurrence of hepatic complications. Kaplan 
Meier estimates of transplant-free survival after the 
onset of a first hepatic complication (T0) are shown. 
Patients either had a first episode of ascites (N=175), 
variceal bleeding (N=65), encephalopathy (N=22) or a 
combination of these (N=16). 
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years (95%CI 2.9-5.0), after occurrence of encephalopathy 3.2 years (95%CI 1.8-4.6), after 
occurrence of ascites 1.6 years (95%CI 1.0-2.3) and after multiple concurrent complications 
0.6 years (95%CI 0.1-1.2). The difference in survival after occurrence of complications was 
significant for variceal bleeding as compared to ascites (p=0.001). No significant differences 
were found with respect to ascites versus encephalopathy (p=0.506) or variceal bleeding 
versus encephalopathy (p=0.232).
Prognostic factors at the time of complications 
Several laboratory and clinical parameters at the moment of the first hepatic complication 
proved to be predictive of subsequent transplantation-free survival in univariate analyses. 
In multivariable Cox regression analysis, a lower calendar year of complications (p=0.022); 
serum albumin below the LLN (p<0.001); and serum bilirubin above the ULN (p<0.001) 
remained independently predictive of poor transplantation-free survival (Supplementary 
Table 4). When transplant-free survival after occurrence of a first major complication was 
stratified according to time period of occurrence of these complications, transplant-free 
survival complications was significantly shorter for patients that were affected earlier 
in calendar time (p=0.01), in particular after variceal bleeding (Figure 5). At the time of 
complications serum albumin and bilirubin levels were normal in 17% of the affected 
patients. With a median transplantation-free survival of 7.2 years (95%CI 5.1-9.3), prognosis 
of patients with normal serum albumin and bilirubin at time of their first hepatic complication 
was significantly better than the median 1.6 years (95%CI 1.2-1.9) survival of patients with 
abnormal serum albumin and/or bilirubin (p<0.001) (Supplementary Figure 4).
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Figure 5. Transplant-free survival after first occurrence of a major hepatic complication stratified according to 
time period of patient inclusion. (A) a first major hepatic complication (B) ascites, (C) variceal bleeding and (D) 
encephalopathy.
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DISCUSSION
In this long-term study of a large, internationally representative cohort of PBC patients 
treated with UDCA, the current standard therapy, we found that the overall cumulative 
incidence of major non-neoplastic hepatic complications was 9% after 10 years and 15% 
after 15 years. The cumulative incidence of these complications decreased over the past 
decades.  Furthermore, in patients responding well to UDCA treatment and a low APRI after 
12 months of treatment, the 10-year complication risk was reduced to only 3%, which is in 
marked contrast with a 10-year risk of 37% in patients with a high APRI and non-response to 
UDCA. Our data confirm that these complications are of critical importance in the course of 
the disease and are predictive of poor survival. 
The decrease in cumulative incidence of major hepatic complications over time may be 
explained by a number of reasons. Firstly, our data shows that over the past decades, patients 
are increasingly being diagnosed in an early stage of disease2. Secondly, likely related to 
the gradual introduction of UDCA and increasing evidence for a therapeutic benefit of this 
agent in the last decades of the 20th century, we found that the interval between diagnosis 
and initiation of UDCA treatment strongly decreased over time. Also, other developments, 
such as timely detection and widespread primary prophylaxis of variceal bleeding, may have 
contributed to a decreasing incidence of complications38. In keeping with previous studies 
on specific complications, risk factors we found to be associated with future development 
of complications are largely the same as those related to transplant-free survival8, 16, 22, 31, 39. 
Similarly to baseline factors associated with future development of hepatocellular 
carcinoma40 and with risk of overall mortality in PBC30, biochemical non-response to UDCA 
therapy proved to be a strong risk factor for the occurrence of major hepatic complications 
during follow-up. This finding stresses the clinical importance of evaluating biochemical 
response to UDCA after one year of therapy. Interestingly, our data confirmed the additional 
prognostic value of APRI independent of biochemical response16. Stratification by both 
biochemical response and APRI identified a subgroup of approximately 20% of our cohort 
with a very low long-term risk of major, non-neoplastic hepatic complications. 
As in other chronic liver disease, the development of hepatic complications is predictive 
for high mortality in PBC. In agreement with a systematic review assessing survival after 
occurrence of cirrhosis-associated complications across several liver diseases41, median 
survival after the first complication in our cohort was approximately two years. The present 
study also shows that a subgroup of patients develop major hepatic complications in the 
absence of biochemical features of markedly advanced liver disease. The subsequent 
prognosis of these patients was considerably better than when liver function was more 
severely compromised. Our data furthermore indicate that the particular type of hepatic 
complication is predictive of subsequent survival. Interestingly, patients suffering from 
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variceal bleeding as the first major complication have a more favorable prognosis than 
patients who first develop ascites. The calendar year of occurrence of these events was 
an independent predictor of subsequent prognosis, with better outcomes for more recent 
cases, particularly for variceal bleeding. Improved patient care seems a likely explanation 
for this observation, which is in agreement with studies reporting improved prognosis after 
variceal bleeding over the last decades42, 43. 
Ascites is generally considered the most frequent first decompensating event in patients 
progressing from compensated to decompensated cirrhosis44-47. Our finding that ascites is 
also the most frequent first decompensating event in PBC is in agreement with the results of 
the classical long-term cohort study performed in Northeast England, reporting that ascites 
was both the most prevalent cirrhotic complication at the time of diagnosis as well as during 
follow-up48. Although the development of ascites or other complications is associated with 
poor prognosis, a subset of approximately 10% of our patients, particularly those with well-
preserved hepatic function, was found to be alive without transplantation after 10 years. 
This indicates that major cirrhotic complications can occur relatively early in the course 
of PBC. Although portal hypertension due to nodular regenerative hyperplasia or other 
non-cirrhotic architectural histological changes has been reported in PBC49-51 this seems 
a very rare entity and cirrhosis is the usual underlying cause of portal hypertension21, 52. 
More detailed characterization of the patients in our cohort with favorable long-term 
prognosis despite major hepatic complications was not the explicit aim of the current study 
but could be an interesting subject for future study.
Limitations of this study relate mostly to the nature of this study. Although the cumulative 
database includes prospectively followed-up patients, not all information relevant for this 
study, such as laboratory data at the time of hepatic events, was uniformly available in 
the individual data-sets. We were able to correct this by means of multiple imputations. 
Importantly, we do not have data on possible additional major hepatic complications after 
the first event. These data may provide an additional predictive value for survival and could 
be explored as such in the future. For practical reasons, this study did not address other, 
more rare complications of (cirrhotic) liver disease such as hepatopulmonary syndrome, 
portopulmonary hypertension, and cirrhotic cardiomyopathy. However, we speculate that it 
is unlikely that the main results of the present analyses would have been markedly different 
if we would have been able to do so. Our study group addressed hepatocellular carcinoma 
as a major potential complication of PBC in a previous large cohort study40. For this reason 
it was decided not to reassess this malignancy in the present study, but to concentrate on 
non-neoplastic, in particular portal hypertension-related complications. However, when 
analyses were repeated while censoring patients diagnosed with HCC during follow-up, 
the cumulative incidence of major non-neoplastic complications was very comparable. 
Furthermore, while this is a multi-center, international study, not all ethnicities are well-
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represented in our cohort. Interestingly, preliminary results of a Japanese study appear to 
confirm most of our results, particularly with regard to risk factors and prognosis53. Lastly, 
due to the nature of this study we cannot rule out that a selection bias might exist. Hence, 
since some relatively specialized centers are included in the cohort, incidence of major 
hepatic complications might be even lower in a general population of patients with PBC.
 
In conclusion, this large, international cohort study shows that in UDCA-treated PBC, major 
hepatic complications are not rare and develop in up to 15% of patients within 15 years of 
follow up. On the other hand, our data indicate that the incidence of these complications 
is decreasing over time, and that nowadays the large majority of patients treated with 
UDCA will remain free of serious complications such as ascites or variceal bleeding, and that 
subsequent survival has improved. Biochemical non-response to UDCA and high APRI are 
important risk factors for major hepatic complications. 
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SUPPLEMENTARY DATA
Supplementary Figure 1 Flowchart of study populati on. The initi al study populati on consisted of 3335 pati ents, of 
whom 111 pati ents were excluded. The populati on used for analyses consists of 3224 pati ents. 
Supplementary Figure 2 Cumulati ve incidence of major fi rst hepati c complicati ons in study cohort where all 
pati ents with a diagnosis of HCC before or at the same ti me of occurrence of major complicati ons were censored 
at ti me of HCC diagnosis and pati ents with an unknown HCC status were excluded from analysis.
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Supplementary Figure 3 A) Cumulative incidence of all first complications combined, stratified according the time 
period of patient inclusion; B) Cumulative incidence of ascites as first complication; C) Cumulative incidence of 
variceal bleeding as first complication; D) Cumulative incidence of encephalopathy as first complication. Please 
note that the sum of the incidences of the separate major complications (B, C and D) in the different time periods 
do not equal the totals (A) because of the existing competing risk of these endpoints. 
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Supplementary Figure 4. Transplantati on-free survival following occurrence of hepati c complicati ons according to 
serum albumin and total bilirubin levels. 
Abbreviati ons: LLN, lower limit of normal; ULN, upper limit of normal. 
Supplementary Table S1. Center-specifi c follow-up of the study populati on
Follow-up (years)
N Range Median (IQR) Range
The Netherlands 
(nati onwide cohort)
738 1973 - 2012 8.9 0.6 – 24.2
Canada (Toronto) 462 1974 - 2011 7.7 0.9 – 34.3
Italy (Milan, 2 centers) 341 1968 - 2012 9.3 0.6 – 25.8
USA (Texas) 320 1977 - 2012 8.9 0.8 – 23.7
France (Paris) 303 1977 - 2011 6.2 0.6 – 22.5
Italy (Padua) 248 1976 - 2012 7.7 0.5 – 23.8
Spain (Barcelona) 244 1981 - 2012 12.7 0.6 – 23.8
Belgium (Leuven) 126 1974 - 2012 7.0 0.7 – 20.2
USA (Rochester) 117 1975 - 2012 3.0 0.6 – 17.3
Germany (Jena) 107 1979 - 2015 6.0 0.7 – 22.7
Greece (Larissa) 96 1991 - 2015 8.8 0.5 – 23.1
United Kingdom (London) 41 1983 - 2012 8.8 0.5 – 19.3
Canada (Edmonton) 31 1991 - 2012 6.5 1.8 – 18.4
USA (Seatt le) 30 1995 - 2012 2.9 0.7 – 17.4
Gent 20 1996 - 2015 7.7 0.6 – 19.7
Abbreviati ons: IQR, interquarti le range. 
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Supplementary Table S2. Baseline cohort characteristics in different time periods 
≤ 1990 1990 - 2000 > 2000
N = 425 N = 1541 N = 1258
Age, yearsa 50.9 (11.2) 54.5 (12.4) 54.5 (12.4)
Female, n (%) 358 (90.6) 1405 (91.2) 1132 (90.0)
AMA+, n (%) 382 (90.0) 1398 (90.7) 1134 (90.1)
Year of diagnosisb 1986 (1983-1988) 1994 (1991-1997) 2005 (2002-2008)
Year of enrolmentb,c 1989 (1988-1990) 1995 (1993-1998) 2005 (2002-2008)
Follow up, yearsb 10.9 (5.7-16.9) 11.3 (7.0-15.0) 5.3 (3.1-8.1)
Interval diagnosis - UDCA > 2 yrs, n (%) 242 (56.9) 469 (30.4) 118 (9.4)
Histological disease stage, n (%)d
Stage I 60 (27.8) 335 (32.2) 335 (47.5)
Stage II 70 (32.4) 363 (34.9) 217 (30.8)
Stage III 46 (21.3) 158 (15.2) 110 (15.6)
Stage IV 40 (18.5) 185 (17.8) 43 (6.1)
Biochemical disease stagee, n (%)
Bilirubin≤ULN and albumin≥LLN 195 (63.3) 594 (75.8) 450 (74.9)
Bilirubin>ULN or albumin<LLN 99 (32.1) 159 (20.3) 123 (20.5)
Bilirubin>ULN and albumin<LLN 14 (4.5) 31 (3.8) 28 (4.7)
Serum total bilirubin ×ULNb 0.60 (0.43-0.93) 0.63 (0.47-0.90) 0.68 (0.47-1.1)
Serum ALP ×ULNb 2.17 (1.36-3.79) 2.25 (1.43-3.91) 2.02 (1.27-3.60)
Serum AST ×ULNb 1.50 (1.00-2.29) 1.50 (1.00-2.27) 1.38 (0.89-2.17)
Serum ALT ×ULNb 1.70 (1.05-2.72) 1.75 (1.10-2.75) 1.58 (0.96-2.53)
Serum albumin ×LLNa 1.16 (0.15) 1.17 (1.08-1.26) 1.14 (1.05-1.23)
Serum platelet count ×103/mm3a 254 (88) 243 (195-294) 237 (174-291)
APRIf 0.59 (0.37-0.93) 0.63 (0.40-1.00) 0.58 (0.33-1.05)
≤ 1990: Data on histological disease stage was missing for n=209 (49.2%), biochemical disease stage was missing 
for n=117 (27.5%,) total bilirubin was missing for n=90 (21.2%), ALP was missing for n=109 (25.6%), AST was 
missing for n=118 (27.8%), ALT was missing for n=118 (27.8%), albumin was missing for n=107 (25.2%), platelet 
count was missing for n=209 (49.2%).
1990 - 2000: Data on histological disease stage was missing for n=480 (31.1%), biochemical disease stage was 
missing for n=757 (49.1%,) total bilirubin was missing for n=511 (33.2%), ALP was missing for n=540 (35.0%), 
AST was missing for n=588 (38.1%), ALT was missing for n=596 (38.7%), albumin was missing for n=724 (47.0%), 
platelet count was missing for n=700 (45.4%).
> 2000: Data on histological disease stage was missing for n=553 (44.0%), biochemical disease stage was missing 
for n=657 (52.4%,) total bilirubin was missing for n=430 (34.2%), ALP was missing for n=365 (29.0%), AST was 
missing for n=364 (28.9%), ALT was missing for n=394 (31.3%), albumin was missing for n=635 (50.5%), platelet 
count was missing for n=608 (48.3%).
a Data is expressed as mean and standard deviation;  
b Data is expressed as median and interquartile range; 
c  Equals the year of start of treatment with ursodeoxycholic acid; 
Histological stage according to Ludwig and Scheuer’s classification27; 
e Biochemical disease stage was classified according to the Rotterdam criteria28; 
f AST/platelets Ratio Index16, 52;
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Supplementary Table S3. Factors associated with major hepatic complications after 12 months of UDCA therapy - 
a sensitivity analyses on complete cases
Univariate analysis Multivariable analysis
HR 95% CI p HR 95% CI p
Age (per 10 years) 1.10 0.98 - 1.23 0.103
Age < 40 years 0.73 0.49 - 1.07 0.113
Male sex 1.58 1.10 - 2.26 0.013
AMA negative 1.35 0.84 - 2.17 0.209
Year of diagnosis (per 10) 0.55 0.45 - 0.66 <0.001 0.85 0.63 - 1.14 0.278
Interval diagnosis - UDCA > 2 yrsa 1.92 1.49 - 2.48 <0.001
Advanced diseaseb 5.23 3.97 - 7.07 <0.001
Total bilirubin ×ULNc 3.85 3.22 - 4.59 <0.001
ALP ×ULNc 2.43 1.97 - 2.99 <0.001
AST ×ULNc 3.36 2.77 - 4.08 <0.001
ALT ×ULNc 2.08 1.72 - 2.51 <0.001
Albumin ×LLN 0.01 0.004 - 0.0. <0.001
Platelets (per 50x10³/mm³) 0.50 0.39 - 0.65 <0.001
AST/ALT ratioc 1.55 1.28 - 2.41 0.003
APRId, continuousc 2.22 1.56 - 3.15 <0.001
APRI> 0.54 11.6 7.10 - 19.0 <0.001 8.88 5.25 - 15.0 <0.001
UK-PBC score (per 20)e 1.53 1.40 - 1.63 <0.001
UK-PBC score ≤ mediane 2.76 2.14 - 3.69 <0.001
GLOBE-score, continuous 2.71 1.77 - 4.16 <0.001
Biochemical non-responsef 4.96 3.56 - 6.90 <0.001 3.40 2.19 - 5.26 <0.001
Total bilirubin was missing for n=703 (21.8%), ALP was missing for n=647 (20.6%), AST was missing for n=751 
(23.3%), ALT was missing for n=722 (22.4%), albumin was missing for n=1365 (42.3%), platelet count was missing 
for n=1423 (44.1%). 
a Years of untreated PBC diagnosis before starting UDCA therapy; 
b Abnormal serum albumin and/or bilirubin28; 
c These variables were transformed with natural logarithm;  
d AST/Platelets Ratio Index16, 54; 
e The median UK-PBC score in this study cohort was -103.331; 
f Based on (age-dependent) GLOBE score thresholds12;  
Abbreviations: HR, hazard ratio; CI, confidence interval; AMA, anti-mitochondrial antibodies; ULN, upper limit of 
normal; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LLN, lower 
limit of normal; APRI, AST/Platelets Ratio Index.
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Supplementary Table S4. Covariates associated with reduced transplant-free survival at the moment of hepatic 
complications.
Univariate analysis Multivariable analysis
HR 95% CI p HR 95% CI p
Male sex 1.32 0.83 2.08 0.240
AMA positive 1.01 0.62 1.64 0.979
Age (per 10 years) 1.13 0.98 1.30 0.106
Calendar year (per 10 years) 0.76 0.69 0.83 0.057 0.72 0.54 0.95 0.022
Total bilirubin 2.41 1.99 2.93 <0.001
ALP 1.33 1.05 1.69 0.019
AST 1.98 1.55 2.54 <0.001
ALTa 1.23 0.98 1.53 0.076
AST/ALT ratio 2.50 1.72 3.64 <0.001
APRI 1.33 1.10 1.61 0.003
Albumin 0.65 0.52 0.82 <0.001
Platelets (per 50x10³/mm³ decline) 1.06 0.97 1.15 0.238
Total bilirubin > ULN 2.86 2.00 4.09 <0.001 2.75 1.91 3.96 <0.001
ALP > 2x ULN 1.46 1.09 1.95 0.012
ALT > 2x ULN 1.10 0.79 1.53 0.574
AST > 2x ULN 1.73 1.28 2.32 <0.001
Albumin < LLN 2.24 1.63 3.08 <0.001 2.45 1.58 3.83 <0.001
Platelets < 100 (x10³/mm³) 1.01 0.74 1.36 0.997
APRI > 2x ULN 1.81 1.34 2.44 <0.001
AST/ALT ratio > ULN 2.20 1.41 3.43 0.001
a. These variables were transformed with natural logarithm.  
Abbreviations: AMA, anti-mitochondrial antibodies; ALP, alkaline phosphatase; ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; APRI, AST to Platelets Ratio Index; ULN, upper limit of normal; LLN, lower limit 
of normal
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CHAPTER 4
URSODEOXYCHOLIC ACID TREATMENT 
AND LIVER TRANSPLANTATION-FREE 
SURVIVAL IN PATIENTS WITH PRIMARY 
BILIARY CHOLANGITIS     
Journal of Hepatology, 2019
ABSTRACT
Background and aims The clinical efficacy of ursodeoxycholic acid (UDCA) in primary 
biliary cholangitis (PBC) remains subject to debate as definitive randomized controlled 
trials are lacking. We aimed to determine whether UDCA prolongs transplantation (LT) free 
survival in PBC.
Methods This international cohort study included patients from the Global PBC Study 
Group database, originating from 8 countries in Europe and North America. Both UDCA-
treated and untreated patients were included. LT and death were assessed as a combined 
endpoint through Cox regression analyses, with inverse probability of treatment-weighing 
(IPTW). 
Results In the 3902 patients included, the mean (SD) age was 54.3 (11.9) years, 3552 
patients (94.0%) were female, 3529 patients (90.4%) were treated with UDCA and 373 
patients (9.6%) were not treated. The median (IQR) follow-up was 7.8 (4.1-12.1) years. In 
total, 721 UDCA-treated patients and 145 untreated patients died or underwent LT. After 
IPTW, the 10-year cumulative LT-free survival was 79.7% (95%CI 78.1-81.2) among UDCA-
treated patients and 60.7% (95%CI 58.2-63.4) among untreated patients (P<0.001). UDCA 
was associated with a statistically significant reduced risk of LT or death (Hazard Ratio [HR] 
0.46, 95%CI 0.40-0.52, P<0.001). The HR remained statistically significant in all stages of 
disease. Patients classified as inadequate biochemical responders after one year of UDCA 
had a lower risk of LT or death than patients who were not treated (adjusted HR 0.56, 
95%CI 0.45-0.69, P<0.001).
Conclusion The use of UDCA improves LT-free survival among patients with PBC, regardless 
of the disease stage and the observed biochemical response. These findings support UDCA 
as the current universal standard of care in PBC. 
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INTRODUCTION
Primary biliary cholangitis (PBC) is a chronic and usually slowly progressive liver disease with 
autoimmune features, histologically characterized by destruction of the small intrahepatic 
bile ducts1, 2. The disease is primarily diagnosed based on an otherwise unexplained chronic 
elevation of serum alkaline phosphatase levels and the presence of anti-mitochondrial 
antibodies. Early identification of individuals with PBC is clinically challenging as symptoms 
are frequently absent. Identifying and managing patients with PBC is important, however, 
as the disease may silently progress towards cirrhosis and the survival of affected patients 
is substantially impaired3.
UDCA is a choleretic and hydrophilic endogenous bile acid that is considered a safe and 
well-tolerated drug4-6. Based on the cumulative experience obtained with this drug over 
the past decades, UDCA is recommended as the standard treatment for PBC4, 6. Long-term 
cohort studies have suggested an association between UDCA and improved LT-free survival, 
but this was only based on the comparison of observed versus predicted LT-free survival 
according to the Mayo Risk Score, which estimates the prognosis when patients are left 
untreated7-9. Numerous randomized controlled trials (RCTs) have been performed as well, 
but all failed to show a difference in LT-free survival between placebo and UDCA treated 
groups10-19. As did other more extensive meta-analyses, the Cochrane hepatobiliary group 
recently concluded once again that there is no demonstrated benefit of UDCA on LT and/
or mortality17-20. Such positioning statements, in absence of the results of definitive trials, 
have fueled the ongoing discussion about the therapeutic potential of UDCA21-24. This might 
explain the observation in a well-executed national PBC registry that, until recently, as 
much as 20% of patients remained untreated25. In another recent US-based cohort study 
the percentage of UDCA untreated patients was even as high as 30%26. However, the meta-
analyses are based on inadequate RCTs that were limited by a small number of patients, 
insufficient dosages of UDCA, and short follow-up. Therefore, the evaluation of the clinical 
efficacy of UDCA in PBC should not be based on these RCTs alone. Nonetheless, there is 
an understandable reluctance to initiate new long-term, placebo-controlled RCTs in which 
many patients would be denied UDCA therapy, because of minimal safety concerns of UDCA 
and practical implications. 
To support current practice, alternative study designs are thus needed to assess the potential 
benefit of treatment with UDCA in PBC. This would be relevant both to increase awareness 
for timely diagnosis and referral by physicians working in other fields, and to optimize future 
patient management by PBC-treating physicians. A contemporary causal inference method - 
used to emulate a randomized controlled trial in observational data - is inverse probability of 
treatment weighting (IPTW). The Global PBC Study Group cohort, which includes long-term 
follow-up data of both UDCA-treated and untreated patients, provides the opportunity to 
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apply this method. In our first publication, we substantiated alkaline phosphatase (ALP) and 
bilirubin as surrogate markers for clinical outcome in our cohort of 4845 patients with PBC27. 
In the second Gastroenterology publication, in which only the 4119 UDCA-treated patients 
were included, we developed the GLOBE score, a model that accurately predicts long-term 
outcome28. In the current study performed in this cohort, we aimed to assess the effect of 
UDCA therapy on LT-free survival. The second objective was to evaluate the difference in LT-
free survival between patients who do not meet biochemical criteria for response after one 
year of UDCA therapy and patients who remained untreated. 
PATIENTS AND METHODS
Study population and design
Patients were derived from the Global PBC Study Group database. This study group is 
an international collaboration between 15 liver units across 8 countries in Europe and 
Northern America. The database contains individual patient data from long-term follow-up 
cohorts. Both UDCA-treated and untreated patients with an established diagnosis of PBC 
in accordance with internationally accepted guidelines4-6 were eligible for inclusion in this 
study. In order to be eligible, we required the absence of confirmed chronic hepatitis B 
virus or chronic hepatitis C virus infection, Wilson’ disease, alpha-1 antitrypsin deficiency, 
hereditary haemochromatosis, alcoholic liver disease, or overt overlapping features with 
autoimmune hepatitis. We then excluded patients from analysis in case of insufficient 
follow-up data (<6 months follow-up or <2 visits recorded, also in case of an endpoint 
within 6 months of follow-up), and when dates of starting treatment or clinical events were 
unknown. The centers involved in the current study followed their patients according to 
international guidelines, which includes a clinical assessment at least annually in absence 
of cirrhosis and at least 6-monthly in case of advanced disease4, 6. Cirrhosis was defined 
histologically as described by Ludwig29, 30. Methodology of data collection has previously 
been described in further detail27. For the current study 3902 of the 4845 patients included 
in the original cohort were assessed 27. Eighty-six patients were excluded because it was not 
known whether these patients were or were not treated with UDCA. In addition, one center 
is currently withdrawn from the Global PBC Study Group. This study was conducted in 
accordance with the Declaration of Helsinki. The protocol was approved by the institutional 
research board of the corresponding center and at each participating center, in accordance 
with their local regulations.
Statistical analysis 
The primary endpoint was defined as a composite endpoint of LT and all-cause mortality. 
As a secondary endpoint liver-related morbidity was assessed, defined by the composite 
of specific liver-related events (ascites, variceal bleeding, hepatic encephalopathy, 
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hepatocellular carcinoma) or a clinical condition resulting in the need of LT, whichever came 
first.  Baseline was defined as the first center visit for untreated patients. For UDCA-treated 
patients, the start date of UDCA-therapy was considered baseline. In PBC, treatment is lifelong 
and is initiated prompt after diagnosis (in this study: median 2.9 months, interquartile range 
(IQR) 0-29 months). Because PBC is a relatively slowly progressing disease, this treatment 
is commonly initiated long before endpoints occur. Therefore, UDCA was not analyzed as 
a time-dependent covariate. When no events occurred during follow-up, patients were 
censored at time of their last center visit.  
Because treatment was not assigned randomly in our study population and baseline variables 
could influence both the chance of mortality or LT, as well as the chance of receiving treatment 
(i.e. time-dependent confounding), inverse probability treatment weighting (IPTW) was 
used to estimate the outcomes31. Weights were assigned to each individual patient. In order 
to create the weights, a logistic regression model was created that included independently 
significant baseline characteristics and laboratory parameters (age, gender, calendar year 
of diagnosis, total bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), platelet count, and albumin), in which UDCA therapy 
was the dependent variable. The model’s predictive values were saved. Weights were 
subsequently estimated as per (1/predicted value) for UDCA-treated patients and (1/
(1-predicted value)) for untreated patients. Subsequently, the weights were stabilized32. 
Balance assessment was then performed by evaluating differences between the treated 
and untreated patient groups after weighting33 (Supplementary Figure S1). The hazard ratio 
(HR) of UDCA therapy was calculated by Cox proportional hazard regression analyses. In 
observational data, immortal time (person-time accumulated between date of diagnosis 
and date of treatment initiation) bias can potentially lead to overestimation of treatment 
effect34. For this reason, a sensitivity analyses including only patients diagnosed in or after 
1990, when UDCA was universally available and usually initiated promptly after diagnosis, 
was performed.
The association between UDCA and LT-free survival was also explored in patients classified 
as non-responder35 or inadequate responder4 to UDCA. The recently developed GLOBE 
score, calculated after 12 months, was used as primary measure of response to UDCA28. We 
applied the score’s age-specific thresholds, that categorize patients into either having an 
estimated prognosis similar to an age and sex matched general population, or an impaired 
estimated survival. Sensitivity analyses using other response criteria were performed. To 
ensure comparable follow-up time, we adjusted the starting point of follow-up of untreated 
patients according to the moment of assessing biochemical response. The Cox proportional 
hazard regression models used for these analyses were adjusted for patient demographics 
and biochemistry to correct baseline differences between the groups classified as responder, 
non-responder, and untreated population, respectively. Giving the power of our dataset, we 
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constructed a conservative model with extensive adjustment for baseline factors in order to 
estimate the association between UDCA and LT-free survival, adjusting for sex, age, year of 
diagnosis, serum total bilirubin, platelet count, albumin, ALP, AST, and ALT. 
Interactions between UDCA and patient characteristics and baseline laboratory values were 
explored for significance. Where indicated, continuous variables were transformed to their 
natural logarithm to correct for non-linearity. To correct for missing laboratory values, ten 
databases generated by means of multiple imputations (SAS Proc MI, MCMC method), were 
used for analyses36, 37.We assumed missing data occurred at random. Rubin’s rules were 
used for estimation of the parameters and the standard error38, 39. The imputation model 
variables included both those potentially predicting outcome and outcomes themselves. 
The (continuous) biochemical values were imputed at baseline, after one year, and after 
two years of follow-up. The biochemical values included for imputation were: ALP, AST, ALT, 
total bilirubin, albumin, and platelet count. In case of non-normality, the natural logarithm 
of these variables was used. No categorical or binary variables were imputed. 
All statistical tests were two-sided, and a P-value <0.05 was considered to be statistically 
significant. The significance level for interactions was set at p=0.01 to correct for multiple 
testing. Statistical analyses were performed in SPSS Statistics V.21.0 (Armonk, NY: IBM Corp.) 
and SAS version 9.4 (SAS Institute Inc., Cary, NC).
RESULTS
Study population
In total, 3902 patients with PBC were included. At baseline, the mean (standard deviation) 
age was 54.3 (11.9) and, the vast majority of patients was female (n= 3552, 91.0%). Three 
thousand five hundred and twenty-nine patients (90.4%) were treated with UDCA and 373 
patients (9.6%) were not treated with UDCA. Table 1 shows the baseline characteristics 
according to the treatment with UDCA. Patients treated with UDCA were younger and had 
higher circulating serum liver tests, while in the subgroup of patients with available baseline 
histology, on average, patients not treated with UDCA had more advanced stages of disease. 
Although statistically significant, these numerical differences were small. Coinciding with 
the gradual more widespread introduction of UDCA treatment since the early nineties 
of the last century, the median year of diagnosis was earlier in untreated patients (1992, 
interquartile range [IQR] 1982-2000) as compared to UDCA-treated patients (1997, IQR 
1990-2003). Balance assessment showed no remaining statistically significant differences 
regarding baseline patient characteristics between the untreated and the UDCA-treated 
population after adjustment with IPTW (Supplementary Figure S1). 
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Liver Transplantation-free survival according to UDCA therapy
During a median follow-up duration of 7.8 (IQR 4.1-12.1) years 299 patients underwent LT 
and 567 patients died. LT or death (as a combined endpoint) was reached by 721 UDCA-
treated patients and 145 untreated patients. The incidence rate of LT or death was 23.21 per 
1000 person-years (95% confidence interval [CI] 21.52-24.91) in patients treated with UDCA 
and 58.81 per 1000 person-years (95% CI 49.24-68.38) in patients not treated with UDCA 
(p<0.001). After IPTW adjustment, the 5-year cumulative LT-free survival was 90.8% (95% CI 
90.0-91.7) among UDCA-treated patients and 81.0% (95% CI 79.3 – 82.7) among untreated 
patients (Figure 1). At 10 years of follow-up, the cumulative LT-free survival rates were 79.7% 
(95% CI 78.1-81.2) and 60.7% (95% CI 58.2-63.4), respectively (Table 2). Weights-adjusted 
Cox proportional hazard regression analyses showed that UDCA therapy was associated 
with a statistically significant reduction in the hazard of LT or death (Hazard Ratio [HR] 0.46 
(95%CI 0.40-0.52, p<0.001). 1958 of 3902 patients (50%) could be included in analyses 
regarding the dosage of UDCA. The association between UDCA therapy and improved LT-
free survival remained statistically significant among those treated with <13 mg/kg (n=914) 
of UDCA (HR 0.50, 95%CI 0.43-0.57, p<0.001), but was stronger for patients treated with ≥13 
mg/kg of UDCA (n=671) (HR 0.29, 95%CI 0.21-0.39, p<0.001). In the study cohort of 3902 
patients, data on liver-related morbidity was available for 2982 (76.4%) patients, of whom 
266 were untreated, and 2716 were UDCA-treated. In total, 381 events were found. After 
10 years of follow-up, the weights-adjusted cumulative incidence of liver-related morbidity 
Figure 1. Transplant-free survival according to UDCA treatment. The solid line represents the weights-adjusted 
survival of UDCA-treated patients (n=3529), the dotted line reflects the weights-adjusted survival of untreated 
patients (n=373) (p<.001). The 95% confidence intervals are reflected by the grey lines. The survival figure was 
constructed using an IPTW-adjusted Cox proportional hazard model.
Abbreviations: UDCA, ursodeoxycholic acid; IPTW, inverse probability of treatment weighting.
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Table 1. Baseline characteristics  
Overall
N = 3902
UDCA-treated
N = 3529
Untreated
N = 373 P value
Age at diagnosis, years 52.3 (11.9) 52.1 (11.7) 54.1 (13.4) <0.001
Female, n (%) 3552/3902 (91.0) 3209/3529 (90.9) 343/373 (92.0) 0.510
AMA positive, n (%) 3507/3862 (90.8) 3175/3491 (90.9) 332/371 (89.5) 0.418
Year of diagnosis 1996 (1990-2003) 1997 (1990-2003) 1992 (1982-2000) <0.001
Histological disease stage, n (%) <0.001
    Stage I 784/2173 (36.1) 739/2076 (35.6) 45/97 (46.4)
    Stage II 671/2173 (30.9) 657/2076 (31.6) 14/97 (14.4)
    Stage III 365/2173 (16.8) 351/2076 (16.9) 14/97 (14.4)
    Stage IV 353/2173 (16.2) 329/2076 (15.8) 24/97 (24.7)
Serum bilirubin (ULN) 0.63 (0.44-1.00) 0.62 (0.44-1.00) 0.65 (0.43-1.38) 0.081
Serum ALP (ULN) 2.29 (1.41-3.95) 2.32 (1.46-4.00) 1.94 (1.11-3.51) <0.001
Serum AST (ULN) 1.53 (1.03-2.31) 1.56 (1.05-2.34) 1.25 (0.75-2.00) <0.001
Serum ALT (ULN) 1.68 (1.05-2.63) 1.71 (1.09-2.68) 1.20 (0.75-1.83) <0.001
Serum albumin (LLN) 1.15 (1.06-1.25) 1.15 (1.06-1.25) 1.15 (1.03-1.26) 0.840
Platelet count (x10³/mm³) 245 (190-300) 248 (195-303) 217 (146-271) <0.001
Biochemical disease stage, n (%) <0.001
    Early 1576/2296 (68.6) 1376/1980 (69.5) 200/316 (63.3)
    Advanced 559/2296 (24.3) 484/1980 (24.4) 75/316 (23.7)
    Severe 161/2296 (7.0) 120/1980 (6.1) 41/316 (13.0)
Abbreviations: UDCA, ursodeoxycholic acid; AMA, anti-mitochondrial antibodies; ALP, alkaline phosphatase; AST, 
aspartate aminotransferase; ALT, alanine aminotransferase.
was 27.6% (95%CI 24.4-30.6) among the patients without UDCA and 13.5% (95%CI 11.8-
15.1) among those with UDCA (p<0.001). In weights-adjusted Cox regression analyses UDCA 
therapy was associated with a statistically significant reduction in the hazard of liver-related 
morbidity (HR 0.45, 95%CI 0.36-0.55, p<0.001). In a sensitivity analysis in the subcohort 
diagnosed ≥1990, in which the median interval between diagnosis and initiation of UDCA 
treatment was 0.096 years (IQR 0.000-0.586), we found a similar association between UDCA 
and LT-free survival (HR 0.38, 95%CI 0.32-0.46).
Association between UDCA and Liver Transplantation or death in subgroups
In order to assess the stability of the association between UDCA therapy and improved 
LT-free survival, the IPTW-adjusted survival analyses were stratified according to various 
categorized baseline characteristics. The association between UDCA and improved LT-free 
survival was statistically significant in both males and females, younger and older patients, 
patients with early disease and patients with more advanced disease, as well as patients 
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with a favorable and an unfavorable biochemical profi le (Table 3, Supplementary Figure S3). 
The HRs of UDCA with respect to LT or death were stati sti cally signifi cant among all 
subgroups of pati ents (Table 3). The esti mated HRs diff ered according to baseline age, ALP, 
and albumin (Fi gure 2). The interacti on terms with UDCA were stati sti cally signifi cant for 
age and albumin. 
Table 2. Clinical endpoints, incidence rates and liver transplantati on-free survival according to the use of UDCA. 
With UDCA Without UDCA P Value
No. of clinical endpointsa 721 145
Incidence rate per 1000 person-yearsb 23.2 (21.5-24.9) 58.8 (49.2-63.4) <.001
5-year cumulati ve LT-free survival (%)b,c 90.8 (90.0-91.7) 81.0 (79.3-82.7) <.001
10-year cumulati ve LT-free survival (%)b,c 79.7 (78.1-81.2) 60.7 (58.2-63.4) <.001
P value were assessed using Cox proporti onal hazard analyses and the Chi2 conti ngency table.
a Liver transplantati on or death
b Reported with 95% confi dence interval
c Adjusted using inverse probabily treatment weighti ng
Abbreviati ons: No, number; UDCA, ursodeoxycholic acid; LT, liver transplantati on.
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Fig. 2. Strati fi ed associati on between UDCA therapy and transplant-free survival according to baseline serum 
ALP and albumin levels and age groups. Assessed using an IPTW-adjusted Cox proporti onal hazard model. A) 
adjusted HR of UDCA according to baseline alkaline phosphatase (x ULN); B) adjusted HR of UDCA according to 
baseline age, showing the youngest quarti le, the middle 50%, and the oldest quarti le; C) adjusted HR of UDCA 
according to baseline albumin (for which a defi nite explanati on). The bars represent the weights-adjusted hazard 
rati os of UDCA and their 95% confi dence intervals.
Abbreviati ons: ALP, alkaline phosphatase; IPTW, inverse probability of treatment weighti ng; HR, hazard rati o; 
UDCA, ursodeoxycholic acid; ULN, upper limit of normal; LLN, lower limit of normal.
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Fig. 3. Transplant-free survival stratified after 12 months of follow-up for treatment response versus no UDCA 
treatment. Survival figures were constructed using an IPTW-adjusted Cox proportional hazard model. The grey 
line represents the weights-adjusted survival of untreated patients (n=373), black solid line reflects the adjusted 
survival of patients classified as incomplete responder (n=733) according to the GLOBE score[28] and the 
dotted line reflects the adjusted survival of patients classified as complete responder (n=2700) according to the 
GLOBE score. All curves were adjusted for sex, age, year of diagnosis, bilirubin, albumin, platelet count, alkaline 
phosphatase, aspartate aminotransferase and alanine aminotransferase. The 95% confidences interval is reflected 
by the light grey dotted lines.
Abbreviations: UDCA, ursodeoxycholic acid; IPTW, inverse probability of treatment weighting.
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Among the 3529 UDCA-treated patients, 3433 had a follow up of at least 12 months. Of these 
3433 patients, 733 patients (21.4%) were classified as inadequate responders according 
to the GLOBE score 1 year after the start of UDCA therapy. After these initial 12 months, 
the adjusted cumulative 5-year LT-free survival was 95.3% (95% CI 94.8-95.9) in UDCA 
responders and 91.2% (95% CI 90.2-95.9) in patients with an inadequate response to UDCA, 
as opposed to 84.7% (95% CI 83.1-86.4) in the untreated patients (Figure 3). Multivariate 
Cox regression analysis showed that patients with inadequate response to UDCA had a 
statistically significant lower LT or death rate as compared to untreated patients (adjusted 
HR 0.56, 95%CI 0.45-0.69, p<0.001), but the favorable LT-free survival as opposed to those 
without therapy was stronger in UDCA responders (adjusted HR 0.25, 95%CI 0.20-0.30, 
p<0.001). These results were similar when response was assessed after 24 months (adjusted 
HR 0.62, 95%CI 0.52-0.74, p<0.001 and adjusted HR 0.27, 95%CI 0.22-0.33, p<0.001) and 
when applying other response criteria (Paris I, Paris II, Rotterdam, Toronto or Barcelona) 
(Supplementary Table S1)
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Table 3. Stratified association between UDCA therapy and liver transplant-free survival
Characteristic N HR of UDCAa 95% CI p-valueHR UDCA
p-value
Interaction
Sex 0.789
Male 350 0.52 0.35-0.77 0.0011
Female 3552 0.44 0.38-0.52 <0.0001
Age, years
     Reference       ≤46.0 974 0.33 0.24-0.46 <0.0001
46.0-62.7 1948 0.46 0.37-0.56 <0.0001 0.122
>62.7 979 0.60 0.48-0.76 <0.0001 0.002
Cirrhosisb 0.312
No 1820 0.32 0.24-0.42 <0.0001
Yes 353 0.31 0.24-0.40 <0.0001
Biochemical disease stagec
Early 2649 0.37 0.30-0.47 <0.0001
Intermediate 985 0.32 0.25-0.40 <0.0001 0.196
Advanced 268 0.50 0.37-0.70 <0.0001 0.271
ALP
Reference     ≤ 2x ULN 1679 0.61 0.45-0.82 0.0014
2-4x ULN 1285 0.46 0.36-0.59 <0.0001 0.195
> 4x ULN 938 0.36 0.25-0.52 <0.0001 0.046
Bilirubin 0.334
≤ ULN 2930 0.39 0.32-0.48 <0.0001
> ULN 972 0.40 0.33-0.48 <0.0001
Albumin 0.006
< LLN 549 0.32 0.24-0.43 <0.0001
≥ LLN 3353 0.46 0.40-0.54 <0.0001
Platelet count 0.951
< 150x109 531 0.48 0.35-0.65 <0.0001
≥ 150x109 3371 0.44 0.37-0.52 <0.0001
P-values were assessed using IPTW-adjusted Cox proportional hazard models.
a The Hazard Ratios were adjusted for the weights;
b Baseline histological data was available for 2173 patients;
c Biochemical disease stage according to Rotterdam criteria[8].
Abbreviations: HR, hazard ratio; CI, confidence interval; UDCA, ursodeoxycholic acid; ALP,
alkaline phosphatase; ULN, upper limit of normal; LLN, lower limit of normal; IPTW, inverse
probability of treatment weighting.
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DISCUSSION
In this large, international follow-up study including both UDCA-treated and untreated 
patients, we report that UDCA therapy improves LT-free survival in PBC, with a dose-response 
relationship. Importantly, a statistically significant association between UDCA therapy and 
reduced all-cause mortality or LT was found in all stages of disease. These findings imply a 
strong recommendation for all patients with PBC to use UDCA. Even in UDCA-treated patients 
classified as inadequately responding to UDCA according to accepted criteria, an improved 
LT-free survival was found in comparison to untreated patients. This indicates that UDCA 
should not be stopped in these inadequate responders and that future therapeutic options 
for this patient group should initially be considered as add-on medication. Additionally, our 
results underline the importance of adequate dosing of UDCA of at least 13 mg/kg. 
The 2.2 fold risk reduction associated with UDCA treatment that we report is more 
pronounced than in the previous (meta-)analyses that quantified the benefit of UDCA with 
relative risk reductions of approximately 1.540-42. This may be explained by the longer follow-
up and subsequent higher incidence of clinical endpoints in our study cohort, but also by 
the use of more adequate dosages of UDCA over time and the subsequent larger associated 
risk reduction. While most previous studies did not establish evidence for a clinical benefit 
of UDCA at all, one combined analysis of three of the available RCTs did report a significantly 
improved survival in patients with advanced disease40. Irrespective of disease severity, a clear 
understanding about the potential impact of UDCA is relevant for all patients, for patient 
counseling and therapeutic compliance, but also for cost justification. An important novelty 
of the current study is thus the encouraging demonstration of a statistically significant 
association between UDCA therapy and prolonged LT-free survival throughout all subgroups 
of PBC patients, including those with and without cirrhosis, and irrespective of biochemical 
disease stage or other baseline biochemistry. This finding opposes the widely held belief 
that UDCA may be particularly useful in early stage disease. Although the aforementioned 
combined analysis suggested a therapeutic benefit in advanced disease40, a clear beneficial 
effect of UDCA in late stage PBC has often been considered doubtful or even unlikely24, 43. We 
did not identify any subgroup of patients without an improved LT-free survival associated 
with UDCA therapy, even when subgroups were further stratified into more extreme values 
of biochemistry and age (data not shown). These analyses were possible due to the large 
number of patients and long follow-up duration in this study. Prior studies, and especially 
prior RCTs, were lacking such power and this has indeed been the major criticism regarding 
the lacking evidence of clinical gain of UDCA therapy in PBC to date. Yet, these prior studies 
may have contributed to the fact that still not all patients with PBC are receiving UDCA 
treatment today, despite the recommendations in current international guidelines4, 6. A 
recent real-life American cohort study revealed that 30% of patients remained untreated44, 
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and a similar percentage of untreated patients is reported in a yet unpublished German 
study which included patients diagnosed after 2015. 
Our analyses showed that in younger PBC patients, there is a stronger LT-free survival benefit 
of UDCA than in older patients. In the elderly, survival is also driven by extrahepatic factors 
which are unlikely to be influenced by UDCA, attenuating the HR. We are lacking detailed 
data on cause of death for further clarification. This result might seem counterintuitive as 
previous studies showed that young PBC patients are less likely to meet the criteria for 
response to UDCA after one year of treatment, that are mainly based on liver blood tests 
after 12 months of treatment9, 25, 45-50. It should be realized, however, that the biochemistry 
of young patients is often worse than that of older patients (confirmed in our cohort, data 
not shown) and that achievement of crude dichotomous biochemical response criteria 
is related to the baseline level of these laboratory parameters51. The frequently applied 
response criteria evaluate neither absolute nor relative improvements within the individual. 
Patients with high levels of ALP are therefore likely to realize major improvements of their 
biochemistry, with considerable clinical benefit, while still being classified as non-responders 
or, at least, inadequate responders. Indeed, here we show that the relative risk reduction 
of LT or death associated with UDCA therapy is greater among those patients with higher 
baseline ALP. 
Another finding of importance is that among patients classified as inadequate responder 
according to the different international response criteria, when adjusted for relevant 
baseline predictors of both biochemical response and long-term outcome, the risk of LT or 
death with UDCA treatment was still 1.8-fold lower as compared to patients that were left 
untreated. Nonetheless, this effect was more pronounced in patients classified as responder, 
who have been shown to have a survival comparable to the general population28. While 
response criteria are clearly well able to identify patients in need of second-line treatment, 
not meeting these criteria should not be interpreted as an absence of treatment effect. 
Denomination of either ‘non-response’ or ‘inadequate response’ to UDCA may therefore 
be inappropriate, as these terms do not capture the remaining therapeutic benefit in these 
patients. Incomplete response may be a more suitable alternative. While various second-
line treatment options are currently emerging for PBC, our result stresses the importance 
not to withhold patients from UDCA therapy. UDCA has been extensively studied on long-
term effects and a causal benefit of UDCA on survival seems likely, even more so because 
of the results of the IPTW analyses in our study, including the dose-response association. 
Furthermore, UDCA has proven to be very safe when adequately dosed and is inexpensive4, 6, 52. 
At present, the novel therapies for PBC should thus be primarily considered as add-on 
treatment. Further studies should assess whether monotherapy with these new drugs has 
the potential to result in a similar or superior clinical benefit.
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Our study comprises both strengths and limitations. Although our study is not a RCT, we 
make use of a large real life cohort of both treated and untreated patients. This previously 
enabled the in-depth assessment of biochemical surrogate markers in PBC, which led to the 
development and validation of the GLOBE score27, 28. The novelty of the study we present 
here is that we assessed the association between UDCA and LT-free survival by applying 
IPTW estimates, so that the power of the entire cohort was preserved. IPTW is a causal 
inference method, developed to emulate RCTs in observational data53. The long-term RCT 
that would be required to ultimately prove that the relation between UDCA therapy and 
improved prognosis is causal would be both hugely difficult in terms of practicality, and 
would generally be considered as unethical by having to withhold patients from UDCA 
treatment for many years. While the limitations of existing randomized controlled trials 
were extensively discussed, the current study is not free from limitations either. Residual 
confounding can never be ruled out in our cohort study in which the reasons for non-
treatment are also unknown. However, it would be misleading to refrain from causal 
language since it is clearly the aim of this study to contribute to the body of evidence for 
the therapeutic effect of UDCA54. Moreover, because of the favorable safety profile, there 
are no evident contra-indications for the use of UDCA. Thus, it is difficult to imagine which 
unmeasured and unevenly distributed patient characteristic would completely diminish 
the strong association between UDCA and a prolonged LT-free survival. Secondly, time-
dependent bias such as immortal time could potentially have led to overestimation of the 
association between UDCA and LT-free survival. However, in our sensitivity analyses among 
patients included from 1990 onwards, in which the time between diagnosis and start of 
UDCA was generally very short, the HR was similar. In order to ensure sufficient power for 
subgroup analyses, we preserved the entire cohort for all primary analyses. Moreover, our 
overall estimate might be considered conservative as we found a stronger HR in patients 
receiving an adequate dose of UDCA (>13 mg/kg), which is the regular dosage used today. 
Thirdly, we were not able to analyze all-cause mortality as a solitary endpoint, because 
we lack follow-up data after an event of LT. However, today LT-free survival is considered 
clinically most relevant in PBC and is thus used as primary endpoint in recent studies and 
by regulating authorities. Furthermore, because of the nature of this study and the fact 
that liver biopsy is no longer required for the diagnosis of PBC, our histology data were 
incomplete. Data on fibrate therapy, which was recently shown to have a beneficial effect on 
surrogate end-points in PBC55, is not available in our study. However, this is unlikely to have 
had a major influence on our results as only a minority of the more recent patients in our 
large cohort may have received off-label treatment with fibrates. 
 
In conclusion, this large multi-center study indicates that UDCA therapy improves LT-free 
survival in all patients with PBC, both in those with early and advanced disease, as well as in 
patients not meeting accepted criteria for response to UDCA.
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SUPPLEMENTARY DATA
Supplementary Table S1. Adjusted HR of UDCA treatment for inadequate response versus no UDCA treatment 
and response to UDCA versus no UDCA treatment, according to the different international response criteria for 
response to UDCA treatment. 
Adjusted HR UDCAa 95% CI P value
GLOBE
Inadequate response vs. no UDCA 0·558 0·453-0·686 <·0001
Response vs. no UDCA 0·289 0·234-0·357 <·0001
Paris II
Inadequate response vs. no UDCA 0·459 0·381-0·553 <·0001
Response vs. no UDCA 0·297 0·231-0·380 <·0001
Toronto
Inadequate response vs. no UDCA 0·461 0·368-0·576 <·0001
Response vs. no UDCA 0·317 0·259-0·387 <·0001
Rotterdam
Inadequate response vs. no UDCA 0·504 0·325-0·784 <·0001
Response vs. no UDCA 0·389 0·329-0·461 0·0037
Paris I
Inadequate response vs. no UDCA 0·556 0·448-0·690 <·0001
Response vs. no UDCA 0·291 0·240-0·357 <·0001
Barcelona
Inadequate response vs. no UDCA 0·511 0·415-0·630 <·0001
Response vs. no UDCA 0·316 0·262-0·387 <·0001
P-values were assessed using an IPTW-adjusted Cox proportional hazard model.
a  The stratified Hazard Ratios were adjusted for sex, age, year of diagnosis, albumin, platelet count, bilirubin, 
alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase.
Abbreviations: UDCA, ursodeoxycholic acid; HR, hazard ratio; CI, confidence interval.
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Supplementary Figure S1. Baseline characteristi cs strati fi ed for treatment aft er inverse probability of treatment 
weighti ng adjustments. The boxplots represent the median and interquarti le range, the whiskers represent the 
5th and 95th percenti les.
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Supplementary Figure S2. Transplant-free survival according to UDCA treatment, stratified for baseline 
characteristics. The solid line represents the weights-adjusted survival of UDCA-treated patients, the dotted line 
reflects the weights-adjusted survival of untreated patients. The 95% confidence intervals are reflected by the 
grey lines
The survival figures were constructed using IPTW-adjusted Cox proportional hazard models. 
Abbreviations: UDCA, ursodeoxycholic acid; IPTW, inverse probability of treatment weighting.
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CHAPTER 5
THE NUMBER NEEDED TO TREAT WITH 
URSODEOXYCHOLIC ACID TO PREVENT 
LIVER TRANSPLANTATION OR DEATH 
IN PRIMARY BILIARY CHOLANGITIS     
Gut, 2019
ABSTRACT
Objectives Clinical benefit of ursodeoxycholic acid (UDCA) in primary biliary cholangitis 
(PBC) has never been reported in absolute measures. The aim of this study was to assess 
the number needed to treat (NNT) with UDCA to prevent liver transplantation (LT) or death 
among patients with PBC. 
Methods The NNT was calculated based on the untreated LT-free survival and hazard ratio’s 
(HR) of UDCA with respect to LT or death as derived from inverse probability of treatment 
weighting-adjusted Cox proportional hazard analyses within the Global PBC Study Group 
database.
Results We included 3902 patients with a median follow-up of 7.8 (4.1-12.1) years. The 
overall HR of UDCA was 0.46 (95%CI 0.40-0.52) and the 5-year LT-free survival without 
UDCA was 81% (95%CI 79-82). The NNT to prevent one LT or death within 5 years (NNT
5Y
) 
was 11 (95% CI 9-13). Although the HR of UDCA was similar for patients with and without 
cirrhosis (0.33 vs. 0.31), the NNT5y was 4 (95%CI 3-5) and 20 (95%CI 14-34), respectively. 
Among patients with low ALP (≤2x the upper limit of normal [ULN]), intermediate ALP (2-4x 
ULN) and high ALP (>4x ULN) the NNT5y  to prevent one LT or death was 26 (95%CI 15-70), 11 
(95%CI 8-17), and 5 (95%CI 4-8), respectively. 
Conclusion In this large international PBC cohort, the absolute clinical efficacy of UDCA 
with respect to LT or death varied with baseline prognostic characteristics, but was high 
throughout. These findings strongly emphasize the incentive to promptly initiate UDCA 
treatment in all patients with PBC and may improve patient compliance.
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INTRODUCTION
Primary biliary cholangitis (PBC) is a chronic disease of the liver, characterized by destruction 
of the small intrahepatic bile ducts and formation of hepatic fibrosis1, 2. It was recently 
estimated that nowadays 40% of the patients with PBC will develop cirrhosis within 10 years, 
at which point patients are at increased risk of liver failure and hepatocellular carcinoma3. 
As a result, the overall survival of patients with PBC is substantially impaired as compared to 
that of a matched general population4. 
The choleretic and hydrophilic bile acid ursodeoxycholic acid (UDCA) is currently considered 
as the standard of care for patients with PBC5-7. Based on long-term clinical experience, 
UDCA is considered to have a favorable safety profile. The strong association between UDCA 
therapy and prolonged liver transplantation (LT)-free survival was recently substantiated 
in both a large American cohort and our own international cohort, with a dose-response 
relationship highlighting the importance of the 13-15 mg/kg dose recommendation8. 
Still, even in recent Western cohorts as much as 30% of patients remained untreated and 
suboptimal UDCA dosages were frequently used9, 10. More awareness of and attention for 
the clinical efficacy of UDCA is thus needed in order to optimize the medical management 
and clinical outcome of the population with PBC.
While previous studies only assessed the relative reduction of the risk of clinical outcomes 
with UDCA therapy, our understanding of the impact of UDCA could benefit from reports 
of absolute measures of clinical efficacy. The number needed to treat (NNT) to prevent one 
clinical event represents such an absolute clinical efficacy measure with clear interpretation 
for physicians, patients and policymakers. Currently, it is not known how many patients with 
PBC should be treated with UDCA to prevent one LT or death. Although previously we showed 
that the relative risk reduction with UDCA is stable over various patient characteristics, the 
absolute risk reduction may not be8. In this study we aimed to assess the NNT with UDCA 
to prevent one LT or death among patients with PBC. Secondary aims were to evaluate the 
NNT in various subgroups of patients with PBC and to estimate the NNT for the individual 
PBC patient. 
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PATIENTS AND METHODS
Study population and design
For the current study we used the data of patients included in the database of the Global PBC 
Study Group, which is an international collaboration between liver units across 8 countries 
in Europe and Northern America. The database contains data from representative long-
term followed cohorts on an individual patient level of both UDCA-treated and untreated 
patients. All patients had an established diagnosis of PBC according to the internationally 
accepted guidelines6, 7. Patients were only included in case of sufficient follow up (>6 
months and ≥2 recorded visits), and when dates of starting UDCA treatment and/or clinical 
events were known. For the current analyses we excluded patients in case an auto-immune 
overlap syndrome or other concomitant liver disease was present. Further details on the 
methodology of data collection have been described in further detail elsewhere8, 12. In line 
with our previous work, 3902 patients were included for the current analyses8. This study 
was conducted in accordance with the Declaration of Helsinki. The protocol was approved 
by the institutional research board of the corresponding center and at each participating 
center, in accordance with their local regulations.
Statistical analysis 
The outcome measure of the current study was the combined endpoint of LT and all-cause 
mortality. Baseline was considered to be the first center visit in untreated patients and the 
start treatment in patients receiving UDCA. Treatment with UDCA for PBC is recommended 
lifelong and usually initiated promptly after diagnosis. In our study the median (interquartile 
range [IQR]) interval between the first center visit and start of UDCA was 2.9 months (0-29). 
Patients were censored at time of LT or at time of their last center visit in case no events 
occurred during the follow-up. Missing baseline data was assumed to be missing at random 
and was handled by means of multiple imputation (SAS Proc MI, MCMC method). Hereto, 
10 databases were generated with use of Rubin’s rules to estimate the parameters and the 
standard error. The biochemical values included for imputation were: alkaline phosphatase 
(ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, 
albumin, and platelet count. Categorical or binary variables were not imputed.
Because treatment was not assigned randomly in our study population, our analyses were 
performed following inverse probability treatment weighting (IPTW)13. Hereto, following 
stabilization, weights were assigned to each individual patient based on the predictive 
values derived from a logistic regression model including baseline patient characteristics 
and laboratory parameters (age, gender, calendar year of diagnosis, total bilirubin, alkaline 
phosphatase (ALP), alanine aminotransferase (ALT), platelet count, albumin) with UDCA 
therapy as dependent variable8, 14. After weighting a balance assessment was performed 
which previously showed that there were no remaining differences in baseline characteristics 
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between the UDCA-treated and untreated patients15. Subsequently, the association 
between time to LT or death and UDCA therapy was assessed through Cox proportional 
hazard regression analyses. 
The NNT to prevent one LT or death within [t] years with UDCA therapy can be calculated 
with the LT-free survival in patients without treatment and the estimated benefit of UDCA 
on LT-free survival, which are both derived from IPTW-adjusted Cox regression analyses. 
The NNTs were estimated using the following formula: NNT = (1/(LT-free survivaluntreated[t]
HR UDCA)-(LT-free survivaluntreated[t])).[16] The 95% confidence intervals (CI) of both the LT-free 
survival and the HR of UDCA were taken into account to address the uncertainty of the NNT. 
Unrounded numbers of HR and untreated survival were used to calculate the NNT. The NNT 
was always rounded up. Although the NNT to prevent one LT or death can be calculated for 
every time point [t] during the follow-up (NNT
[t]y
), we primarily report the NNT to prevent 
one LT or death within 5 years (NNT5y) throughout the manuscript. Stratified analyses were 
performed based on categorized baseline characteristics. 
The individualized NNT5y was estimated with use of the GLOBE score, a validated objective 
prognostic tool which was developed to accurately assess the LT-free survival after 1 year of 
UDCA therapy. The GLOBE score is calculated with the formula: 0.044378 x age + 0.93982 x 
LN(bilirubin) + 0.335648 x LN(ALP) + 2.266708  x albumin + 0.002581 x platelets (per 10
9/L) 
+ 1.216865 (bilirubin and alkaline phosphatase in ‘x upper limit of normal’ and albumin in 
‘x lower limit of normal’)17. First, the predictive accuracy of the GLOBE score (calculated 
with the variables at baseline) for LT or death was assessed in untreated patients using the 
c-statistic18, 19. Calibration analyses were performed by comparing the predicted mortality 
rates with those observed. Second, a multivariable Cox regression model for LT or death 
including the GLOBE was constructed. Linearity was assessed by including polynomial 
terms, which remained included in the multivariate model in case these were statistically 
significantly associated with the outcome measure. Subsequently, the HR of UDCA was 
calculated for each value of the GLOBE score. 
All statistical tests were two-sided, and a P-value <0.05 was considered to be statistically 
significant. The significance level for interactions was set at p<0.01 to correct for multiple 
testing. Statistical analyses were performed in SPSS Statistics V.21.0 (Armonk, NY: IBM Corp.) 
and SAS version 9.4 (SAS Institute Inc., Cary, NC).
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RESULTS
Cohort characteristics
Included in the study were 3902 patients with PBC, predominantly female (91.0%) and 
with a mean (standard deviation) age of 54.3 (11.9). Treated with UDCA were 3529 (90.4%) 
patients and not treated with UDCA were 373 (9.6%) patients. Table 1 shows the baseline 
characteristics according to the treatment with UDCA prior to IPTW. Following adjustment 
with IPTW there were no remaining baseline characteristics which differed statistically 
significantly between the two groups. Patients were followed for a median during of 7.8 
(IQR 4.1-12.1) years during which a total of 299 patients underwent LT and 567 patients 
died. The primary endpoint of LT or death was observed in 721 UDCA-treated patients and 
145 untreated patients. 
NNT
5y
 with UDCA to Prevent One LT or Death
Following IPTW adjustment, the 5-year cumulative LT-free survival without UDCA therapy 
was 81.0% (95% CI 79.3 – 82.7). The overall adjusted HR of UDCA for LT or death was 0.46 
(95%CI 0.40-0.52, p<0.001). As a result, the NNT5y to prevent LT or death in one patient was 
11 (95% CI 9-13). With a proportional HR of UDCA over time, the cumulative LT-free survival 
in untreated patients at (t) years drives the estimated NNT to prevent one LT or death over 
that specific duration of therapy. 
Figure 1. Adjusted NNT to prevent one LT or death according to the treatment duration with 95% CI. 
With a 10-year cumulative LT-free survival of 60.7% (95% CI 58.2 – 63.4) in absence of UDCA, the NNT10y to 
prevent one LT or death was 6 (95%CI 5-7). Figure 1 shows the NNT(t)y to prevent one LT or death according to 
various durations of UDCA therapy. 
Abbreviations: CI, confidence interval; LT, liver transplantation; NNT, number needed to treat; UDCA, 
ursodeoxycholic acid.
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Table 1. Baseline characteristics
Overall
N = 3902
UDCA-treated
N = 3529
Untreated
N = 373
P value
Age at diagnosis, yearsᵃ 52.3 (11.9) 52.1 (11.7) 54.1 (13.4) <0.001
Female, n (%) 3552/3902 (91.0) 3209/3529 (90.9) 343/373 (92.0) 0.510
AMA positive, n (%) 3507/3862 (90.8) 3175/3491 (90.9) 332/371 (89.5) 0.418
Year of diagnosisb 1996 (1990-2003) 1997 (1990-2003) 1992 (1982-2000) <0.001
Histological disease stage, n (%)c <0.001
    Stage I 784/2173 (36.1) 739/2076 (35.6) 45/97 (46.4)
    Stage II 671/2173 (30.9) 657/2076 (31.6) 14/97 (14.4)
    Stage III 365/2173 (16.8) 351/2076 (16.9) 14/97 (14.4)
    Stage IV 353/2173 (16.2) 329/2076 (15.8) 24/97 (24.7)
Serum bilirubin (ULN)b 0.63 (0.44-1.00) 0.62 (0.44-1.00) 0.65 (0.43-1.38) 0.081
Serum ALP (ULN)b 2.29 (1.41-3.95) 2.32 (1.46-4.00) 1.94 (1.11-3.51) <0.001
Serum AST (ULN)b 1.53 (1.03-2.31) 1.56 (1.05-2.34) 1.25 (0.75-2.00) <0.001
Serum ALT (ULN)b 1.68 (1.05-2.63) 1.71 (1.09-2.68) 1.20 (0.75-1.83) <0.001
Serum albumin (LLN)b 1.15 (1.06-1.25) 1.15 (1.06-1.25) 1.15 (1.03-1.26) 0.840
Platelet count (x10³/mm³)b 245 (190-300) 248 (195-303) 217 (146-271) <0.001
Biochemical disease stage, n 
(%)d
<0.001
    Early 1576/2296 (68.6) 1376/1980 (69.5) 200/316 (63.3)
    Advanced 559/2296 (24.3) 484/1980 (24.4) 75/316 (23.7)
    Severe 161/2296 (7.0) 120/1980 (6.1) 41/316 (13.0)
 
Serum bilirubin was missing for 1020 (26%) patients, serum ALP for 1069 (27%), serum AST for  1175 (30%), serum 
ALT for 1294 (33%), serum albumin for 1533 (39%), and platelet count for 1720 (44%), AMA status was missing for 
40 (1.9%).  
ᵃ Data is expressed as mean and standard deviation;
b Data is expressed as median and interquartile range;
c Histological disease stage according to Ludwig and Scheuer’s classification20;
d Biochemical disease stage according to Rotterdam criteria21.
Abbreviations: AMA, antimitochondrial antibodies; ALP, alkaline phosphatase; ULN, upper limit of normal; AST, 
aspartate aminotransferase; ALT, alanine aminotransferase; LLN, lower limit of normal; UDCA, ursodeoxycholic 
acid. 
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Figure 2. Observed versus predicted LT-free survival according to categorized risk groups. The observed and 
mean predicted liver LT-free survival of patients in our cohort with: 1) a GLOBE score  ≤ -0.21, i.e. 5-year risk of LT/
death ≤ 5%; 2) GLOBE 0.21 - 0.51, i.e. 5-year risk 5-10%; 3) GLOBE 0.51 - 0.91 i.e. 5-year risk of 10-20%; and 4) a 
GLOBE score of > 0.91, corresponding with a 5-year risk of >20%. Abbreviation: LT, liver transplantation.
Relative Risk Reduction versus Absolute Risk Reduction in Stratified Subgroups
Table 2 presents the adjusted HRs of UDCA with respect to LT or death, the adjusted 
cumulative LT-free survival in UDCA-untreated patients and the adjusted NNT to prevent one 
LT or death within 5 and 10 years for various subgroups of patients. As previously described, 
the HR of UDCA for LT or death was stable over the baseline characteristics and only differed 
statistically significantly among patients stratified according the their baseline age, and 
ALP and albumin levels8. As example, the relative reduction of the risk of LT or death with 
UDCA therapy was somewhat - although not statistically significantly - lower among patients 
with early biochemical disease (adjusted HR 0.37, 95%CI 0.30-0.47) or patients intermediate 
biochemical disease (adjusted HR 0.32, 95%CI 0.25-0.40) versus patients with advanced 
biochemical disease (adjusted HR 0.50, 95%CI 0.37-0.70). In absolute terms, however, the 
adjusted NNT5y to prevent one LT or death was substantially higher among those with early 
biochemical disease (22, 95%CI 17-32) as opposed to those with intermediate or advanced 
disease (5 [95%CI 4-6] and 5 [95%CI 3-8], respectively). The beneficial NNT in patients with 
advanced biochemical response is explained by the higher 5-year cumulative incidence of 
LT or death (26.2% [95%CI 20.4-33.7]). The IPTW-adjusted HR of UDCA was statistically 
significantly stronger among the youngest quartile of patients (≤46.0 years; 0.33 [95%CI 
THE NUMBER NEEDED TO TREAT WITH URSODEOXYCHOLIC ACID TO PREVENT LIVER TRANSPLANTATION OR DEATH 121 
5
Table 2. The NNT with UDCA to prevent one LT or death in 5 and 10 years in subgroups of patients with PBC
Characteristic aHR (95%CI)ᵃ
p-value
HR
Untreated LT-free 
survival5y (95%CI) 
NNT5y 
(95%CI)
Untreated LT-
free survival10y 
(95%CI) 
NNT10y 
(95%CI)
Sex
   Males 0.52 (0.35-0.77) 0.0011 0.68 (0.60-0.76) 8 (5-21) 0.55 (0.46-0.64) 6 (4-15)
   Females 0.44 (0.38-0.52) <.0001 0.82 (0.80-0.84) 11 (9-14) 0.62 (0.59-0.64) 6 (5-7)
Age (years)
   ≤46.0 0.33 (0.24-0.46) <.0001 0.83 (0.79-0.86) 9 (7-14) 0.60 (0.55-0.66) 5 (3-6)
   46.0-62.7 0.46 (0.37-0.56) <.0001 0.80 (0.78-0.83) 10 (8-14) 0.67 (0.64-0.71) 7 (5-9)
   >62.7 0.60 (0.48-0.76) <.0001 0.81 (0.77-0.84) 14 (9-28) 0.52 (0.47-0.58) 7 (5-13)
Cirrhosisb
   No 0.32 (0.24-0.42) <.0001 0.92 (0.90-0.95) 20 (14-34) 0.71 (0.66-0.76) 6 (5-8)
   Yes 0.31 (0.24-0.40) <.0001 0.48 (0.42-0.54) 4 (3-5) 0.33 (0.27-0.39) 3 (3-4)
Disease stagec
   Early 0.37 (0.30-0.47) <.0001 0.92 (0.91-0.94) 22 (17-32) 0.78 (0.75-0.80) 8 (6-11)
   Intermediate 0.32 (0.25-0.40) <.0001 0.62 (0.57-0.67) 5 (4-6) 0.22 (0.17-0.28) 3 (3-4)
   Advanced 0.50 (0.37-0.70) 0.0001 0.26 (0.20-0.34) 5 (3-8) 0.14 (0.92-0.20) 5 (4-9)
ALP
   ≤ 2x ULN 0.61 (0.45-0.82) 0.0014 0.90 (0.87-0.92) 26 (15-70) 0.79 (0.75-0.82) 13 (8-35)
   2-4x ULN 0.46 (0.36-0.59) <.0001 0.82 (0.79-0.85) 11 (8-17) 0.59 (0.56-0.64) 6 (4-8)
   > 4x ULN 0.36 (0.25-0.52) <.0001 0.66 (0.62-0.70) 5 (4-8) 0.41 (0.36-0.46) 4 (3-5)
Bilirubin
   ≤ ULN 0.39 (0.32-0.48) <.0001 0.91 (0.90-0.92) 19 (15-27) 0.75 (0.72-0.78) 7 (6-10)
   > ULN 0.40 (0.33-0.48) <.0001 0.49 (0.45-0.53) 4 (4-5) 0.20 (0.16-0.25) 4 (3-4)
Albumin
   < LLN 0.32 (0.24-0.43) <.0001 0.35 (0.29-0.41) 3 (3-4) 0.15 (0.11-0.21) 3 (3-4)
   ≥ LLN 0.46 (0.40-0.54) <.0001 0.87 (0.86-0.89) 16 (13-21) 0.68 (0.66-0.71) 7 (6-9)
Platelet count
   < 150x109 0.48 (0.35-0.46) 0.0007 0.52 (0.47-0.58) 5 (4-9) 0.27 (0.22-0.34) 4 (3-7)
   ≥ 150x109 0.44 (0.37-0.52) <.0001 0.86 (0.84-0.87) 14 (11-18) 0.68 (0.65-0.70) 7 (5-8)
ᵃ The Hazard Ratios were adjusted for sex, age, year of diagnosis, albumin, platelet count, bilirubin, alkaline 
phosphatase, aspartate aminotransferase and alanine aminotransferase;
b Baseline histological data was available for 2173 patients;
c Biochemical disease stage according to Rotterdam criteria29;
Abbreviations: 5y, 5 years; 10y, 10 years;  adj., adjusted; ALP, alkaline phosphatase; CI, confidence interval; HR, 
hazard ratio; LLN, lower limit of normal; LT, liver transplantation; NNT, number needed to treat; PBC, primary 
biliary cholangitis; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.
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Figure 3. HR of UDCA on LT-free survival according to the GLOBE score. The graph shows a non-linear 
relationship, in which the function of the GLOBE score was significant to the fourth degree. 
Abbreviations: HR, hazard ratio; UDCA, ursodeoxycholic acid. 
Figure 4. Individualized NNT5y according to the GLOBE score, visualized against the estimated 5-year risk of 
liver transplantation or death. The solid line represents the estimated 5-year risk of LT or death, plotted against 
the right Y-axis. The dotted line represents the number needed to treat for 5 years to prevent the occurrence of 
one LT or death, plotted against the left Y-axis. The grey bars represent a histogram of the number of patients in 
our cohort according to their GLOBE score, plotted against the left Y-axis. 
Abbreviations: LT, liver transplantation; NNT, number needed to treat.
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0.24-0.46]) as compared to those in the interquartile age range (46.0-62.7 years; 0.46 
[95%CI 0.37-0.56]) and the oldest quartile of patients (>62.7 years; 0.60 [95%CI 0.48-0.76]), 
while the cumulative 5-year LT-free survival rates without UDCA were rather similar among 
the three age groups. The stronger adjusted HR of UDCA among patients ≤46 years resulted 
in an adjusted NNT5y to prevent one LT or death of 9 [95%CI 7-14), which was lower as 
compared to 10 (95%CI 8-14) in those aged 46.0-62.7 years and 14 (95%CI 9-28) in those 
older than 62.7 years.
Predicted Individual NNT to prevent one liver transplantation or death 
In the untreated population, the discriminative ability of the GLOBE score was strong with 
a C-statistic of 0.81 (95% CI 0.78 - 0.85). The observed 5-year transplant-free survival was 
in line with the predicted estimates using the GLOBE score (Figure 2). Figure 3 shows the 
polynomial function of the HR of UDCA according to the GLOBE score, which was significant 
to the fourth degree. Using the estimated 5-year survival that relates to every value of the 
GLOBE score, we predicted the NNT5y for any given GLOBE score (Figure 4). A NNT5y ≤10 to 
prevent one LT/death is achieved in patients with a GLOBE score ≥0.94 (NNT10y=5), a NNT5y 
of 20 in patients with a GLOBE score of 0.10 (NNT10y=9), while the NNT5y is ≥50 in case the 
GLOBE score is <-0.62 (NNT10y=20).
Relative Risk Reduction versus Absolute Risk Reduction According to Biochemical Response
In our cohort, 2084 (59.1%) UDCA-treated patients had an ALP<1.67 xULN at year 1, and their 
5- and 10-year LT-free survival rates were 94.0% and 84.7%. These patients had a lower risk 
of LT or death (adjusted HR 0.35, 95%CI 0.29-0.42, p<0.0001) as opposed to those without 
UDCA. In contrast, 1445 (40.9%) patients had an suboptimal biochemical response. In these 
patients the 5- and 10-year LT-free survival rates were 88.0% and 70.9%. Although less strong, 
a suboptimal response to UDCA remained associated with a statistically significantly lower 
risk of LT or death as compared to no UDCA (adjusted HR 0.42, 95%CI 0.36-0.50, p<0.0001). 
Among patients with an ALP<1.67 xULN, the median GLOBE score prior to UDCA treatment 
was -0.0266, which translates into estimated 5- and 10-year LT-free survival rates of 94.0% 
and 84.7%. As a result, the NNT was 26 (95%CI 24-29) and 11 (95%CI 10-12) to prevent 1 LT 
or death in 5 or 10 years, respectively. In contrast, the median GLOBE score prior to UDCA 
treatment was 0.6978 among patients with a suboptimal biochemical response, leading to 
estimated 5- and 10-year LT-free survival rates of 88.0% and 70.9%. As a result, their NNT5y 
was 15 (95%CI 14-18) and the NNT10y was 7 (95%CI 6-8).
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DISCUSSION
In our large international cohort, the overall number of patients with PBC which needed to 
be treated with UDCA to prevent one LT or death within five years was 11, as the related 
relative risk reduction was 2.2 and the cumulative 5-year incidence of LT/death in untreated 
patients was approximately 19%. This NNT, as absolute measure of clinical efficacy, 
further decreased in case one LT/death had to be prevented over longer periods of time. 
This is relevant, as UDCA is recommended as lifelong therapy for patients with PBC. The 
NNT fluctuated according to the baseline patient characteristics, which is predominantly 
explained by differences in the natural history of PBC in various subgroups. Nevertheless, 
the clinical efficacy of UDCA in terms of the number needed to treat to postpone one LT or 
death with at least five years can be considered low throughout. 
In the current study, the NNT was assessed across all relevant patient subgroups. We 
previously found that the relative reduction in the risk of LT/death associated with UDCA was 
generally stable8. For instance, the HR of UDCA was similar among patients with cirrhosis 
(HR 0.33) and patients without cirrhosis (HR 0.31). However, the absolute clinical efficacy 
of UDCA was considerably lower among patients with cirrhosis (NNT5y 4) as compared to 
those without cirrhosis (NNT5y 20). This difference is explained by the substantially higher 
cumulative 5-year incidence of LT/death in untreated patients with cirrhosis (52%) than 
in those without cirrhosis (7%). This emphasizes the relevance of appreciating the clinical 
setting when evaluating the clinical benefit of a therapeutic intervention, which is considered 
when using the NNT as a measure of efficacy. The relative risk reduction associated with 
UDCA with respect to LT/death did differ according to ALP, age and albumin8. ALP is an 
established prognostic marker for long-term outcome12, 22. Among patients with a high ALP 
level (>4 ×ULN) the HR of UDCA was stronger and the cumulative 5-year incidence of LT/
death in absence of treatment was higher in comparison to patients with lower ALP levels. 
Both factors contributed to the considerably lower NNT5y to prevent LT/death in patients 
with high ALP (5) than in those with low ALP levels (≤2 ×ULN: 26) before the initiation of 
UDCA. Young age was associated with a stronger relative risk reduction related to UDCA 
treatment. Although younger age is normally inversely associated with the risk of death, 
patients that develop PBC at young age are known to have a more aggressive phenotype23.
Indeed, the cumulative LT-free survival among untreated PBC patients ≤46 years in our 
cohort was similar as compared to that of older patient subgroups. As a result, the NNT5y 
was only slightly lower in patients ≤46 years (9) as compared to patients aged 46-63 years 
(10) and >63 (14). In line with the above, the absolute clinical efficacy of UDCA therapy 
was stronger among patients with a suboptimal biochemical response at year 1, despite an 
inferior relative risk reduction. Although this might seem counterintuitive, this is explained 
by the impaired untreated LT-free survival in these patients when compared to those with 
an ALP < 1.67 xULN after year 1. 
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As exemplified in the previous paragraph, the untreated prognosis strongly affects the 
absolute clinical efficacy of UDCA. For an individual patient, multiple baseline characteristics 
need to be considered, while it would be desirable to estimate a single patient-specific NNT. 
We showed that the GLOBE score, originally developed as an objective tool to estimate LT-
free survival after 1 year on UDCA treatment, also accurately predicts prognosis in untreated 
patients. Hereafter, we estimated the individualized clinical efficacy of UDCA according to 
the GLOBE score. In this analysis we allowed the HR of UDCA to fluctuate with the GLOBE 
score as it incorporates ALP and age, the two variables with most profound and significant 
impact on the relative risk reduction of UDCA. An estimation of an individual NNT can be 
helpful for patient counseling and supporting therapeutic compliance. For example, patients 
might be more willing to accept perceived side effects due to an improved understanding of 
the expected absolute risk reduction. Noteworthy is that a high NNT with UDCA was usually 
a result of a favorable natural history rather than the absence of a relative benefit of UDCA.
To the best of our knowledge, this is the first study to assess the benefit of UDCA treatment 
in PBC in absolute risk reduction as measured by the NNT to prevent clinical endpoints. 
Assessment of the NNT is rare in the field of hepatology, but has recently gained popularity 
in many other fields of medicine. The advantage of the NNT is that it is easy to interpret for 
both patients and physicians as it combines the therapy-induced relative risk reduction and 
the patients’ a priori risk of unfavorable outcome in a single parameter. The NNT can be 
expressed for any given treatment duration, which is especially relevant for chronic diseases 
such as PBC in which lifelong treatment is required. While policymakers may be interested 
in long-term effects of therapy, patients are more likely to prioritize short-term benefits. 
Moreover, physicians’ willingness to treat is reported to be dependent of the measure in 
which treatment benefit is presented. Providing information on both relative and absolute 
clinical efficacy may therefore prevent misinterpretation and aid well-informed decision 
making in daily clinical practice24-26. As part of our study we validated the GLOBE score to 
accurately predict the LT-free survival in untreated patients with PBC. The availability of such 
an objective natural history score is relevant, also in light of novel second-line therapies 
which will no longer be compared with a placebo arm given the strong evidence for a 
beneficial effect of UDCA for all patients with PBC8. The GLOBE score can thus aid to evaluate 
the potential additional benefit of new drugs that are added to treatment with UDCA, and 
might be preferable over older prediction models such as the Mayo Risk Score as it is solely 
based on readily available and objective parameters27.  
Strengths of the current study include the use of a large, internationally representative 
cohort with long-term follow-up and many clinical endpoints in both UDCA-treated and 
untreated patients. Furthermore, to ensure accurate estimation of the NNT, both the 95% 
CI of the HR of UDCA as well as the CI of the estimated survival in the untreated population. 
A number of limitations should also be noted. First, a potential selection bias in this study 
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is represented by the fact that the majority of included patients were treated in tertiary 
liver centers. Second, potential improvement in survival within the timespan that is chosen 
to express the NNT is not considered when using the NNT as measure of risk reduction, 
which could thus lead to an underestimation of treatment benefit. Third, the NNT assumes 
a causal relationship between UDCA and prolonged LT-free survival. This has long been 
subject to debate, especially due to Cochrane reporting an absence of treatment benefit28. 
As this is a retrospective study in which IPTW was used to adjust for the small differences in 
baseline characteristics, residual confounding can never be fully ruled out. We are lacking 
data on the reasons for not treating PBC patients with UDCA, but especially shortly after its 
introduction it can be hypothesized that physicians may have been unaware of UDCA or not 
convinced about its benefits. Also, patients may have been unwilling to use this relatively 
new drug at that time. Because UDCA has no relevant contra-indications, however, we 
consider it to be unlikely that the association between UDCA and improved LT-free survival 
is completely confounded by a patient-related factor which would have influenced both the 
chance of receiving UDCA and the risk of LT or death. In fact, both the positive association 
with clinical outcome in extensively adjusted analyses in large cohort studies, and the 
finding of an improved LT-free survival in UDCA-treated patients with advanced disease in 
an older randomized controlled trial, have provided a general consensus on the assumed 
causal UDCA treatment benefit6-8, 29. 
In conclusion, in this first study to assess the efficacy of UDCA in absolute measures, we 
report that the NNT with UDCA to prevent LT or death is generally low, but can be assessed 
for individual patients with PBC. These results provide a clear understanding of the clinical 
importance of optimized UDCA therapy for patients and doctors, thereby stimulating 
compliance and treatment uptake.
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CHAPTER 6
CLINICAL APPLICATION OF THE GLOBE 
SCORE AND UK-PBC SCORE IN A REAL 
WORLD TRIAL COHORT OF PATIENTS 
WITH PRIMARY BILIARY CHOLANGITIS    
Hepatology Communications, 2018
ABSTRACT
Introduction The Global Primary Biliary Cholangitis (PBC) Study Group and United Kingdom-
PBC (UK-PBC) Consortium have demonstrated that dichotomous response criteria are not 
as accurate as continuous equations at predicting mortality or liver transplantation in PBC. 
The aim of this analysis was to assess the clinical utility of the GLOBE and UK-PBC risk scores 
using data from POISE, a phase 3 trial investigating obeticholic acid (OCA) in patients with 
PBC. 
Methods Data (N 5 216) at baseline and month 12 were used to calculate the GLOBE and UK-
PBC risk scores to assess the projected change in risk with OCA versus placebo. Additionally, 
the benefit of OCA was assessed in patients not meeting the POISE primary endpoint. 
Results Both the GLOBE and UK-PBC risk scores predicted a significant reduction in long-term 
risk of death and liver transplantation after OCA treatment (P < 0.0001). The differences in 
the relative risk reduction from baseline in the 10-year event risk after 1 year for OCA 10 mg 
versus placebo was 26% (GLOBE) and 37% (UK-PBC). The scores also predicted a significantly 
decreased risk in patients treated with OCA who did not meet POISE response criteria after 
1 year of treatment compared to an increased risk with placebo (P < 0.0001). 
Conclusion This analysis demonstrates the use of the GLOBE and UK-PBC risk scores to 
assess risk reduction of a cohort treated with OCA. While validation of this risk reduction 
in studies with clinical outcomes is needed, this study highlights the potential use of these 
scores in individualizing risk prediction in PBC both in clinical practice and therapeutic trials.
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INTRODUCTION
In primary biliary cholangitis (PBC), progression of liver disease is highly variable1,2.In many 
cases, the disease is detected at an early stage and treatment with ursodeoxycholic acid (UDCA) 
improves biochemistry, impedes hepatic fibrosis, and can restore normal life expectancy3-5. 
However, in a substantial proportion of patients, the response to treatment with UDCA is 
inadequate. These patients experience progressive liver disease that may eventually lead to 
liver failure or hepatocellular carcinoma6. It is well established that the liver biochemistry on 
treatment with UDCA strongly predicts long-term outcomes in PBC7-11. 
The response to treatment with UDCA (so-called UDCA response) may therefore be defined 
in terms of the liver biochemistry measured at a specific time (usually 12 months) after 
starting treatment. Several definitions of the UDCA response have been proposed7-11.
One of these definitions was the Toronto criteria, and a composite of Toronto along with 
other criteria were used to define treatment response criteria for POISE, a phase 3 trial of 
treatment with obeticholic acid (OCA) reported by Nevens et al 12. By these criteria, response 
was defined as alkaline phosphatase (ALP) ) <1.67 x the upper limit of normal (ULN), 15% 
reduction in ALP, and total bilirubin ULN. For prognostication, definitions of UDCA response, 
such as the Toronto, Paris, Rotterdam, and Barcelona criteria, have two major limitations: 
first, they dichotomize UDCA response and thereby the long-term risk of death or liver 
transplantation (LT), whereas both are, in reality, a continuum; second, they do not account 
for the stage of disease. Two independent research groups, the Global PBC Study Group and 
the United Kingdom (UK)-PBC Consortium, developed and externally validated continuous 
prognostic models (the GLOBE score and UK-PBC risk score, respectively) that address these 
limitations13,14. These models include the liver biochemistry following treatment with UDCA 
as well as surrogate measurements of disease stage (e.g., serum albumin and platelet count). 
They estimate the risk of LT or death (overall death for the GLOBE score and liver-related 
death for the UK-PBC risk score) in patients with PBC at specific time points. Both scores 
outperformed previous response criteria7-11,13,14 in terms of prognostic utility and could 
potentially help physicians identify patients at high risk of disease progression and in need 
of second-line therapy. They have also been validated in patients not treated with UDCA, 
strongly suggesting that such scoring systems reflect disease activity and stage expressed by 
the laboratory investigations, regardless of treatment. Recently published guidelines from 
the European Association for the Study of the Liver propose these criteria as tools to select 
patients for second-line therapies and possibly for a better design of clinical trials in PBC in 
the future15. 
The aim of this study was to explore the utility of the GLOBE score and UK-PBC risk score 
in a trial data set comprising individual patient data from the phase 3 POISE trial of OCA. 
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In addition, we use validated risk scores to evaluate the predicted risk reduction of OCA 
therapy in patients with PBC who inadequately respond to UDCA. 
METHODS 
Study population
The patient demographics and study design of the POISE trial were reported by Nevens 
and colleagues12 (Table 1). Briefly, POISE was a phase 3, randomized, double-blind, placebo-
controlled trial. PBC diagnosis was defined by American Association for the Study of Liver 
Diseases and European Association for the Study of the Liver guidelines15,16. Patients were 
recruited across 13 countries. All patients were over 18 years old, met the study entry 
criteria of ALP 1.67 3 ULN and/or total bilirubin >ULN but 0.80). Similar results were found 
when the score was validated in an untreated population, with a C statistic of 0.81. 
GLOBE score
The GLOBE score has recently been validated externally17. 
GLOBE score = 
0.044378 x age at start of UDCA therapy + 0.93982 x ln(bilirubin x ULN at 1 year follow-up) 
+ 0.335648 x ln(ALP x ULN at 1 year follow-up) – 2.266708 x albumin level x the lower limit 
of normal (LLN) at 1 year follow-up - 0.002581 x platelet count per 109 /L at 1 year follow-up 
+ 1.216865. 
UK-PBC risk score 
Derivation of the UK-PBC risk score has been described in detail13. The score was developed 
based on 1,916 UDCA-treated participants from the UKPBC Research Cohort. The final 
model, shown below, consisted of the baseline albumin and platelet count as well as total 
bilirubin, transaminases, and ALP after 12 months of UDCA treatment. Linear predictors 
and baseline survivor functions were combined in equations to score the risk of an LT or 
liver-related death occurring within 5, 10, or 15 years. The risk score was validated in an 
independent cohort of 1,249 UDCA-treated participants from the UK-PBC Research Cohort. 
In the validation cohort, the 5-, 10-, and 15-year risk scores were highly accurate (C statistic 
>0.90). Similar results were found when the score was validated in an untreated population 
from the United Kingdom. The UK-PBC risk score has recently been validated externally17. 
UK-PBC risk score = 
1 – baseline survival function^exp(0.0287854 x [ALP after 12 months of therapy x ULN 
– 1.722136304] – 0.0422873 x [((ALT where this was available, otherwise AST, after 12 
months of therapy x ULN/10)^–1) – 8.675729006] + 1.4199 x [ln(bilirubin after 12 months of 
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therapy x ULN/10) + 2.709607778] – 1.960303 x [albumin at baseline x LLN – 1.17673001] – 
0.4161954 x [platelet count at baseline x LLN –1.873564875]). 
Statistical analyses
Individual patient data at baseline and month 12 from the POISE trial were used to calculate 
both scores to compare the projected improvement in risk/ survival after 1 year of OCA 
treatment versus placebo in patients enrolled in the POISE trial. The P value for comparing 
each OCA treatment to placebo is obtained using the rank analysis of covariance model 
with baseline value as a covariate. Individual baseline values were based on a mean of all 
available study evaluations prior to OCA treatment or placebo. In order to evaluate the 
change in risk using the GLOBE score, the participant’s contemporaneous age was used in 
place of his or her age at the start of UDCA therapy. P < 0.05 was considered significant. All 
calculations represented were determined using SAS version 9.4.
RESULTS 
The demographic characteristics of the POISE trial cohort are reported in the original 
publication12. In summary, average (± SD) age was 56 ± 10 years, 91% of patients were female, 
and 94% Caucasian. The average age at time of PBC diagnosis was 47 ± 11 years, with 93% 
of patients receiving UDCA for >12 months prior to the beginning of the trial, with a mean 
daily dose of 16 ± 5 mg/kg. All three patient groups were generally well balanced, as shown 
in Table 1. As reported by Nevens et al.12, there was a statistically significant reduction of 
the least squares mean values of ALP, ALT, and AST, both in the OCA 5- 10-mg and the OCA 
10-mg dose groups compared to the placebo group after 12 months of OCA treatment 
(Table 2). There was a statistically significant difference in mean total bilirubin level in 
Table 1. Baseline Demographics
Placebo ± UDCA
(n=73)
OCA 5-10 mg ± UDCA
(n=70)
OCA 10 mg ± UDCA
(n=73)
Age, years 56 ± 10 56 ± 11 56 ± 11
Female, n (%) 68 (93) 65 (93) 63 (86)
Caucasian, n (%) 66 (90) 67 (96) 70 (96)
Weight, kg 70 ± 13 68 ± 13 71 ± 15
BMI, kg/m2 26 ± 4 26 ± 5 26 ± 5
UDCA use, n (%) 68 (93) 65 (93) 67 (92)
Daily UDCA dose, mg/kg 15 ± 4 17 ± 5 16 ± 5
Duration PBC, years 8 ± 5 8 ± 6 9 ± 7
Data are Mean ± SD where applicable
Abbreviations: UDCA, ursodeoxycholic acid; OCA, obeticholic acid.
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both treatment groups compared to the placebo group after 12 months of treatment. No 
statistical differences were found in the albumin and platelet count between the three arms. 
Scatter plots showing changes in the laboratory measurements (included in the scores) 
after 12 months of treatment and their relationship with the primary composite endpoint 
(POISE criteria) used in the trial are shown in Figure 1. Nearly all OCA-treated patients had 
a biochemical improvement in ALP, AST, and ALT, including those who did not meet the trial 
response criteria. No significant differences between OCA and placebo were observed in 
change from baseline for albumin or platelet count. Baseline and 12-month POISE data were 
used to calculate the GLOBE score and UK-PBC risk score. Complete biochemical data at 12 
months were available for 68, 60, and 59 patients in the placebo, OCA 5-10-mg, and OCA 
10-mg treatment groups, respectively. After 12 months of treatment with OCA 6 UDCA, both 
scores showed reductions in median risk. Assessment of the change in 5-, 10-, and 15-year 
event risk associated with OCA is shown in Figure 2. The comparisons between OCA and 
placebo arms on the reduction of event risk achieved statistical significance for both OCA 
dosages across all time points (P < 0.0001). Both models predicted improvements in long-
term (liver-related and all-cause) risk of mortality or LT after OCA treatment. Furthermore, 
both models predicted increased risk over time in patients receiving placebo for 1 year, 
despite 93% of patients receiving concomitant UDCA, the current standard of care for 
PBC. While both scores showed improvements in projected risk reductions for the OCA 
treatment groups, the GLOBE score tended to indicate greater worsening in projected risk 
after 1 year of the placebo group compared with risk predicted by the UK-PBC risk score. 
Using the GLOBE score, the differences in relative risk reduction from baseline in LT or all-
cause mortality after 5, 10, and 15 years between OCA 5-10 mg and placebo were 26.9%, 
23.5%, and 20.2%, respectively (Table 3). Comparing the difference between OCA 10 mg and 
placebo, the relative risk reductions were 29.6%, 25.8%, and 22.0%, respectively. Applying 
the UK-PBC risk score, the differences in relative risk reductions from baseline between OCA 
5- 10 mg and placebo of LT or liver-related death after 5, 10, and 15 years were 33.7%, 32.2%, 
and 30.6%, respectively. The differences in relative risk reduction between OCA 10 mg and 
placebo were 39.1%, 37.2%, and 35.6%, respectively. Previous studies have demonstrated 
that patients who are diagnosed with PBC at younger ages may be less likely to respond to 
UDCA therapy2. The change in risk following OCA treatment in both scores was assessed 
above and below the median age of diagnosis (48 years) in POISE (Supporting Figure S1). 
Both subgroups showed a change in risk consistent with the total POISE cohort.
Patients treated with OCA and diagnosed before the age of 48 years showed a significant 
reduction (P < 0.01) in risk across all estimated time points with the GLOBE score and UK-PBC 
risk score in contrast to an increase in risk in placebo-treated patients (Supporting Figure 
S1A,B). Similarly, patients diagnosed after the age of 48 or older had significant reductions 
in projected risk with OCA treatment (P < 0.01) with both scores compared to an increase 
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Table 2. Laboratory Measures at Baseline and 12 Months
Placebo ± UDCA
(n=73)
OCA 5-10 mg ± UDCA 
(n=70)
OCA 10 mg ± UDCA
(n=73)
ALP (U/L)
Baseline 327.5 (115.0) 325.9 (116.2) 316.34 (103.9)
12 Months 321.3 (142.9) 219.5 (99.8) 192.3 (61.3)
Change from Baseline -14.4 (14.7) -112.5 (14.4)*** -129.9 (14.6)***
AST (U/L)
Baseline 48.8 (22.4) 52.3 (25.3) 50.5 (31.1)
12 Months 51.6 (39.0) 39.5 (25.1) 36.4 (19.2)
Change from Baseline 1.0 (4.2) -13.0 (4.2)** -15.0 (4.3)***
ALT (U/L)
Baseline 56.0 (30.3) 61.6 (39.0) 56.3 (39.7)
12 Months 52.8 (28.5) 39.0 (33.9) 32.1 (20.6)
Change from Baseline -5.0 (3.3) -21.3 (3.3)*** -25.3 (3.4)***
Total Bilirubin (µmol/L)
Baseline 11.8 (7.2) 10.2 (5.5) 11.3 (6.6)
12 Months 13.2 (8.7) 9.9 (4.8) 9.7 (4.7)
Change from Baseline 2.0 (0.7) -0.3 (0.7)** -0.9 (0.7)***
Albumin (g/L)
Baseline 42.8 (3.1) 43.0 (3.1) 43.7 (2.7)
12 Months 41.8 (3.6) 42.7 (3.5) 43.1 (3.3)
Change from Baseline -1.2 (0.4) -0.6 (0.4) -0.9 (0.4)
Platelets (109/L)
Baseline 223.6 (87.1) 224.8 (79.6) 232.9 (87.8)
12 Months 222.5 (101.6) 225.4 (87.0) 228.5 (78.7)
Change from Baseline 6.5 (8.4) 4.9 (8.2) 2.9 (8.5)
Patient Age
Baseline 55.5 (10.0) 55.8 (10.5) 56.2 (11.0)
12 Months 56.3 (10.2) 56.6 (10.0) 56.2 (10.2)
Baseline and 12 months are Mean (SD), change from baseline data are LS Mean (SE). **p<0.01, ***p<0.0001. 
P-value for comparing active treatments to Placebo is obtained using an ANCOVA model with baseline value as a 
covariate and fixed effects for treatment and randomisation strata factor.
Abbreviations: UDCA, ursodeoxycholic acid; OCA; obeticholic acid; ALP, alkaline phosphatase; AST, asparate 
aminotransferase; ALT, alanine aminotransferase.
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Figure 1. Individual Values in the Biochemical Components of the Globe and UK-PBC Scores. (A) ALP (U/L). (B) 
Total bilirubin (µmol/L). (C) ALT (U/L). (D) AST (U/L). (E) Albumin (g/L). (F) Platelet Count (x 109/L). All pati ents 
are identi fi ed as having met the POISE primary response criteria or not.  The diagonal line through each plot 
represents 0% change from baseline; in fi gure (A) a second diagonal line shown represents a 15% reducti on. 
Abbreviati ons: UDCA, ursodeoxycholic acid; OCA; obeti cholic acid; ALP, alkaline phosphatase; AST, asparate 
aminotransferase; ALT, alanine aminotransferase.
F
E
Figure 2. Improvements in Risk with GLOBE Score and UK-PBC Risk Score Aft er 12 Months of OCA Treatment. 
(A) Predicted median (Q1, Q3) change in risk from baseline with the Globe score. (B) Predicted median (Q1, Q3) 
change in risk from baseline with the UK-PBC risk score. P<0.0001 for all values in OCA treatment arms in both 
models. P-value for comparing acti ve treatments to Placebo is obtained using the Rank ANCOVA model with 
baseline value as a covariate.
Abbreviati ons: UDCA, ursodeoxycholic acid; OCA; obeti cholic acid; IQR, interquarti le range.
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Table 3. Median Difference in Risk Between Placebo and OCA Treatment Groups After 12 Months of Treatment
Difference in Estimated Scores Relative Difference in Estimated Scores†
OCA 5-10 mg ─ 
Placebo
(n=60)
OCA 10 mg ─ 
Placebo  
(n=59)
OCA 5-10 mg ─ 
Placebo
(n=60)
OCA 10 mg ─ 
Placebo  
(n=59)
GLOBE Score
5 years
-2.34 
(-3.49, -1.30)
-2.56 
(-3.65, -1.57)
-26.94 
(-38.03, -14.75)
-29.62 
(-40.69, -18.82)
10 years
-5.15 
(-7.43, -2.92)
-5.67 
(-7.72, -3.53)
-23.51 
(-33.49, -12.75)
-25.78 
(-35.64, -16.60)
15 years
-6.83 
(-9.94, -3.81)
-7.38 
(-10.19, -4.74)
-20.20 
(-28.97, -10.69)
-22.02 
(-30.35, -13.85)
UK-PBC Risk Score
5 years
-0.80 
(-1.22, -0.40)
-0.87 
(-1.26, -0.53)
-33.65 
(-49.64, -17.39)
-39.05 
(-54.44, -23.76)
10 years
-2.47 
(-3.70, -1.26)
-2.69 
(-3.85, -1.68)
-32.18 
(-47.87, -16.74)
-37.24 
(-52.48, -22.96)
15 years
-4.06 
(-6.20, -2.14)
-4.58 
(-6.52, -2.83)
-30.64 
(-45.81, -15.83)
-35.59 
(-49.94, -21.66)
P<0.0001 for all values in OCA treatment arms in both models. All values are Median (95% CI). †Relative 
differences are based on median differences in % change from baseline between Placebo and OCA.
Abbreviations: UDCA, ursodeoxycholic acid; OCA, obeticholic acid.
in risk with placebo (Supporting Fig. S1C,D). Finally, we explored the change in risk for the 
subgroup of patients classified as inadequate responders to OCA therapy at 12 months. The 
median change in risk in patients not meeting the POISE primary endpoint after 12 months 
of OCA, which requires ALP below 1.67 3 ULN with at least a 15% reduction in ALP and 
total bilirubin at or below ULN, is shown in Figure 3. Patients who did not meet the POISE 
response criteria at month 12 had significant improvements in estimated risk at 5, 10, and 
15 years with both scores compared to placebo (P < 0.01). We also evaluated the change 
in risk for patients classified as non-responders by alternative response criteria, including 
Paris, Rotterdam, Toronto, and Barcelona. For patients who had an inadequate response 
by these criteria, we report the median change in projected risk following 12 months of 
treatment as well as median baseline risk for context. Patients classified as non-responders 
by these criteria showed significant improvements in estimated event risk at 5, 10, and 15 
years with both scores after 1 year of OCA treatment compared to placebo in most cases 
(Supporting Table S1). 
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Figure 3. Risk Improvement in OCA “Non-Responders” with GLOBE Score and UK-PBC Risk Score Aft er 12 
Months of OCA Therapy. (A) Predicted median (Q1, Q3) change in risk from baseline with the Globe score. (B) 
Predicted median (Q1, Q3) change in risk from baseline with the UK-PBC risk score. P<0.01 for all values in OCA 
treatment arms in both models. P-value for comparing acti ve treatments to Placebo is obtained using the Rank 
ANCOVA model with baseline value as a covariate.
Abbreviati ons: UDCA, ursodeoxycholic acid; OCA, obeti cholic acid; IQR, interquarti le range.
DISCUSSION
In this analysis, we quanti fi ed the projected risk– benefi t of OCA treatment in pati ents with 
PBC who inadequately responded or were intolerant to UDCA by applying liver biochemistry 
data from the phase 3 POISE trial to both the GLOBE score and UK-PBC risk score. Our 
fi ndings promote the uti lity of such scoring systems in a clinical trial setti  ng. Moreover, 
these results shed further light on the nature and scale of benefi t from OCA treatment as 
demonstrated in the POISE trial by Nevens et al12. Our analysis has two major conclusions. 
The fi rst is that while the dichotomous POISE trial criteria accurately strati fy pati ents into 
those at low or high risk of clinical outcomes, the GLOBE score and UK-PBC risk score enable 
the anti cipated survival benefi t for PBC pati ents treated with OCA to be quanti fi ed. This is 
an important step forward in assessing the eff ecti veness of OCA therapy and other potenti al 
new therapies for PBC. 
The second conclusion is that the use of dichotomous response criteria in the POISE trial may 
underesti mate therapeuti c benefi t. This fi nding is aligned with those presented in the studies 
in which the GLOBE score and UK-PBC risk score were developed and validated as well as 
with the results from a Chinese study validati ng this in a long-term follow-up cohort18. These 
studies all reported that the GLOBE score and UK-PBC risk score were superior in identi fying 
pati ents with inadequate treatment response when compared to dichotomous response 
criteria in populati ons of pati ents with PBC that were treated with UDCA monotherapy13,14.
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Importantly, we found OCA treatment to be associated with a significant benefit of projected 
survival, even in patients not reaching the threshold for response by the original POISE 
criteria and other well-known dichotomous response criteria. This is a result of the inability 
of the trial criteria to take into account high baseline levels of ALP and/or total bilirubin 
and subsequent improvements in these markers, which were robust but did not meet the 
thresholds defined by the primary endpoint. For example, patients with highly elevated 
ALP levels at baseline (i.e., the highest risk group, in greatest need of improvement) were 
less likely to meet the dichotomous response criteria even when a substantial reduction 
of ALP and/or total bilirubin was seen. The therapeutic benefit overlooked by using the 
dichotomous trial criteria not only implies an underestimation of efficacy but could also 
impact future treatment options for the most severely affected patients, especially given 
the current cost–utility analysis of OCA as measured by the incremental cost-effectiveness 
ratio threshold that may not be applicable to a rare disease19. 
In this analysis, we observed differences in the projected risks between the GLOBE score 
and the UKPBC risk score. These differences are most likely explained by the different 
endpoints used in the two scores; the GLOBE score takes into account LT and all-cause 
mortality while the UK-PBC risk score considers LT and liver-related death. Consequently, 
as the GLOBE score considers all causes of death, the baseline risk of an endpoint is higher 
using the GLOBE score. Likewise, the risk of all-cause mortality increases faster over time 
(with aging) than the risk of liver-related death and therefore shows a steeper trajectory of 
risk for the GLOBE score. We acknowledge that the two scoring systems were developed to 
predict adverse outcome in patients taking UDCA. Neither score was validated in patients 
taking OCA. We believe the scores are applicable in the current context, however, because 
both were validated in cohorts of patients who had not received treatment with UDCA. 
Nevertheless, neither score can identify effects of OCA independent of those reflected by 
changes in liver biochemistry on treatment. In addition, we acknowledge the limitation that 
both scores depend on endpoints that are surrogates for clinical outcomes. Although these 
surrogate endpoints for outcome are likely to be accurate, other factors, such as toxicity 
or other adverse events, should not be overlooked when evaluating risks and benefits of 
new therapeutic agents. Therefore, the accuracy of predictions in the current analysis await 
confirmation by the ongoing phase 4 trial of OCA evaluating clinical outcomes in patients 
with PBC (COBALT; NCT02308111)20. This analysis showed a median reduction in the 10-
year event risk of 2.1% using the GLOBE score and 1.3% using the UK-PBC risk score after 
12 months of treatment with OCA 10 mg compared to a median increase of 3.3% (GLOBE) 
and 1.1% (UK-PBC) after 12 months of placebo. This represents a difference in relative risk 
reduction from baseline between OCA 10 mg and placebo of 25.8% with the GLOBE score and 
37.2% with the UK-PBC risk score. However, we emphasize that this is a selected trial cohort. 
In a real-life population with more advanced or aggressive disease, the impact of this new 
treatment might be different. Importantly, transient elastography is not included in either of 
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the scores. Despite the prognostic value of transient elastography21-23, a great advantage of 
both presented risk scores in our study is that they are able to predict outcomes accurately 
based on readily available biochemical parameters and without the need for a dedicated 
instrument and skilled operator required for transient elastography. 
In conclusion, we found that 1 year of OCA therapy was projected by both scores to reduce 
the risk of death and LT in this patient population, including patients not meeting the 
dichotomous POISE primary endpoint. We believe that the application of the GLOBE score 
and UK-PBC risk score in clinical practice would be an important step toward individualizing 
risk prediction in PBC and may eventually replace the use of other dichotomous therapy 
response criteria in clinical practice.
144 CHAPTER 6
REFERENCES
1)  Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al.; 
Global PBC Study Group. Levels of alkaline phosphatase and bilirubin are surrogate end 
points of outcomes of patients with primary biliary cirrhosis: an international follow-up 
study. Gastroenterology 2014;147:1338-1349.e5. 
2.  Carbone M, Mells G, Pells G, Dawwas MF, Newton JL, Heneghan M, et al. Sex and age 
are determinants of the clinical phenotype of primary biliary cirrhosis and response to 
ursodeoxycholic acid. Gastroenterology 2013;144:560-569.e.7. 
3.  Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined 
analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. 
Gastroenterology 1997;113:884-890. 
4.  Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term 
ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 
1999; 29:644-647. 
5.  Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of 
ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. 
Gastroenterology 2005; 128:297-303.
6.  Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL, et al.; Global PBC 
Study Group. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a 
multicentre international study. Gut 2016;65:321-329. 
7.  Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C, et al. Biochemical 
response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. 
Hepatology 2008;48:871-877.
8.  Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary 
biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 
2006;130:715-720. 
9.  Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, et al. Baseline 
ductopenia and treatment response predict long-term histological progression in primary 
biliary cirrhosis. Am J Gastroenterol 2010;105:2186-2194. 10) Kuiper EM, Hansen BE, 
de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, et al.; Dutch PBC 
Study Group. Improved prognosis of patients with primary biliary cirrhosis that have a 
biochemical response to ursodeoxycholic acid. Gastroenterology 2009;136:1281-1287. 
11.  Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical 
response to treatment and prediction of long-term outcome. J Hepatol 2011;55:1361-
1367. 
12.  Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al.; POISE Study 
Group. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J 
Med 2016;375:631-643. 
ESTIMATED RISK REDUCTION WITH OCA TREATMENT 145
6
13.  Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, et al.; UK-PBC Consortium. 
The UK-PBC risk scores: derivation and validation of a scoring system for long-term 
prediction of end-stage liver disease in primary biliary cirrhosis. Hepatology 2016;63:930-
950. 
14.  Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, et al.; 
Global PBC Study Group. Development and validation of a scoring system to predict 
outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. 
Gastroenterology 2015;149:1804-1812. 
15.  European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the 
diagnosis and management of patients with primary biliary cholangitis. J Hepatol 
2017;67:145-172. 
16.  Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American 
Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 2009;50:291-
308. 
17.  Yang F, Yang Y, Wang Q, Wang Z, Miao Q, Xiao X, et al. The risk predictive values of UK-
PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the 
additional effect of anti-gp210. Aliment Pharmacol Ther 2017; 45:733-743. 
18.  Cheung KS, Seto WK, Fung J, Lai CL, Yuen MF. Prognostic factors for transplant-free survival 
and validation of prognostic models in Chinese patients with primary biliary cholangitis 
receiving ursodeoxycholic acid. Clin Transl Gastroenterol 2017;8:e100. 
19.  Samur S, Klebanoff M, Banken R, Pratt DS, Chapman R, Ollendorf DA, et al. Long-term 
clinical impact and costeffectiveness of obeticholic acid for the treatment of primary biliary 
cholangitis. Hepatology 2017;65:920-928. 
20.  https://clinicaltrials.gov/ct2/show/NCT02308111 
21.  Floreani A, Cazzagon N, Martines D, Cavalletto L, Baldo V, Chemello L. Performance and 
utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary 
cirrhosis. Dig Liver Dis 2011;43:887-892. 
22.  Corpechot C, Carrat F, Poujol-Robert A, Gaouar F, Wendum D, Chazouilleres O, et al. 
Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in 
primary biliary cirrhosis. Hepatology 2012;56:198-208. 
23.  European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del 
Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver 
disease severity and prognosis. J Hepatol 2015;63:237-264.
146 CHAPTER 6
SUPPLEMENTARY DATA
Supplemental Figure 1. Improvements in Risk with GLOBE score and UK-PBC Risk Score Aft er 12 Months of 
OCA Treatment by Median Age of PBC Diagnosis. (A) Predicted median (Q1, Q3) change in risk from baseline 
with the Globe score in pati ents diagnosed with PBC before the age of 48 years. (B) Predicted median (Q1, Q3) 
change in risk from baseline with the UK-PBC risk score in pati ents diagnosed with PBC before the age of 48 years.
(C) Predicted median (Q1, Q3) change in risk from baseline with the Globe score in pati ents diagnosed with PBC 
at the age of 48 years or later. (D) Predicted median (Q1, Q3) change in risk from baseline with the UK-PBC risk 
score in pati ents diagnosed with PBC at the age of 48 years or later. P<0.01 for all values in OCA treatment arms in 
both models. P-value for comparing acti ve treatments to placebo is obtained using the Rank ANCOVA model with 
baseline value as a covariate.
Abbreviati ons: IQR, interquarti le range; UDCA, ursodeoxycholic acid; OCA, obeti cholic acid.
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CHAPTER 8
TRENDS IN LIVER TRANSPLANTATION 
FOR PRIMARY BILIARY CHOLANGITIS 
IN EUROPE OVER THE PAST 
THREE DECADES 
Alimentary Pharmacology & Therapeutics, 2018
ABSTRACT
Background The importance of primary biliary cholangitis (PBC) as indication for liver 
transplantation (LT) over time is likely influenced by the introduction of therapies, and 
changes in selection criteria and disease epidemiology. 
Aim We aimed to assess time trends in LT for PBC and to evaluate characteristics of the 
patient population during the past three decades. 
Methods Patients undergoing LT from 1986-2015 in centres reporting to the European Liver 
Transplantation Registry were included. We excluded combined organ transplantations and 
patients <18 years. Trends were assessed using linear regression models. 
Results We included 112,874 patients that underwent LT between 1986-2015, of which 6029 
(5.3%) patients had PBC. After an initial increase in the first decade, the annual number of 
LT for PBC remained stable around 200. The proportion of LT for PBC decreased from 20% in 
1986 to 4% in 2015 (p<.001). PBC was the only indication showing a consistent proportional 
decrease throughout all decades. From the first to the third decade, the age at LT increased 
from 54 (IQR47-59) to 56 years (IQR48–62) and the proportion of males increased from 
11% to 15% (both p<.001). MELD scores increased from 15 (IQR12-19) in 1996-2005, to 17 
(IQR13-22) in 2006-2015 (p<.001). 
Conclusions In our European-wide study spanning 30 years, we found a proportional 
decrease in PBC as indication for LT. However, despite treatment with ursodeoxycholic acid 
and improved disease awareness, the absolute annual number of LTs has stabilized and LT 
remains indicated for a subgroup of PBC patients. 
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INTRODUCTION
Primary biliary cholangitis (formerly called primary biliary cirrhosis, PBC) is a chronic 
cholestatic liver disease, characterized by progressive intrahepatic bile duct destruction 
which may eventually lead to fibrosis, cirrhosis, and death1.In the 20 years following the first 
human liver transplantation in 1963, PBC was the leading indication for liver transplantation 
in Europe, accounting for 30%-50% of all liver transplantations2.However, despite increasing 
disease prevalence3,4, PBC is no longer a leading indication for liver transplantation. The 
recent change in nomenclature is figurative for the changed prognosis of patients over the 
past decades5. 
Today, patients are usually diagnosed with PBC at an early stage, which allows for timely onset 
of therapy, often resulting in improvement of biochemical parameters and prognosis6–12.
However, patients who respond incompletely still have a significantly impaired prognosis 
compared to an age- and sex-matched general population13,14. In case of liver failure, liver 
transplantation remains the only therapeutic option to prevent premature death. However, 
changes in selection criteria for liver transplantation and in the epidemiology, as well as the 
introduction of ursodeoxycholic acid (UDCA) as an effective treatment, may have impacted 
the relative importance of PBC as indication for transplantation. 
Previous European studies that have assessed trends in liver transplantation for PBC 
reported a decrease in transplantations. However, these studies were either single center or 
single-country studies, often covered relatively short study periods, or are now outdated15–17. 
A long-term European-wide study is currently lacking, as is data on possible changes over 
time in the characteristics of the subgroup of patients with PBC who still require liver 
transplantation. Thus, the primary aim of this study was to assess the time trends in the 
number of liver transplantations for PBC across Europe over the past three decades, both in 
absolute and proportional measures. Secondly, we aimed to evaluate the potential changes in 
characteristics of patients with PBC undergoing liver transplantation during this time period.
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MATERIALS AND METHODS
Study design
Patient data were obtained through the European Liver Transplantation Registry (ELTR). 
ELTR data are available to all the members of the European Liver and Intestine Transplant 
Association (ELITA) for research purposes, once the study protocol is approved. All patients 
transplanted in ELTR-associated centers from 1 January 1986 until 31 December 2015, were 
assessed. Patients who underwent combined organ transplantation and patients aged under 
18 years at the time of liver transplantation were excluded. In order to more thoroughly 
assess patients’ characteristics, all patients with PBC who were listed for liver transplantation 
at any of the three liver transplantation centers in the Netherlands during the study period 
were included for in-depth analyses. This study was conducted in accordance with the 
principles of the Declaration of Helsinki. The protocol was approved by ELITA and the Dutch 
Organ Transplant Registry. The protocol was reviewed and approved by the institutional 
research board of the corresponding center, and at each participating center, in accordance 
with local regulations.
Data collection
Data collected for our primary analyses included date of birth, gender, date of listing for 
liver transplantation, date of liver transplantation, and the biochemical parameters used to 
calculate the model for end-stage liver disease (MELD) score at the time of transplantation.18 
Indications for liver transplantation by primary and secondary etiologies were classified 
using the ELTR etiology codes. Patients with PBC were identified using these etiology codes, 
including patients with PBC-autoimmune hepatitis (PBC-AIH) overlap syndrome (defined as 
interface hepatitis on liver histology combined with alanine aminotransferase (ALT) ≥5× upper 
limit of normal or IgG ≥2×)19 and patients with an additional diagnosis of hepatocellular 
carcinoma. For our in-depth analyses, all patients with PBC listed for liver transplantation 
during the study period in the Netherlands were identified using the Dutch Organ Transplant 
Registry (NOTR) and the three local liver transplantation center registrations. For these 
patients, the following additional data were extracted from medical records: date of PBC 
diagnosis, date of initiation of UDCA treatment when applicable, secondary indication for liver 
transplantation and biochemical parameters including total bilirubin, alkaline phosphatase 
(ALP), aspartate aminotransferase (AST), albumin, creatinine, and INR at time of diagnosis, 
at time of initiation with UDCA treatment, at 1 year after treatment initiation, at time of 
listing for liver transplantation, and at time of liver transplantation. These measures were 
used to calculate the Barcelona, Paris I, and GLOBE response criteria for patients 1 year after 
the initial start of UDCA treatment14,20,21. The secondary indication for liver transplantation 
was classified as either liver failure, an additional diagnosis of hepatocellular carcinoma, or 
quality of life (QOL) (defined as therapy-refractory fatigue or pruritus after following the 
EASL guidelines for management of cholestatic liver diseases or a mean score of ≥4 in the 
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fatigue or pruritus domain of the PBC-40)22. The biochemical disease stage was determined 
based on serum albumin and bilirubin concentrations according to the Rotterdam criteria, 
classifying PBC into early (normal total bilirubin and normal albumin), moderately advanced 
(abnormal total bilirubin or abnormal albumin), or advanced disease (abnormal total 
bilirubin and abnormal albumin).10 UDCA treatment status was classified as “yes” when 
patients were treated with UDCA at time of listing, independent of treatment duration, 
dosage, and/or combination with other treatment.
Calculations
MELD scores provided in the registry data were used when available, also when this 
concerned patients with MELD exception points. If no MELD score was declared, we 
calculated it based on laboratory values using the following formula: 0.957 x Natural 
logarithm (ln) of (creatinine in mg/dL) + 0.378 x ln (bilirubin in mg/dL) + 1.120 x ln (INR) + 
0.643.18 For our analyses, we preferred declared MELD scores over laboratory MELD scores 
when available, since laboratory MELD scores do not take into account possible MELD score 
exception points. To exclude erroneous data, for all biochemical parameters included in the 
MELD score, clinically feasible minimum and maximum values were defined based on clinical 
expertise. Values exceeding these ranges were excluded from analyses and considered 
missing. The ranges were defined as follows: serum creatinine 0.01-11.3 mg/dL (20-1000 
μmol/L), serum bilirubin 0.06-58 mg/dL (1-1000 μmol/L), INR 0.5-10, and albumin 10-60 
g/L. The MELD score was considered to range from a minimum of 6 to a maximum of 4023.
Statistical analyses
Linear regression least-square models were used to assess trends over time for our primary 
endpoints. For normally distributed continuous variables, the one-way ANOVA was used 
for the comparison of more than two groups. In case of skewed distribution of continuous 
variables, the Mann-Whitney U test was used for the comparison of two groups, and the 
Kruskal-Wallis test for more than two groups. For categorical variables, differences between 
the three decades were compared using the chi-squared test. For comparative purposes, 
the study period was divided into three groups according to the date of transplantation. 
Every group represents the time span of one decade (1 January 1986 - 31 December 1995; 
1 January 1996 - 31 December 2005; 1 January 2006 - 31 December 2015). Statistical 
analyses were performed using SPSS version 21. A P-value of less than 0.05 was considered 
statistically significant. 
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RESULTS
Study populati on
Between 1 January 1986 and 31 December 2015, 128 802 pati ents underwent liver 
transplantati on in 166 European Liver Transplantati on Registry centres. We excluded 15 
928 pati ents because of combined organ transplantati on or age <18 years at ti me of liver 
transplantati on. Thus, 112 874 pati ents were included in our study populati on. Of this total, 
6029 (5.3%) were transplanted for PBC. In comparison, 26 861 (23.8%) were transplanted 
for viral hepati ti s, 23 207 (20.6%) for alcoholic cirrhosis, 20 047 (17.8%) for cancers, and 
9226 (8.2%) for autoimmune diseases of the liver other than PBC. Pati ent characteristi cs for 
those transplanted for PBC are presented in Table 1.
Primary Indicati ons for liver transplantati on — changes in absolute and proporti onal 
numbers
In 1986, 283 liver transplantati ons were performed, as compared to 5646 in 2015. The 
number of transplantati ons increased by 184 per year (95% CI 183-184, P < 0.001) (Figure 1A). 
The absolute annual number of transplantati ons for PBC peaked to 279 in 1994.  Thereaft er, 
the annual transplant rate for PBC decreased to an average of 200 in the last decade (Figure 
1B). These changes correspond with an average annual increase of 21.5 (95% CI 21.3-21.7; 
P < 0.001) transplantati ons in the fi rst decade, followed by a decrease of −1.9 (95% CI −2.1 
to −1.7; P < 0.001) in the second decade, and a marginal annual decrease of −0.3 (95% 
CI −0.5 to −0.1; P = 0.002) in the last decade. The proporti on of pati ents undergoing liver 
transplantati on for PBC as compared to other indicati ons decreased from 20.3% in 1986% 
to 3.7% in 2015 (Figure 2A). The greatest decrease was in the fi rst decade, with an annual 
Figure 1. Annual absolute number of liver transplantati ons in ELTR centres from 1986-2016 for (A) all primary 
disease eti ologies, and (B) PBC. 
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Table 1. Characteristi cs of pati ents transplanted for PBC in ELTR centres from 1986-2016. 
Overall Decade of Liver Transplantati on
1986-2016 1986-1996 1996-2006 2006-2016 p – value
N = 6029 N = 1869 N = 2157 N = 2003
Age a
Overall 55.2 (48.1-61.2) 53.9 (47.3-59.4) 55.7 (49.0-61.4) 56.1 (48.4-62.4) <.001
Female 55.1 (48.1-61.1) 53.6 (47.1-59.1) 55.6 (49.0-61.4) 55.9 (48.6-62.3) <.001
Male 55.2 (48.1-61.2) 55.6 (47.3-59.4) 57.0 (48.1-62.1) 56.9 (48.4-62.4) .616
Gender (%)
Female 5267 (87.4) 1664 (89.0) 1904 (88.3) 1699 (84.8) .532
Male 761 (12.6) 205 (11.0) 253 (11.7) 303 (15.1)
PBC (%)
PBC 5907 (98) 1866 (99.8) 1904 (88.3) 1699 (84.8) <.001
PBC – AIH 38 (0.6) 0 (0.0) 10 (0.5) 28 (1.4)
PBC – HCC 84 (1.4) 3 (0.2) 24 (1.1) 57 (2.8)
MELD score a 16.2 (12.7-20.9) 17.0 (13.8-20.5) 15.3 (12.3-19.1) 16.8 (12.8-21.7) <.001
Creati nine (mg/dL) a 0.9 (0.7-1.1) 1.0 (0.81-1.26) 0.9 (0.8-1.1) 0.80 (0.6-1.1) <.001
Bilirubin (mg/dL) a 5.9 (2.7-11.8) 7.2 (3.5-13.2) 5.4 (2.7-10.3) 6.0 (2.6-12.9) .001
INR a 1.3 (1.1-1.5) 1.2 (1.1-1.5) 1.2 (1.1-1.4) 1.3 (1.1-1.6) <.001
Albumin (g/L) b 31.0 (27.0-36.0) 30.0 (26.0-35.0) 31.0 (27.0-36.0) 31.0 (26.6-36.0) .137
a. Shown as median (IQR)
b. Shown as mean ± sd 
Missing values: INR n=9 (6%), MELD score n=9 (6%).
Abbreviati ons: PBC, primary biliary cholangiti s; AIH, auto immune hepati ti s; HCC, hepatocellular carcinoma; QOL, 
quality of life; MELD, model for end-stage liver disease; INR, internati onalized normal rati o.
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proporti onal decrease of 0.9% (95% CI −0.92 to −0.88; P < 0.001). Thereaft er, the proporti on 
of transplantati ons for PBC annually decreased with 0.3% (95% CI −0.343 to −0.337; P < 
0.001) in the second decade and 0.1% (95% CI −0.064 to −0.057; P < 0.001) in the third 
decade. No other leading disease aeti ology showed a persistent signifi cant proporti onal 
decrease over all three decades (Figure 2B). 
Age 
The overall median age at ti me of transplantati on was 55 years (interquarti le range [IQR] 
48-61) for pati ents with PBC, and 53 years (IQR 44-59) for non-PBC pati ents (P<.001). For 
PBC pati ents, the median age at ti me of transplantati on increased signifi cantly from 54 
(IQR 47-59) in the fi rst decade to 56 (IQR 49-61) in the second decade (P < 0.001), while 
no signifi cant age diff erence was found thereaft er (P = 0.255) (Figure 3). Furthermore, a 
change in distributi on of pati ents’ age at ti me of transplantati on was found (Figure 4). The 
proporti on of pati ents aged >60 increased from 23% in the fi rst decade to 35% in the last 
decade (P > 0.001), whereas the proporti on of pati ents between 40-49 and 50-59 years 
decreased from 27% and 42% in the fi rst decade, to 21% and 36% respecti vely in the last 
decade (both P < 0.001). 
Gender 
A total of 761 (12.6%) male and 5267 (87.4%) female pati ents with PBC were transplanted, 
corresponding to a male to female rati o of 1:6.9. For non-PBC aeti ologies, 74 484 (69.7%) 
males and 32 348 (30.3%) females underwent transplantati on, corresponding to a female 
to male rati o of 1:0.43. In PBC pati ents, the proporti on of transplantati ons for males 
increased signifi cantly from 11.0% in the fi rst decade to 15.1% in the third decade (P < 
0.001) (Figure 5). In the fi rst decade, males were signifi cantly older than females with a 
median age of 56 years (IQR 49-61) and 55 years (IQR 48-60) respecti vely (P < 0.05), but no 
diff erences were found in the second (P = 0.755) and third decades (P = 0.695) (Figure S1A). 
Figure 2. Proporti on of liver transplantati ons in ELTR centres from 1986 to 2016 for (A) PBC and (B) PBC and other 
leading indicati ons.
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Figure 4. Percentage of male versus female pati ents transplanted for PBC in Europe from 1986 to 2016.
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Figure 5. a) MELD scores at ti me of LT for pati ents with PBC transplanted in Europe from 1996-2015; b) MELD 
scores of pati ents transplanted for PBC versus non-PBC aeti ologies in 1996-2005 versus 2006-2015. MELD scores 
are reported as median with their interquarti le ranges. As a result of a lack of biochemical data from the fi rst 
decade of the study period, data is shown for 1996-2015. In this period, MELD scores were available for 2,749 
(46%) of pati ents with PBC and 51,410 (48%) of non-PBC pati ents.  
Abbreviati ons: LT, liver transplantati on; MELD, model for end-stage liver disease.
Figure 3. A) Age (median, interquarti le range) at ti me of liver transplantati on for PBC in Europe from 1986 to 
2016, B) Proporti onal age distributi on for transplanted PBC pati ents in Europe from 1986-2016.
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MELD scores
In patients with PBC, the median MELD score at time of transplantation increased from 
15.3 (IQR 12.2-19.2) in the second decade to 16.8 (IQR 12.8-21.6) in the last decade (P < 
0.001). An increase in MELD score between these decades was also found in non-PBC liver 
transplantations, in which the median MELD score increased from 15.6 (IQR 11.7-21.2) to 
16.1 (IQR 11.1-23.0) (P < 0.001) (Figure 5). There were no significant differences in MELD 
scores between PBC and non-PBC patients in either the second or the third decade (P = 
0.101 and P = 0.119 respectively). In PBC patients, no significant difference in MELD score 
was found between females (16.1, IQR 12.5-20.8) and males (16.9, IQR 13.0-21.0) (P = 
0.160). 
CHARACTERIZATION OF NATIONWIDE COHORT 
Mortality on the waiting list 
From 1 January 1986 to 31 December 2015, 184 patients with PBC were placed on the 
waiting list for transplantation in the Netherlands. Of this total, one patient (0.5%) was 
alive without transplantation at the end of follow up. Twenty-nine (15.8%) patients died 
on the waiting list or were removed from the waiting list due to clinical deterioration. Eight 
of these events occurred between 1986 and 1995, eight between 1996 and 2005, and 13 
between 2006 and 2015, corresponding to a waitlist mortality of 12%, 16%, and 33% in the 
consecutive decades. In addition, three (1.6%) patients were removed at personal request 
or due to improved condition. The remaining 151 (82.1%) were transplanted.
Study population
Characteristics and biochemistry of the 151 patients who were transplanted for PBC in the 
Netherlands are presented in Table S1. The median age at the time of transplantation was 
54 years (IQR 48-59). Transplanted patients were diagnosed with PBC at a median age of 46 
(IQR 40-51), and listed at a median age of 53 (IQR 47-59). Males were significantly older than 
females at the time of transplantation, with a median age of 58 (IQR 53-64) as compared to 
53 (IQR 49-58) (P = 0.006), while the MELD score at the time of liver transplantation did not 
differ between the sexes (P = 0.838).
Primary indications for liver transplantation: Absolute changes over time
The absolute number of transplantations for PBC nearly halved over time, from 65 in the first 
decade to 36 in the third decade (P < 0.001) (Figure S2). Of the 151 patients transplanted 
for PBC, 129 (85.4%) were listed for the primary indication PBC alone, 16 (10.6%) patients 
had a PBC-AIH overlap syndrome, and six (4.0%) patients had an additional diagnosis of 
hepatocellular carcinoma. The proportion of patients with PBC transplanted due to poor 
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quality of life significantly increased from 2% to 12% to 17% in the three consecutive 
decades (P = 0.004).
UDCA treatment and response for all patients with PBC
A total of 102 (67.5%) transplanted patients were treated with UDCA at the time of listing. 
The proportion of patients who were treated with UDCA increased significantly over time, 
from 37% in the first, to 92% in the last decade (P < 0.001). Table 2 shows the biochemical 
response for these UDCA-treated patients according to the Barcelona, Paris I, and GLOBE 
response criteria.14,20,24,25 In this cohort of transplanted patients with PBC, 6-47% of 
patients showed a biochemical response to treatment, depending on the response criteria. 
The Paris I criteria identified the lowest percentage of complete biochemical responders 
after 12 months of UDCA treatment (6%). When classification by different response criteria 
was compared, this proportion was significantly lower than the percentage of complete 
responders as classified by the Barcelona criteria (30%) (P = 0.008) and by the GLOBE criteria 
(28%) (P = 0.004).
Table 2. Biochemical response to 12 months of UDCA therapy in patients that underwent LT in the Netherlands 
between 1986-2016. 
Overall Decade of Liver Transplantation
1986-2016 1986-1996 1996-2006 2006-2016
N = 102 N = 28 N = 41 N = 33
Barcelona criteria
Responder, n(%) 16 (30) 3 (20) 10 (40) 3 (21)
Incomplete responder, n(%) 38 (70) 12 (8) 15 (60) 11 (79)
Missing, n(%) 48 (47) 13 (46) 16 (39) 19 (58)
Paris I criteria
Responder, n(%) 4 (6) 1 (5) 1 (4) 2 (10)
Incomplete responder, n(%) 61 (94) 19 (95) 26 (96) 18 (90)
Missing, n(%) 37 (36) 8 (29) 14 (34) 15 (46)
GLOBE criteria
Responder, n(%) 16 (28) 0 (0) 9 (39) 7 (39)
Incomplete responder, n(%) 41 (72) 16 (100) 14 (61) 11 (61)
Missing, n(%) 45 (44) 12 (43) 18 (44) 15 (46)
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DISCUSSION
This study represents the largest European-wide study on time trends in liver transplantations 
for PBC to date, covering the past 30 years. The percentage of transplantations for PBC as 
compared to other etiologies decreased to less than one-fifth of its original proportion of 20%. 
In contrast, the absolute number of transplantations for PBC has remained virtually stable 
over the last 10 years. Characteristics of patients undergoing transplantation for PBC have 
changed over time, whereby they are now older, have higher MELD scores, and are more 
likely to be male than 30 years ago. However, differences over time were quantitatively small. 
The current study is the first to demonstrate a stable annual absolute number of 
transplantations for PBC over the past 10 years in Europe. This result confirms that today, 
in a minority of patients, we are still unable to prevent liver failure which underlines the 
necessity of additional therapeutic options for this group. A study by Lee et al. that assessed 
transplantations trends for PBC in the United States showed an absolute annual decrease 
without reaching a steady state, but their study period only covered 11 years and ended in 
200613. Our finding seems in contrast to the recent study by Webb et al. reporting a decrease 
in the United Kingdom and the United States up until 2014. However, a true comparison 
is difficult, since the latter study only reported listings for transplantation and not actual 
liver transplantation, and measured numbers as a ratio against the total (increasing) general 
population. However, the steady absolute number of transplantations for PBC is also 
discordant with an overall increase in overall numbers of annual transplantations and with 
the increasing prevalence of PBC over the past decades3,4. Therefore, the stable absolute 
number of transplantations for PBC that we report could possibly be interpreted as a relative 
decrease. 
Although we found an annual number of approximately 200 transplantations for PBC over 
the past 10 years the true number of PBC patients in need of liver transplantation may be 
higher. First, 16% of all listed patients with PBC in our secondary analysis in the Dutch cohort 
died while on the waiting list for transplantation or were removed due to deteriorating 
clinical condition. This result is in line with a recent study showing a waiting list mortality 
of 12% for PBC patients, which was higher than for most other aetiologies26. Second, as 
compared to the number of Dutch patients who underwent transplantation for PBC 
reported in the ELTR database, we identified an additional 10% of patients after extensive 
review of medical records of all listed patients in the entire Dutch cohort. Evidently, not 
all transplanted patients with PBC had been reported as such, and were possibly labelled 
with more general etiologies lacking further specification, such as cirrhosis or autoimmune 
disorders. Even more so, a minority of patients might have been incorrectly diagnosed 
when PBC was not recognized by treating physicians as the underlying cause of cirrhosis. 
Furthermore, within the top five primary indications for transplantation, PBC was the only 
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one that showed a constant proportional decrease over three decades. We speculate that 
several factors may have contributed to this decrease. First is the possible influence of UDCA 
treatment. Recently, the Global PBC Study Group reported a strong association between 
UDCA treatment and improved transplant-free survival11. The number of transplantations 
for PBC peaked several years after UDCA was introduced in the early nineties, with a 
subsequent much more stable number of transplantations. Second, the introduction of 
urgency-based allocation may have influenced the proportional decrease in transplantations 
for PBC. Since MELD-based allocation in 2006, patients’ time on the waitlist is no longer a 
factor in allocation, possibly impeding the chance of receiving a transplantation for patients 
with a relatively slowly progressing disease such as PBC1. 
We also identified several changes in the characteristics of patients undergoing 
transplantation for PBC over the past three decades. We found an increase in age at time of 
transplantation. This was in line with the results from a long-term study from Birmingham and 
a recent larger study covering both the UK and the USA16,27. Most noticeable, however, was 
our finding of an increasing proportion of patients with PBC transplanted at age >60 years. 
This may be related to an overall improved medical care and physical condition, permitting 
transplantation at higher ages. The influence of possible changes in environmental triggers 
involved in the development of PBC should also be considered, especially since a recent large 
study showed that the age at PBC diagnosis has markedly increased over the years28. However, 
with a median age at diagnosis of 46 years in patients with PBC listed for transplantation 
within our in-depth population, this population undergoing liver transplantation for PBC 
was much younger at diagnosis than the large overall cohorts reported by the Global PBC 
Study Group (55 years) and the UK-PBC Study Group (55 years)21,29. This suggests that young 
patients may be more likely to develop end-stage disease requiring liver transplantation, as 
has previously been reported30. Furthermore, we found that an increasing number of males 
were transplanted for PBC over time, which was also reported in the United States27. The 
increasing male to female ratio reported in epidemiological studies could contribute to these 
findings, as well as data that suggest males are less likely to respond well to treatment with 
UDCA30,31. The MELD score at time of transplantation was slightly but significantly higher 
after 2006, as compared to the period between 1996 and 2005. This might be explained by 
the introduction of MELD-based allocation in 2006. This increase was found for both PBC 
and non-PBC patients, although more pronounced in patients with PBC. We identified no 
differences in MELD scores between PBC and non-PBC patients. 
In our in-depth analysis of the Dutch cohort, the patients’ characteristics were comparable 
to the European-wide cohort. Notably, we found that the proportion of patients with PBC 
who underwent transplantation for poor quality of life increased from 2% before 1995 
to 17% in the last decade. Furthermore, we found that despite international guidelines 
recommending that all patients with PBC be treated with UDCA32,33, 8% were not treated 
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with UDCA during the last decade. Although we were unable to validate these findings in 
the European data, these factors might also have impacted the remaining number of liver 
transplantations for PBC over the last decade. 
To the best of our knowledge, our study was the first to assess time trends in liver 
transplantation for PBC throughout Europe over a sizeable period of 30 years, during 
which UDCA was introduced as the standard of care. We were able to include all liver 
transplantations reported to the ELTR, resulting in a large population of 6029 transplanted 
PBC patients. The additional nationwide in-depth analysis over the same study period 
enabled us to characterize the population in need for liver transplantation more extensively 
over time. However, some limitations should be taken into account. Biochemical data were 
incomplete in both the ELTR data and the Dutch in-depth analysis. However, due to the 
large population and the similar patterns found in both analyses, we believe this has not 
introduced an important bias. Second, our in-depth analyses are based on data of Dutch 
patients only and the extent to which findings can be generalized is uncertain. Nevertheless, 
since patient characteristics and MELD scores at transplantation were comparable to the 
PBC population in the ELTR database and similar transplantation patterns over time were 
observed, the results of our nationwide in-depth analyses may well be representative of the 
European PBC population in need of liver transplantation. 
In conclusion, we found that, despite a relative decrease, the absolute number of 
transplantations for PBC has reached a steady state. Still, over 200 European patients with 
PBC undergo liver transplantation annually. These patients are slightly older, have higher 
MELD scores, and are more likely to be male than 30 years ago. Effective second-line 
therapies may further reduce the need for liver transplantation in patients with PBC in the 
future. 
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SUPPLEMENTARY DATA 
Supplementary Figure S1. Age at time of liver transplantation per decade stratified by gender for patients with 
PBC transplanted in (A) Europe, and (B) the Netherlands from 1986-2016. 
19
86
19
87
19
88
19
89
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
0
5
10
15
Year of transplantation
A
bs
ol
ut
e 
nu
m
be
r o
f t
ra
ns
pl
an
ta
tio
ns
Figure S2. Annual absolute number of liver transplantations for PBC patients in the Netherlands from 1986-2016.  
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Supplementary Table S1. Characteristics of patients transplanted for PBC in the Netherlands centres from 1986-2016. 
Overall Decade of Liver Transplantation
1986-2016 1986-1995 1996-2005 2006-2015 p - value
N = 151 N = 65 N = 50 N = 36
Age at LT a
Overall 53.6 (47.8-58.6) 53.4 (48.0-57.8) 54.3 (48.2-60.7) 52.9 (44.6-60.4) .442
Female 53.1 (46.8-57.6) 53.3 (48.0-57.1) 53.8 (47.5-59.0) 52.4 (44.5-59.6) .596
Male 58.3 (53.4-63.5) 58.3 (49.3-63.0) 58.6 (53.9-63.7) 59.2 (50.5-63.7) .921
Gender (%)
Female 133 (88.1) 59 (90.8) 42 (84.0) 32 (88.9) .532
Male 18 (11.9) 6 (9.2) 8 (16.0) 4 (11.1)
PBC (%) <.001
PBC 129 (84.9) 64 (98.5) 40 (80.0) 25 (69.4)
PBC – AIH 16 (10.5) 1 (1.5) 8 (16.0) 7 (19.4)
PBC – HCC 6 (4.6) 0 (0.0) 2 (4.0) 4 (11.1)
Sub indication (%) .004
Liver Failure 135 (89.4) 64 (98.5) 43 (86.0) 28 (77.8)
HCC 3 (2.0) 0 (0.0) 1 (2.0) 2 (5.6)
Poor QOL 13 (8.6) 1 (1.5) 6 (12.0) 6 (16.7)
Disease stage (%) b .238
Early 10 (6.6) 2 (3.1) 3 (6.0) 5 (13.9)
Moderate 35 (23.2) 13 (20.0) 13 (26.0) 9 (25.0)
Advanced 106 (70.2) 50 (76.9) 34 (68.0) 22 (61.1)
MELD score a 16.8 (13.2-20.7) 17.4 (14.7-19.5) 14.3 (12.3-18.3) 19.9 (13.0-25.8) .006
Creatinine (mg/dL) a 0.7 (0.6-0.9) 0.7 (0.6-1.0) 0.7 (0.6-0.8) 0.7 (0.6-0.9) .528
Bilirubin (mg/dL) a 7.4  (3.6-15.7) 8.8 (4.1-15.1) 5.3 (2.6-10.6) 11.4 (3.9-20.7) .091
INR a 1.2 (1.0-1.4) 1.1 (1.0-1.4) 1.0 (1.0-1.3) 1.3 (1.1-1.8) .002
Albumin (g/L) c 30.9 (6.4) 29.7 (5.5) 30.8 (7.5) 33.0 (5.9) .046
a.Shown as median (interquartile range)
b.Biochemical disease stage as defined by the Rotterdam criteria12
c. Shown as mean (standard deviation)  
Missing values: Creatinine, n=0 (0%); Bilirubin, n=32 (21.1%);  INR, n=9 (6%); Albumin, n=0 (0%); MELD score n=9 (6%).
Abbreviations: PBC, primary biliary cholangitis; AIH, auto immune hepatitis; HCC, hepatocellular carcinoma; QOL, 
quality of life; MELD, model for end-stage liver disease; INR, internationalized normal ratio.
Harms MH, van Buuren HR, Hansen BE, Metselaar HJ. 
Aliment Pharmacol Ther. 2019 Feb;49(4):473-474.
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We would like to thank Gerussi et al1 for their interest in our study and for highlighting 
valid remarks and questions that our paperraises2. Rightfully, the authors state that “non-
response” to first-line therapy leaves patients prone to the need for liver transplantation 
(LT).Although- as previously proposed3 - we believe the term “non-response” should 
be avoided and should rather be replaced with “incomplete response” given that these 
patients do in fact still benefit from ursodeoxycholic acid (UDCA) treatment, we would like 
to stress that our in-depth analyses in the Dutch population show that a minority of patients 
with primary biliary cholangitis (PBC) that are initially classified as “complete responders” 
after the first year of therapy, eventually also undergoes LT. This might be explained by the 
fact that some patients should actually be reclassified as “incomplete responders” when re-
evaluating the response status during follow-up, as recently shown by Goet et al4. Secondly, 
the authors suggest that, in addition to epidemiological changes and a reduced rate of 
biochemical response in males, diagnostic delay might impact the increasing proportion of 
males transplanted for PBC. However, it seems unlikely that diagnostic delay in males has 
worsened over the past decades, leaving this as an implausible explanation for our finding. 
Another comment was that potential underreporting of autoimmune variant syndrome 
in PBC might impact our findings. Although research on the incidence and prevalence of 
such variant syndromes is limited, and studies on the impact of concomitant autoimmune 
hepatitis on long-term outcome are conflicting5,6,exploring this further could indeed improve 
therapeutic strategies for this subgroup of patients with PBC, with a potential reduction 
in LTs as a result. Overall, we agree with Gerussi et al that our study stresses the unmet 
need of effective second-line therapies in PBC that reduce progression to liver failure, and 
the correct implementation of such drugs in clinical practice. As new potentially effective 
therapies including obeticholic acid and fibrates currently brighten the therapeutic horizon, 
we propose to renew this study after a decade or so, hopefully to find a renewed reduction 
in the absolute number of LTs for PBC.
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BACKGROUND
Primary biliary cholangitis (PBC) is a chronic disease that can lead to hepatic fibrosis which 
can eventually result in the development of cirrhosis. When left untreated, survival of 
patients with PBC is significantly impaired compared with the general population. 
Because PBC is a rare disease with a relatively slow disease progression, research in the 
field of PBC has long been considered challenging. Over the past decade, large national 
and international collaborations have enabled the performance of high-quality research 
on big data with long-term follow-up in PBC. A previous landmark study performed by the 
Global PBC Study Group identified alkaline phosphatase (ALP) and bilirubin as independent 
surrogate markers of long-term clinical outcome1. This consensus has provided the field 
with an opportunity to assess the effect of potential therapeutic agents in a timely and 
ethical manner. Other important work is represented by the development of continuous 
risk scores2, 3 based on readily available clinical parameters, correlating with a projected liver 
transplantation (LT)-free survival. 
 
PROGNOSIS
 
Serum bilirubin has been extensively studied in terms of its association with long-term 
outcome in PBC4. Today it is a well-established marker of prognosis, both in UDCA-treated 
and untreated populations5, 6. Shapiro et al. already showed in 1979 that the behavioral 
pattern of bilirubin has two distinct phases: a first phase in which bilirubin is fairly stable 
for many years, followed by a phase with a rapid increase. Thus, since serum bilirubin is 
often not abnormal in the early stages of disease, it is often considered a ‘late biomarker’. 
Lammers et al. showed that a threshold of 1.0 times the upper limit of normal (ULN) had 
the highest predictive ability1. This finding may have impacted the development of both 
inclusion criteria as well as primary endpoints of recent large clinical trials for second-
line therapies, that included this ULN threshold for bilirubin7, 8. Chapter 2 describes the 
prognostic relevance of serum bilirubin within the current normal range. We show that a 
threshold of 0.6 xULN has a good discriminative ability and that above 0.6 x ULN there is a 
linear relationship with risk of LT/death, both in patients that received UDCA treatment, as 
well as in patients that remained untreated. For patients with an initial serum bilirubin ≥0.6 
x ULN, a reduction resulting in bilirubin <0.6 x ULN after one year of UDCA was associated 
with prolonged transplant-free survival. Our results imply that therapeutic goals may strive 
beyond ‘normalization’ and that future interventional studies could include patients with 
a bilirubin above 0.6 x ULN, and should consider this threshold as part of the primary or 
secondary endpoint. Although our study has mainly focused on serum bilirubin, we also 
show that ALP levels below 1.67 – a threshold previously used in biochemical response 
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criteria, and as inclusion criteria and endpoint in clinical trials9, 10 – are associated with LT-
free survival as well. Future studies are required to assess whether prognostic significance 
within the normal range can also be demonstrated for other biochemical measurements.
CIRRHOTIC COMPLICATIONS
Although today most patients are diagnosed in an early stage of disease, a fairly recent British 
study showed that up to 40% of patients had developed cirrhosis after 10 years of follow-
up11. Subsequently, those patients are at risk of clinical complications that are associated 
with the presence of cirrhosis. Evidently, such decompensating events are associated with 
an increased risk of death or liver transplantation12, 13. Studies on these events in patients 
with PBC were rare, especially in patients treated with UDCA, as are the majority of PBC 
patients today. In Chapter 3, we studied non-neoplastic major cirrhosis-related complications 
including variceal bleeding, encephalopathy, and ascites in a UDCA-treated population. 
We found that overall, the 10-year cumulative incidence of first events was 9% and that in 
keeping with other liver diseases, subsequent survival was poor14. Reassuringly, however, 
this incidence decreased over time, which might be explained by increased awareness for 
PBC leading to diagnosis in early disease stages and by more prompt initiation of UDCA 
therapy after diagnosis. Stratification by both biochemical response and AST to Platelet 
Ratio Index (APRI) enabled us to identify a ~20% subgroup of patients with a very low long-
term risk of complications. Our findings may be especially relevant for patient counseling, 
since PBC represents a condition in which patients are told to face serious and daunting 
disease-related risks. Risk factors for these complications were found to be largely the same 
as those related to liver transplantation (LT)-free survival15-17, in which biochemical response 
is strongly associated with a reduced risk of LT and death. This further stresses the clinical 
importance of evaluating biochemical response to therapy.
THERAPIES AFFECTING THE NATURAL HISTORY
Ursodeoxycholic acid
The clinical picture of PBC was first described by Addison and Gull in 1851, followed by a 
long period of lack of therapeutic options18. After many disappointing clinical trials, UDCA 
was the first therapeutic agents showing promising results in absence of debilitating adverse 
events in the late 1980s. Several long-term cohort studies suggested that UDCA treatment 
was related to an improved LT-free survival, but based their conclusions on the comparison 
of observed survival versus predicted LT- survival according to prognostic models19-21. In 
contrast, randomized controlled trials repeatedly failed to show evidence of UDCA-induced 
survival benefit22-31. This led to a long-lasting discussion in the field of PBC experts, in which 
192 CHAPTER 10
doubts were recently substantiated by an in 2017 published Cochrane meta-analysis that 
concluded no demonstrated benefit of UDCA of LT and/or mortality32. In Chapter 4, the 
association between UDCA and LT-free survival was assessed by applying inverse probability 
of treatment weighting, a form of propensity matching aiming to emulate a clinical trial, 
to a cohort of both UDCA-treated and untreated patients with long-term follow-up. This 
resulted in a 10-year cumulative survival of 79.7% in UDCA-treated patients versus 60.7% 
in patients that remained untreated, corresponding to an overall hazard ratio of 0.46. The 
association remained significant in all subgroup analyses. Although the retrospective nature 
of this study results in the fact that a true causal relationship cannot be concluded, it is 
very difficult to think of any residual confounder that would completely diminish the cogent 
association that is found throughout all subgroup analyses. Importantly, we showed that the 
association between UDCA and prolonged survival remained in patients that were classified 
as inadequate responder. This implies that regardless of treatment response, UDCA should 
be continued. All previous response criteria stratified patients into ‘responders’ versus ‘non-
responder’ or ‘inadequate responders’15, 21, 33-37. Giving the finding of therapeutic benefit in 
all patients, including those without full biochemical response, we propose to replace the 
aforementioned terms by ‘incomplete response’ as this term is able to capture the remaining 
favorable therapeutic effect that these patients benefit from. 
Therapeutic benefit can also be demonstrated as an absolute clinical efficacy measure, such 
as the number needed to treat (NNT) to prevent mortality (or LT). Assessment of the NNT 
is still uncommon in the field of hepatology and gastroenterology, but has recently gained 
popularity in other fields of medicine38-40. The NNT is easy to interpret for both patients and 
physicians, as it combines the relative risk reduction with the patients’ baseline risk in one 
parameter.  This is clinically meaningful, since both risks can differ between patients. In 
Chapter 5, we evaluated the clinical efficacy of UDCA in PBC. We found that that the overall 
NNT to prevent LT/death within 5 years was 11, which can be considered very low. In this 
respect it is important to consider that PBC is a chronic disease in which lifelong therapy 
is recommended. We therefore showed that the NNT further decreases over time, with 
an overall 10-year NNT of 6. We show that the variation in NNT with UDCA to prevent LT/
death is mostly related to patient’s a priori risk, as the relative risk reduction is fairly stable 
throughout subgroups. We were able to show how to estimate the NNT5y for an individual 
patient based on their GLOBE score (a prognostic model previously developed by the Global 
PBC Study Group in UDCA-treated patients), as we show the GLOBE score also performs 
well in untreated patients. Together, our results in chapter 4 and 5 contribute to the body 
of evidence that justifies lifelong treatment with UDCA in all patients with PBC, especially 
in light of its favorable safety profile and relatively low costs. The current relevance of 
our results is stressed by reports of as much of 30% of Western cohorts of PBC patients 
remaining untreated yet today41. Moreover, our conclusions may aid physicians caring for 
patients with PBC in patient counseling and can support patient compliance. 
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Obeticholic acid
For decades, UDCA was the only approved therapeutic agent for PBC. Following the 
publication of the POISE trial8, a phase III placebo-controlled trial of treatment with 
obeticholic acid (OCA), in 2016 this drug was approved by the FDA as the first second-line 
therapy for PBC. This was a milestone in the PBC landscape, especially since the approval 
process has been long and challenging, given the fact that the primary endpoint of the POISE 
trial was not based on hard clinical endpoints. The primary endpoint was based on ALP and 
bilirubin, which were considered to be surrogate markers for clinical outcome. The same 
year, both the Global PBC Study Group and the UK-PBC Study Group presented validated risk 
scores that correlated well with survival2, 3. In Chapter 6, we assessed the projected clinical 
benefit after one year of OCA, based on these risk scores that were applied to data from the 
POISE trial, in which OCA was used as add-on to UDCA in 93% of patients. Using the GLOBE 
score, OCA resulted in an estimated absolute risk reduction of LT/death of approximately 
5% after 10 years, corresponding with a relative risk reduction of 24%. Similar results were 
obtained using the UK-PBC risk score. Although the primary endpoint was met by 47% of 
OCA-treated patients in the trial, we show that nearly all patients receiving OCA treatment 
show biochemical improvements that correspond with a significantly reduced estimated 
risk of adverse clinical outcome. This is also true for the patients who did not meet the 
trial primary endpoint for response. This finding underlines the importance of awareness of 
the limitations of using dichotomous response criteria or endpoints, especially when such 
results undergo subsequent cost-utility analyses42 that could potentially have significant 
consequences for drug availability and/or reimbursement. Although the predictions in our 
study await confirmation by the ongoing phase 4 trial of OCA evaluating clinical outcomes 
in patients with PBC (COBALT; NCT02308111), a recent publication on the open-label 
POISE extension study shows promising results in which biochemical improvements were 
sustained up to 4 years43.
Fibrates
After many years of pilot studies with either bezafibrates or fenofibrates as add-on treatment 
with promising results, a well-executed French placebo-controlled trial showed a spectacular 
improvement of biochemistry induced by add-on bezafibrate treatment associated with 
improved projected survival7, 44. Although some observational data is available, the results 
of an ongoing Chinese trial studying the effects of fenofibrates (NCT02965911) are awaited. 
No previous studies have compared the effects of these fibrate subtypes. In Chapter 7, 
we studied the effects of fibrate treatment in an international cohort of both fenofibrate- 
and bezafibrate-treated patients and assess potential differences. For both fibrate types, 
we found a beneficial effect on biochemistry, in keeping with previous studies. We did 
not identify large differences in the effects on either biochemistry or short-term clinical 
outcome. Although absolute numbers are small, a trend towards more side effects leading 
to treatment discontinuation in the fenofibrate group was a finding of interest that should 
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be validated in future studies. As the beneficial treatment effects do currently not indicate a 
preference for either fibrate subtype, side effects may represent a leading argument in the 
future.  Today, however, the choice of fibrate type is often largely dictated by availability, as 
in many countries only one type is approved. Currently, different fibrate subtypes including 
PPAR-δ agonists with possible anti-fibrotic potential are being studied45.
Treatment strategy
Discussing both OCA and fibrates as second-line add-on therapies raises the question which 
of these agents should qualify as first-choice agent. While well-executed placebo-controlled 
trials should provide more definitive answers, we are now lacking such information. Although 
symptom management is not within the scope of this thesis, the burden of disease-related 
symptoms is significant for patients with PBC46. Pruritus contributes to an impaired quality 
of life in many patients and effective treatment options are limited. While OCA is known 
to provoke or worsen pruritus in a proportion of patients8, observational studies suggest 
a dramatic improvement in pruritus in patients treated with fibrates47. Although these 
promising findings await confirmation by a placebo-controlled trial48 (FITCH; NCT02701166), 
effects on symptoms can be an important factor to take into account when considering 
second-line therapy. Interestingly, a pilot study showed that addition bezafibrate therapy 
was able to further improve both biochemistry and pruritus in patients treated with UDCA 
and OCA49, suggesting that triple therapy should be further explored. However, it should 
be noted that at present, OCA is still the only officially approved second-line agent for PBC. 
Therefore, currently both physicians and patients have to be willing to prescribe/undergo 
off-label therapy with the associated risks when considering fibrates. 
LIVER TRANSPLANTATION
Roughly up until 1980, PBC was the leading indication for LT in Europe, accounting for 30-
50% of all LTs. Despite increasing disease prevalence50, 51, today PBC is no longer a leading 
indication for LT. As the therapeutic horizon has markedly improved since then, prognosis 
is now much more favorable7, 8, 19, 52-55. However, in case of liver failure, liver transplantation 
remains the only therapeutic option to prevent premature death. As changes in selection 
criteria and the introduction of UDCA as an effective treatment likely impacted the relative 
importance of PBC as indication for LT, in Chapter 8 we evaluated time trends in the number 
of liver transplantations for PBC across Europe over the past three decades. Although in 
line with previous smaller, older studies56, 57 we found an initial gradual decrease in absolute 
and relative number of LTs for PBC, over the most recent decade we reported a stabilization 
in the absolute number of LTs for PBC where over 200 patients in Europe receive LT for 
PBC annually. The introduction of urgency-based allocation by MELD-score58 has removed 
time on the waitlist as a contributing factor in liver allocation. This may have decreased 
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PBC patients’ chances of receiving a LT giving the slowly progressive nature of this disease. 
Although outcome after LT for PBC is generally good, the remaining numbers of LT in PBC 
could be considered worrisome, especially since wait-list mortality was recently reported to 
be relatively high for patients with PBC as compared to other liver disease59, suggesting that 
our number might be an underestimation of the actual need for LT.  
CONCLUSIONS
Treatment with ursodeoxycholic acid is associated with a reduced risk of liver transplantation 
or death among all patients suffering from PBC. In absolute terms, the number needed to 
treat to prevent liver transplantation can be considered very low. Additionally, the large 
majority of UDCA-treated patients with PBC nowadays remain free of decompensating 
events. These findings justify the recommendation for lifelong treatment with UDCA for 
all patients with PBC. Nonetheless, an important group of PBC patients remains to have 
a diminished prognosis when compared to the normal population, and a subgroup still 
relies on LT to prevent premature death. Therefore, add-on treatment should be considered 
in case of an incomplete response to UDCA treatment. Second-line therapies include 
obeticholic acid, which induces improvement of biochemistry and prognosis as predicted by 
validated models, and fibrates, that also induce significant improvements in biochemistry. 
Because bilirubin within the currently accepted normal range is associated with LT-free 
survival, physicians may consider striving beyond normalization of bilirubin when evaluating 
treatment response. 
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Primaire biliaire cholangitis (PBC) is een chronische leverziekte die kan leiden tot fibrose en 
uiteindelijk cirrose. Wanneer patiënten niet behandeld worden is hun levensverwachting 
significant slechter dan de normale populatie. 
Omdat PBC een zeldzame ziekte is die zich relatief langzaam ontwikkelt, is het verrichten 
van onderzoek naar deze ziekte zeer lastig gebleken. Gedurende het afgelopen decennium 
hebben grote nationale en internationale samenwerkingsverbanden – zoals de Global PBC 
Study Group - het mogelijk gemaakt om accuraat onderzoek te doen naar lange termijn 
uitkomsten in grote groepen patiënten met PBC. Een eerdere studie verricht door de 
Global PBC Study Group toonde aan dat alkalisch fosfatase en bilirubine onafhankelijke 
surrogaatmarkers zijn voor klinische uitkomstmaten zoals levertransplantatie en overlijden. 
Deze consensus leidde tot de mogelijkheid om de effecten van potentieel therapeutische 
middelen te onderzoeken binnen een relatief kort tijdsbestek. Ook de ontwikkeling van 
continue risico scores die zijn gebaseerd op beschikbare klinische parameters, waren een 
belangrijke stap voorwaarts. 
PROGNOSE 
Bilirubine is uitgebreid onderzocht als voorspeller voor klinische uitkomstmaten. 
Tegenwoordig is het een geaccepteerde marker voor prognose, zowel in onbehandelde 
patiënten als in patiënten behandeld met ursodeoxycholzuur (UDCA). Shapiro et al. 
beschreven reeds in 1979 dat het patroon van bilirubine wordt gekenmerkt door twee 
duidelijk afgrensbare fases: een eerste fase waarin het bilirubine zich redelijk stabiel 
gedraagt gedurende een ruim aantal jaren, gevolgd door een fase met een snelle stijging. 
Omdat bilirubine gedurende de vroege ziektestadia meestal niet abnormaal is, wordt het 
meestal beschouwd als een ‘late biomarker’. Lammers et al. hebben eerder beschreven 
dat een grens van 1.0 x de bovengrens van normaal de beste voorspellende waarde voor 
levertransplantatie of overlijden had. Deze bevinding heeft mogelijk impact gehad op de 
ontwikkeling van zowel inclusiecriteria als primaire uitkomstmaten van klinische studies 
voor tweedelijns therapeutische middelen, waarin deze grens voor bilirubine frequent 
is opgenomen. In hoofdstuk 2 wordt de prognostische relevantie van bilirubine binnen 
de huidige grenzen van normaal beschreven. We laten zien dat een grens van 0.6 x de 
huidige bovengrens van normaal goed in staat is risico te discrimineren, met een lineaire 
relatie. Dit geldt zowel voor onbehandelde patiënten als voor patiënten behandeld met 
UDCA. We demonstreren tevens dat voor patiënten die initieel een bilirubine boven de 
0.6 x de huidige bovengrens hebben, een therapie-geïnduceerde verlaging tot onder die 
grens is geassocieerd met een verbeterde transplantatie-vrije overleving. Deze resultaten 
suggereren dat we met therapie mogelijk moeten streven naar een niveau verder dan 
alleen ‘normalisatie’ en dat voor toekomstige interventiestudies overwogen kan worden om 
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patiënten met een bilirubine boven 0.6x de huidige bovengrens te includeren. Ook zou deze 
grens overwogen kunnen worden als onderdeel van primaire of secundaire uitkomstmaten. 
Alhoewel deze studie zich primair heeft gefocust op bilirubine, laten wij tevens zien dat 
alkalisch fosfatase onder de 1.67 x de huidige bovengrens – een grens die frequent is 
gebruikt in biochemische responscriteria, evenals als inclusiecriterium en eindpunt – ook 
geassocieerd is met transplantatie-vrije overleving. Toekomstige studies moeten uitwijzen of 
andere biochemische markers ook prognostisch zijn binnen de huidige range van normaal. 
COMPLICATIES VAN CIRROSE
Alhoewel tegenwoordig de meeste PBC-patiënten worden gediagnosticeerd in een vroeg 
ziektestadium, liet een recente Britse studie zien dat circa 40% van alle patiënten cirrose 
ontwikkelt na tien jaar follow-up. Deze patiënten hebben vervolgens een verhoogd risico 
op het ontwikkelen van klinische complicaties die zijn geassocieerd met het hebben van 
cirrose, die op hun beurt een toegenomen risico op levertransplantatie en overlijden met 
zich mee brengen. In hoofdstuk 3 hebben we onderzoek gedaan naar niet-neoplastische, 
cirrose-gerelateerde klinische complicaties. Hieronder vielen het ontwikkelen van ascites, 
een varicesbloeding en hepatische encefalopathie. We beschrijven dat de cumulatieve 
10-jaars incidentie van eerste complicaties 9% was in de gehele studiepopulatie en 
dat, net als bij andere leverziekten, de prognose na dergelijke complicaties slecht was. 
Desalniettemin vonden we dat de incidentie van deze complicaties de afgelopen jaren 
is afgenomen, wat mogelijk verklaard kan worden door verbeterde herkenning van het 
ziektebeeld waarbij therapie sneller gestart wordt. We vonden dat circa 20% patiënten 
zowel een goede biochemische respons op ursodeoxycholzuur als een lage APRI-score 
(AST to Platelet Ratio Index) hadden. Deze groep patiënten had een zeer lage kans op het 
ontwikkelen van de eerdergenoemde klinische complicaties. Deze bevindingen kunnen 
relevant zijn voor het voorlichten van patiënten in de spreekkamer. De risicofactoren die in 
deze studie geassocieerd waren met het optreden van cirrose-gerelateerde complicaties zijn 
grotendeels vergelijkbaar met eerder beschreven risicofactoren voor levertransplantatie en 
overlijden, waarbij we vonden dat biochemische respons zeer sterk geassocieerd was. Die 
bevinding benadrukt het belang van het evalueren van biochemische respons op therapie. 
BEHANDELINGEN DIE DE PROGNOSE VERANDEREN
Ursodeoxycholzuur
Het klinisch beeld van PBC werd voor het eerst beschreven door Addison en Gull in 1851, 
waarna een lange tijd volgde waarin er geen therapeutische opties waren voor de ziekte. Na 
vele teleurstellende studies die de werkzaamheid van verschillende medicijnen evalueerden, 
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was ursodeoxycholzuur eind jaren ’80 het eerste medicijn dat veelbelovende resultaten 
opleverde zonder dat er hevige bijwerkingen optraden. Verschillende lange termijnstudies 
wekten de indruk dat ursodeoxycholzuur leidde tot een verbeterde levensverwachting, 
maar deze aannames waren slechts gebaseerd op de vergelijking van geobserveerde 
levensduur met geschatte levensduur op basis van prognostische modellen. Daar tegenover 
stond dat diverse gerandomiseerde studies geen gunstig effect op de levensverwachting 
konden aantonen. Dit leidde tot een langdurige discussie tussen experts op het gebied van 
PBC. De twijfels aan de werkzaamheid van ursodeoxycholzuur werden ondersteund door 
een Cochrane meta-analyse die in 2017 verscheen, waarin werd geconcludeerd dat er geen 
bewijs was voor winst in levensverwachting door behandeling met ursodeoxycholzuur. 
In hoofdstuk 4 onderzochten we de associatie tussen ursodeoxycholzuur therapie en 
transplantatie-vrije overleving door het toepassen van een moderne statistische methode: 
inverse probability of treatment weighting. Dit is een vorm van propensity matching die als 
doel heeft in retrospect een gerandomiseerde studie na te bootsen. Dit was mogelijk door 
de beschikbaarheid van een groot cohort van zowel behandelde als onbehandelde patiënten 
met lange termijn follow-up data. Dit resulteerde in een cumulatieve transplantatie-vrije 
overleving van 79.7% in behandelde patiënten, versus 60.7% in onbehandelde patiënten, 
corresponderend met een hazard ratio van 0.46. Deze associatie was significant in alle 
subgroepen van patiënten. Alhoewel bij een retrospectieve studie ware effectiviteit nooit 
bewezen kan worden, is het bijzonder moeilijk om een residual confounder te bedenken die 
deze associatie geheel teniet zou doen. Van belang is dat we tevens demonstreerden dat 
de overlevingswinst ook werd aangetoond in patiënten die volgens internationale criteria 
werden geclassificeerd als ‘onvoldoende of niet responderend op behandeling’. Met oog op 
de bevinding dat overlevingswinst werd gezien bij alle behandelde patiëntgroepen, stellen 
wij voor de voorgenoemde termen ‘onvoldoende of niet responderend’ te vervangen door 
‘incompleet responderend’. De afwezigheid van het vinden van therapie-gerelateerde 
overlevingswinst in de vroegere gerandomiseerd studies wordt waarschijnlijk verklaard 
door een insufficiëntie follow-up bij deze langzaam progressieve ziekte.
Therapeutisch voordeel kan ook worden geëvalueerd gemeten in een absolute klinische 
effectmaat, zoals de number needed to treat (NNT) om overlijden of levertransplantatie 
te voorkomen. Binnen de hepatologie is het gebruik van deze effectmaat nog relatief 
zeldzaam, maar in andere medische velden is dit al jaren gebruikelijk. De NNT is gemakkelijk 
te interpreteren voor zowel patiënten als zorgverleners omdat het de relatieve risicoreductie 
en het risico van de patiënt wanneer er geen behandeling plaatsvindt, vangt in één 
parameter. Dit is klinisch van groot belang, omdat die beide factoren kunnen verschillen van 
patiënt tot patiënt. Hoofdstuk 5 beschrijft de klinische effectiviteit van ursodeoxycholzuur in 
patiënten met PBC. We vonden dat in de gehele studiepopulatie, de NNT om één overlijden 
of levertransplantatie te voorkomen binnen vijf jaar therapie 11 was. Dit wordt over het 
algemeen als zeer laag beschouwd. Het is belangrijk om te beseffen dat PBC een chronische 
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ziekte is waar levenslange therapie wordt aangeraden, waarbij de grens van vijf jaar dus 
meestal ruimschoots overschreden wordt. We zagen dat de NNT met de tijd afnam, waarbij 
de NNT10jaar slechts 6 bleek. We demonstreerden bovendien dat de variatie in NNT vooral 
afhankelijk was van het risico op een klinisch eindpunt van de onbehandelde patiënt, terwijl 
de relatieve risicoreductie geïnduceerd door ursodeoxycholzuur vrij stabiel was. Daarnaast 
laten we zien hoe de NNT voor de individuele patiënt geschat kan worden op basis van 
de GLOBE score (een prognostisch model eerder ontwikkeld door de Global PBC Study 
Group in behandelde patiënten), door onder andere aan te tonen dat de GLOBE score ook 
betrouwbaar de levensverwachting voorspelt in onbehandelde patiënten. De resultaten 
uit hoofdstuk 4 en 5 dragen gezamenlijk bij aan het bewijs dat het advies om patiënten 
met PBC levenslang te behandelen met ursodeoxycholzuur ondersteunt, zeker gezien de 
afwezigheid van belangrijke bijwerkingen en de lage kosten. Het hedendaagse belang van 
deze resultaten werd benadrukt door een recente studie die toonde dat in een Westerse 
populatie circa 30% van de patiënten met PBC onbehandeld bleven. Ook kunnen onze 
studieresultaten artsen ondersteunen in de voorlichting van patiënten in de spreekkamer 
en kan het de therapietrouw mogelijk verbeteren. 
Obeticholzuur
Jarenlang was ursodeoxycholzuur het enige geregistreerde medicijn voor PBC. Na 
de publicatie van de POISE studie, een fase III placebo-gecontroleerde studie waarin 
obeticholzuur werd geëvalueerd, werd dit middel in 2016 goedgekeurd door de FDA. Dit 
was een mijlpaal in het PBC landschap, zeker gezien de goedkeuring gebaseerd was op een 
surrogaat eindpunt van alkalisch fosfatase en bilirubine in plaats van op harde eindpunten. 
Ditzelfde jaar publiceerden zowel de Global PBC Study Group als de UK-PBC Study Group 
gevalideerde risicoscores die goed correleerden met levensverwachting. In hoofdstuk 6 
evalueerden we de geschatte overlevingswinst geïnduceerd door obeticholzuur, door de 
uitkomsten van de POISE studie toe te passen op deze risico scores. Op basis van de GLOBE 
score resulteerde obeticholzuur in een absolute risicoreductie van circa 5% na 10 jaar op 
levertransplantatie of overlijden, corresponderend met een relatieve risicoreductie van 24%. 
Vergelijkbare resultaten werden gevonden met gebruik van de UK-PBC Risk score. Alhoewel 
het primaire eindpunt van de studie door slechts 47% van de behandelde patiënten werd 
gehaald, vonden wij dat nagenoeg alle patiënten die waren behandeld met obeticholzuur 
verbeteringen van biochemie toonden, waarmee ze bovendien een significante geschatte 
overlevingswinst behaalden. Deze bevinding onderstreept het belang te beseffen wat de 
beperkingen zijn van het gebruik van dichotome uitkomstmaten, zeker wanneer er op basis 
van dergelijke resultaten ook kosten-effectiviteitstudies worden verricht die potentieel 
verstrekkende gevolgen kunnen hebben op de beschikbaarheid en vergoeding van 
middelen. Alhoewel onze resultaten nog in afwachting zijn van klinische bevestiging door 
de momenteel lopende fase vier studie, liet een recente publicatie van de open-label POISE-
extensiestudie zien dat de biochemische respons blijvend was gedurende 4 jaar. 
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Fibraten
Na vele jaren waarin verscheidene pilotstudies met bezafibraten of fenofibraten als add-on 
behandeling naast ursodeoxycholzuur veelbelovende resultaten lieten zien, demonstreerde 
een goed uitgevoerde Franse placebogecontroleerde studie spectaculaire biochemische 
verbeteringen door behandeling met bezafibraten met een verbeterde geschatte overleving 
tot gevolg. Er zijn tot op heden geen grote placebogecontroleerde studies die fenofibraten 
evalueren gepubliceerd, noch zijn er studies die de effecten van deze twee subtypes hebben 
vergeleken. In hoofdstuk 7 onderzochten we de effecten van behandeling met fibraten in 
een internationaal cohort van patiënten die ofwel met bezafibraten, ofwel met fenofibraten 
waren behandeld en evalueerden we eventuele verschillen. Bij beide subtypes vonden we 
een gunstig effect op de biochemie, in lijn met eerdere studies. We vonden geen grote 
verschillen in het effect op biochemie en korte termijn klinische uitkomsten. Alhoewel de 
aantallen beperkt waren, zagen we een trend richting meer discontinuatie van therapie 
leidende bijwerkingen in de groep die werd behandeld met fenofibraten. Deze bevinding 
behoeft verdere validatie in toekomstige studies en is van belang omdat bij een gebrek 
aan belangrijke verschillen in effect, het bijwerkingenprofiel leidend zou kunnen zijn 
in de keuze voor het type fibraat. Momenteel wordt de keuze echter vaak bepaald door 
beschikbaarheid, gezien in veel landen slechts één type fibraat verkrijgbaar is. Momenteel 
worden ook andere fibraat subtypes in studies geëvalueerd, waaronder PPAR-δ agonisten 
met mogelijke anti-fibrotische effecten. 
Therapeutische strategie
Het bespreken van zowel obeticholzuur als fibraten als tweedelijns add-on behandeling 
leidt tot de vraag welke van deze middelen de eerste keus verdient. Goed uitgevoerde 
placebogecontroleerde studies zouden definitieve antwoorden kunnen verstrekken, maar 
die zijn tot op heden niet voor handen. Alhoewel symptoommanagement niet het focus 
is van dit proefschrift, is de ziektelast van PBC-gerelateerde symptomen aanzienlijk. Jeuk 
draagt bij aan een verminderde kwaliteit van leven voor veel patiënten. In veel gevallen zijn 
de beschikbare therapeutische opties hiervoor beperkt. Van obeticholzuur is bekend dat het 
jeuk kan induceren of verergeren, terwijl fibraten lijken te leiden tot een drastische verbetering 
van de jeukklachten. Alhoewel we de resultaten van een Nederlandse gerandomiseerde 
studie naar het effect van bezafibraten op jeuk nog afwachten, kan het effect op symptomen 
een belangrijke factor zijn in de keuze voor een tweedelijns medicament. Preliminaire 
resultaten van een Belgische studie toonden dat het toevoegen van bezafibraten bij patiënten 
die reeds behandeld worden met ursodeoxycholzuur én obeticholzuur, leidde tot zowel een 
biochemische verbetering als een afname van de jeuk. Dit wekt de suggestie dat eventuele 
triple therapie verder geëxploreerd moet worden. Desalniettemin moet genoemd worden 
dat tot op heden obeticholzuur het enige geregistreerde tweedelijns medicijn is voor PBC. 
Zowel patiënten als artsen moeten momenteel derhalve bereid zijn om off-label medicijnen 
in te nemen of voor te schrijven, wanneer fibraten overwogen worden. 
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LEVERTRANSPLANTATIE
Tot rond 1980 was PBC de meest voorkomende indicatie voor levertransplantatie in 
Europa, verantwoordelijk voor 30-50% van alle transplantaties. Ondanks een toenemende 
ziekteprevalentie is PBC tegenwoordig geen veel voorkomende indicatie meer. Omdat de 
herkenning van de ziekte verbeterd is en de therapeutische horizon voor PBC sinds die tijd 
uitgebreid is, is de prognose van patiënten met PBC sterk verbeterd. Desalniettemin is in het 
geval van leverfalen, levertransplantatie nog altijd de enige optie om overlijden te voorkomen. 
Omdat zowel veranderingen in selectiecriteria als de introductie van ursodeoxycholzuur 
waarschijnlijk een belangrijke impact hebben gehad op het relatieve belang van PBC als 
indicatie voor transplantatie, onderzochten wij in hoofdstuk 8 de veranderingen over de tijd 
in het absolute en relatieve aantal levertransplantaties voor PBC in Europa gedurende de 
afgelopen 30 jaar. In lijn met eerdere studies vonden wij gedurende de eerste 20 jaar een 
geleidelijke afname in zowel absolute als relatieve aantallen levertransplantaties bij patiënten 
met PBC. De laatste 10 jaar bleek er echter sprake van een stabilisatie in het absolute aantal 
levertransplantaties voor PBC, waarbij jaarlijks ca. 200 PBC-patiënten levertransplantatie 
ondergingen. Met de introductie van het urgentie-gebaseerde allocatiemodel middels de 
MELD score was tijd op de wachtlijst niet langer een bijdragende factor voor toewijzing van 
een lever. Dit zou ongunstig kunnen zijn voor patiënten met PBC met oog op de langzame 
progressie van deze ziekte. Alhoewel overleving na transplantatie bij patiënten met PBC over 
het algemeen goed is, is het zorgelijk dat het absolute jaarlijkse aantal levertransplantaties 
niet daalt, zeker omdat recente studies vermelden dat de wachtlijstmortaliteit relatief hoog 
is onder patiënten met PBC. Dit wekt de suggestie dat de behoefte aan levertransplantaties 
voor PBC mogelijk onderschat wordt. 
CONCLUSIES 
Behandeling met ursodeoxycholzuur is geassocieerd met een afgenomen risico op 
levertransplantatie en overlijden voor patiënten met PBC. De number needed to treat om 
een levertransplantatie of overlijden te voorkomen kan beschouwd worden als zeer laag. De 
grote meerderheid van patiënten die behandeld worden met ursodeoxycholzuur ontwikkelt 
tegenwoordig geen leverdecompensatie. Deze bevindingen rechtvaardigen het advies om 
patiënten met PBC levenslang te behandelen met ursodeoxycholzuur. Desalniettemin heeft 
een substantieel deel van de patiënten ondanks behandeling met ursodeoxycholzuur een 
prognose die slechter is dan de gewone populatie en is een subgroep van deze patiënten nog 
altijd afhankelijk van levertransplantatie om vervroegd overlijden te voorkomen. Daarom 
moet tweedelijns behandeling overwogen worden in geval van een incomplete respons 
op ursodeoxycholzuur. In dat geval kunnen zowel obeticholzuur als fibraten overwogen 
worden, die beide leiden tot verbetering van biochemie en geschatte overleving. Omdat 
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bilirubine binnen de huidige grenzen van normaal is geassocieerd met transplantatie-vrije 
overleving, kan worden overwogen om voorbij normalisatie te streven wanneer respons op 
therapie geëvalueerd wordt. 
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DANKWOORD
Ik voel mij enorm bevoorrecht dat ik hier vandaag mag staan. Dit proefschrift was er nooit 
geweest zonder de hulp, inzet en betrokkenheid van velen. Graag wil ik deze gelegenheid 
dan ook gebruiken om jullie hiervoor te danken. 
Beste prof. H.J. Metselaar, beste Herold. Dank voor zowel de begeleiding bij mijn projecten, 
als ook voor de ruimte die ik kreeg om samen met mijn copromotoren invulling te geven aan 
mijn promotietraject in de PBC-niche. 
 Henk (dr. H.R. van Buuren) en Bettina (dr. B.E. Hansen), mijn copromotoren, heel hartelijk 
dank voor de kans die jullie mij hebben geboden om deel uit te maken van de Global PBC 
Study Group, ik ben met mijn neus in de boter gevallen. Ik heb me onder toeziend oog van 
jullie kunnen ontwikkelen en heb van collega's van over de hele wereld mogen leren. Ik keek 
altijd uit naar onze meetings, waar meer dan alleen onderzoek werd besproken; ik denk dat 
ik er nog nooit ben weg gegaan zonder ook heel hard te hebben gelachen. 
  Henk, ik moet bekennen dat ik tijdens onze eerste ontmoeting in de kliniek direct onder 
de indruk was. Je leek mij een no-nonsense dokter met verstand van zaken. Die eerste 
indruk bleek nog een onderschatting. Ik bewonder je uitgebreide kennis, wetenschappelijke 
interesse, pragmatisme en bovenal je vermogen om altijd de mens in de patiënt te blijven 
zien. Ik hoop op een dag net zo’n goede, allround dokter te kunnen zijn. Heel veel dank voor 
al je input in het onderzoek en voor de ruimte die je me gaf om daar zelf invulling aan te 
geven. 
 Bettina, toen jij tijdens mijn eerste congres in Boston met de promovendi mee de 
dansvloer op stapte, wist ik direct dat ik een hele leuke baas had getroffen. Gaandeweg 
kwam ik er achter dat ik niet alleen een leuke copromotor had, maar ook één die bij de 
wereldtop in haar vakgebied hoort. Jouw hulp bij mijn projecten was onmisbaar, veel dank 
voor je begeleiding. 
  Mijn dank gaat bovendien uit naar prof. dr. U.H.W. Beuers, prof. dr. D. Rizopoulos en 
prof. dr. R.A. de Man, die wilden deelnemen in mijn leescommissie om dit proefschrift te 
beoordelen. Daarnaast dank ik prof. dr. J.L.C.M. van Saase en prof. dr. B. van Hoek voor het 
plaatsnemen in mijn promotiecommissie. Dear Palak (dr. Trivedi), thank you so much that 
you were willing to be a part of my thesis defense committee, I have always enjoyed our 
cooperation and very much admire your drive and work ethos. 
  Beste prof. dr. R.A. de Man en prof. dr. C.J. van der Woude. Veel dank voor het in mij 
gestelde vertrouwen om mijn MDL-opleiding te kunnen doorlopen in en rondom de stad die 
mijn hart heeft veroverd. Beste Hans (dr. H.E. van der Wiel) en Emile (dr. E.L.E. de Bruijne), 
dank dat ik mijn vooropleiding interne geneeskunde in het IJsselland ziekenhuis onder jullie 
supervisie mag doorlopen.
  Dear members of the Global PBC Study Group. Without your cooperation, the completion 
of this dissertation would not have been possible. Many of you welcomed me into your 
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hospitals and homes and were willing to share valuable data. Many, many thanks, I have 
fond memories of these experiences.
  Marion en Margriet, de backbone van de hepatologie, dank voor de altijd beschikbare 
helpende hand en de ondersteuning tijdens de afronding van dit proefschrift. 
Men zegt wel eens dat collega’s je werk kunnen maken of breken. Lieve collega’s, jullie 
hebben mijn promotietijd absoluut gemáákt. Toen ik voor het eerst mijn toekomstige 
werkplek - de befaamde dakpoli - betrad via de niet bijzonder uitnodigende brandtrap, had 
ik niet kunnen voorzien dat die plek haast een tweede thuis zou worden.  
  De steeds wisselende EMC assistentengroep: dank voor alle leuke borrels, congressen, 
en fiets- en hardloopavonden. Lieve Ad, dankjewel dat jij me benaderde met een 
onderzoeksplan. Het heeft via eindeloos veel koffietjes, sparren over zowel inhoud als 
details en talloze borrels uiteindelijk geleid tot papers om trots op te zijn en een vriendschap 
die me bijzonder dierbaar is.
  Lieve, leuke dakduifjes. De koffietjes, lunches, sparsessies, borrels, feestjes, congressen, 
festivals, skitrips, hoogtepunten en promotie-inzinkingen, het was fantastisch om dit alles 
met jullie te delen. Met een aantal van jullie heb ik mijn tijd op het dak in het bijzonder 
beleefd.
  Allereerst, mijn kamergenootjes! Shannon en Els, tijdens mijn eerste MDL skiweekend 
legden we de basis voor een fantastische tijd op het dak en een vriendschap voor lang daarna. 
Shan, mijn kamergenootje vanaf dag één. Het klikte meteen en er zijn weinig mensen waar 
ik zo intens hard mee kan lachen (om dingen die niemand anders begrijpt..). Wij hebben 
eindeloos veel gepraat maar hebben eigenlijk vaak aan een blik al genoeg. Gelukkig heb 
je onderweg ingezien dat Rotterdam toch echt veel leuker is en werden we zelfs herenigd 
in het YSL! Ik mis je enorm sinds je daar weg bent. Lieve Elsie, na een jaar pikte ik de plek 
van WP in op 425. In de twee jaar die volgden heb jij voorgoed een figuurlijk plekje in mijn 
hart veroverd, en gelukkig zelfs ook een letterlijk plekje om de hoek! Dankjewel dat jij geen 
genoegen neemt met een half antwoord en altijd doorvraagt naar dingen die belangrijk 
zijn, binnen het onderzoek maar vooral ook daar buiten. Te gek dat je vandaag naast mij wil 
staan. Lieve Sophia, toen jij op het dak verscheen wist ik meteen dat wij een match zouden 
zijn. We bleken neighbours in Kralingen en werden zelfgekozen roomies op het dak. Het 
was een voorrecht om mijn laatste tijd op het dak met jou te delen, jij hebt me er absoluut 
doorheen gesleept! Dat jij vandaag mijn paranimf bent is metaforisch voor hoe jij er altijd 
bent, in spannende of moeilijke maar ook in te gekke tijden, dankjewel. 
  Lieve Joan, jouw schaterlach, die regelmatig door de muur heen te horen was, maakt me 
altijd vrolijk. Ik mis je, oude Amsterdammer! Louisa, lieve Lies, partner in crime, team nooit 
meer naar huis is nooit compleet zonder jou. Dank voor de talloze geniale feestjes waarbij 
we de lichten uit (en weer aan..?) hebben gedaan en alle andere momenten die we hebben 
gedeeld. Ik kijk enorm uit naar onze hereniging in het EMC! Lieve Raoel, twee superleuke 
periodes in Toronto kwam ik jou vergezellen en ontdekte ik hoe leuk jij bent! Helaas hebben 
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we het YSL niet samen meegemaakt, maar gelukkig is een gezamenlijke voorliefde voor 
lekker eten en drinken een solide basis van onze vriendschap. Lieve Sil, jij bent altijd overal 
voor in en het lijkt wel alsof er 30 uren in jouw dag zitten, om jaloers van te worden! Bedankt 
voor jouw onuitputtelijke energie en goede vibe! Lieve Stella, jouw positieve instelling en 
uitstraling zijn uniek. Bedankt dat je me altijd vrolijk maakt! Lieve Fanny, jouw werkethos is 
ongekend. Gelukkig kun je net zo hard borrelen als werken, bedankt voor alle gezelligheid! 
Lieve Juul, hoe fijn dat jij team MDL YSL bent komen versterken. Ellendige einden hardlopen, 
fijne gesprekken met een goed glas wijn, slechte gifjes en mooie feestjes, met jou kan alles! 
Wim, dank dat ik mocht verder werken op het fundament wat jij samen met Henk en 
Bettina gelegd hebt en voor alle heerlijk droge grappen. Jorn, bedankt voor de gezellige 
samenwerking. Heel veel succes nog even, de finish is in zicht! Lieve Rozanne, wij bleken 
van hetzelfde hout gesneden. Zo trof ik in jou niet alleen een ideale opvolger, maar ook een 
nieuwe vriendschap. Zowel PBC-inhoudelijk als op de borrels gaan we de er de komende 
jaren iets moois van maken, ik heb er zin in! Alle andere lieve lab-ratten en dak-duiven: dank 
voor deze te gekke tijd, ik heb van jullie genoten! Gelukkig komen we elkaar ongetwijfeld 
snel weer tegen.
 Lieve YSL collega’s, dank voor het herstellen van mijn vertrouwen in de interne geneeskunde 
door mij te laten zien dat ook daar de congressen en skiweekenden onvergetelijk zijn! 
Daarnaast dank ik jullie natuurlijk dat jullie mij na die jaren van vooral wetenschap wegwijs 
hebben gemaakt in de kliniek en voor de ruimte die ik kreeg om mijn proefschrift af te 
ronden en krijg om mijn wetenschappelijke ambities voort te zetten. Vanaf nu heb ik meer 
tijd voor borrels!
En dan mijn familie en vrienden, de mensen die mij maken tot wie ik ben en wie ik wil zijn. 
Jullie wil ik heel graag bedanken. Zonder iemand tekort te willen doen, wil ik een aantal 
mensen in het speciaal noemen.
  Lieve Tanja, lieve roomie. Vier hele mooie jaren hebben wij gedeeld in het mooiste 
paleisje van Blijdorp, waar we stuivertje wisselden met coschappen en promoveren. Ik 
heb hele bijzondere herinneringen aan die tijd. Dat we elkaar de komende jaren dankzij 
jouw ongekende doorzettingsvermogen ook op onderwijsmomenten en MDL-congressen 
zullen zien is de perfecte bonus op onze vriendschap! Lieve Edmée. Jouw trouwheid is 
ongeëvenaard, er is niemand anders van wie ik zo attent op alle momenten die voor mij 
belangrijk waren een kaartje, telefoontje, berichtje of andersoortig steuntje in de rug kreeg. 
Lieve ladies, gelukkig zijn onze vriendschappen zeker niet afhankelijk van deze Maasstad en 
weten we elkaar, ondanks wat extra kilometers, heel goed te vinden. 
  Lieve Charlotte, Inge en Lisanne. Wat ben ik blij dat ik jullie na al die jaren nog steeds mag 
scharen onder mijn dierbaarste vrienden. We hebben over de jaren bijzondere tijden met 
elkaar doorgebracht en dat bleek het fundament voor een vriendschap voor het leven. Nog 
altijd kom ik vol energie weer terug van waar we elkaar dan ook zien. 
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  Ruben, lieve Ruubje. Jouw ambities en je hang naar altijd meer en beter (getuige je boekje/
promotiebijbel) zijn aanstekelijk. Met jou kan ik discussiëren over wetenschap, eindeloos 
over niks praten en daarnaast alles bespreken waar het echt over gaat in het leven. Dank 
voor die fijne vriendschap. 
  Lieve Yagmur, Roos en Bodine. Dank jullie wel voor alle welkome promotie-
afleidingsmomenten. Ondanks dat wij initieel verbonden zijn door het dokter-zijn, gaat het 
(gelukkig) vooral vaak over andere dingen. Rio was natuurlijk legendarisch, maar ik weet 
zeker dat er nog vele onvergetelijke momenten zullen volgen. Ik ben heel dankbaar dat ik 
vriendinnetjes als jullie heb! 
En dan jij, lieve papa. Jij zal voor mij altijd een voorbeeld blijven en waarschijnlijk was jij het 
die mij ergens in mijn achterhoofd motiveerde om dit promotietraject aan te gaan en door 
te zetten. Hoe jij moeilijke vraagstukken wist om te zetten in dagelijkse, vaak supermarkt-
gerelateerde metaforen en daarnaast een bijna grenzeloze passie had voor patiëntenzorg, 
was uniek. Ik mis je.
  Lieve hele grote broer, lieve Job. Je daagt me vaak uit met ingewikkelde raadsels en 
vraagstukken en bent altijd benieuwd naar mijn visie. Je enthousiasme voor wetenschap is 
inspirerend! Dank daarvoor (en voor je eindeloze geduld als ik voor de honderdste keer mijn 
telefoon niet opneem). Nu maar hopen dat ik niet te veel onder doe voor jouw verdediging… 
Lieve Anne-Marie, dankjewel dat je Job zo gelukkig maakt. Hoe leuk dat ik Rio ook met jou 
kon beleven, in de toekomst komen daar vast nog allerlei avonturen bij! 
   Jorijn, liefste zus, jij bent als grote zus degene waar ik al zo lang ik me kan herinneren 
stiekem tegen op kijk omdat jij altijd je eigen, originele pad kiest en nooit bang lijkt voor 
avontuur. Jouw blik op de wereld is out of the box en daardoor heel verfrissend. Dankjewel 
dat jij er ongeacht fysieke afstand altijd voor mij was en bent. Zo fijn dat je nu weer in de 
buurt bent!
   Lieve Sander, Karin, Olivier en Henny. Dank voor jullie warme gastvrijheid als Rutger en ik 
weer eens onverwachts aanschuiven, maar ook voor het begrip voor het drukke leven dat 
ik leid en de afwezigheid op sommige familie-events die daar af en toe mee gepaard gaat. 
Lieve Steven, je wordt enorm gemist. Je had het fantastisch gevonden hier vandaag bij te 
zijn. Ik haal veel inspiratie uit de herinnering aan hoe jij genoot van de grote maar zeker ook 
de kleine dingen en zo elke dag het leven vierde. 
  Lieve Jos, je weet het soms te verbergen voor de buitenwereld, maar je hart is enorm 
groot. Dank voor wie je voor mij en voor mama bent. Allerliefste mama, jij bent mijn rots in 
de roerige branding die ik soms voor mezelf weet te creëren. Je hebt mij een stevige basis 
van vertrouwen en liefde gegeven, waar ik altijd op kan terugvallen. En altijd precies als ik 
het nodig heb, krijg ik een telefoontje van jou. Dank je wel voor alles. 
En dan ten slotte mijn lieve Rutger, mijn eigen kapitein. Wie had kunnen denken dat ‘nog 
even één biertje gaan drinken’ me zoiets moois zou brengen? Jouw vastberadenheid om 
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alles uit het leven te halen is aanstekelijk. Dankjewel dat je mijn passie voor de geneeskunde 
begrijpt, dat je me altijd het gevoel geeft trots op me te zijn - met of zonder mijn ambities en 
prestaties - en dat je me motiveert om te streven naar mijn eigen top. Samen met jou is het 
leven een avontuur, ik kan niet wachten om de rest te gaan ontdekken!

228 CHAPTER 12
POST SCRIPT
12
229
CHAPTER 12
CONTRIBUTING AUTHORS
DANKWOORD
BIBLIOGRAPHY
CURRICULUM VITAE
PHD PORTFOLIO
230 CHAPTER 12
BIBLIOGRAPHY
Harms MH, Gaouar F, Corpechot C, Reig A, Janssen HLA, Floreani A, Mason AL,  Beuers U, 
Trauner M, Halibasic E, Hirschfield GM, Gulamhusein A, Montano-Loza A, Levy C, Van Buuren 
HR, Hansen BE, Pares A. Comparable results of fenofibrate and bezafibrate treatment in 
patients with primary biliary cholangitis. Submitted.
Murillo Perez F, Harms MH, Lindor KD, Van Buuren HR, Hirschfield GM, Corpechot C, Van 
der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, Ponsieon CY, Carbone M, Mason AL, 
Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Nevens F, Kowdley KV, Bruns T, Dalekos G, 
Gatselis N, Thorburn D, Poupon R, Trivedi PJ, Verhelst X, Parés A, Janssen HL, Hansen BE. 
Bilirubin within the normal range is predictive of survival in primary biliary cholangitis. Am J 
Gastroenterol. 2019, provisionally accepted. 
Harms MH, De Veer RC, Lammers WJ, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, 
Trivedi PJ, Hirschfield GM, Parés A, Floreani A, Mayo MJ, Invernizzi P, Battzzati PM, Nevens 
F, Ponsieon CY, Mason AL, Kowdley KV, Hansen BE, Van Buuren HR, Van der Meer AJ. The 
Number Needed to Treat with Ursodeoxycholic Acid Therapy to Prevent Liver Transplantation 
or Death in Primary Biliary Cholangitis. Gut. 2019, in press.
Harms MH, Van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield 
GM, Parés A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsieon CY, Mason 
AL, Kowdley KV, Lammers WJ, Hansen BE, Van der Meer AJ. The Association between 
Ursodeoxycholic Acid Therapy and Liver Transplant-free Survival in Patients with Primary 
Biliary Cholangitis. J Hepatol. 2019 Apr;71(2):357-365.
Harms MH, van Buuren HR, Hansen BE, Metselaar HJ. Editorial: liver transplantation for 
primary biliary cholangitis – the need for timely and more effective treatments. Authors’ 
reply. Aliment Pharmacol Ther. 2019 Feb;49(4):473-474.
Harms MH, Janssen QP, Adam R, Duvoux C, Mirza D, Hidalgo E, Watson C, Wigmore SJ, 
Pinzani M, Isoniemi H, Pratschke J, Zieniewicz K, Klempnauer JL, Bennet W, Karam V, van 
Buuren HR, Hansen BE, Metselaar HJ; European Liver and Intestine Transplant Association 
(ELITA). Trends in liver transplantation for primary biliary cholangitis in Europe over the past 
three decades. Aliment Pharmacol Ther. 2019 Feb;49(3):285-295. 
Harms MH*, Carbone M*, Lammers WJ, Marmon T, Pencek P, MacConell L, Shaprio D, Jones 
DE, Mells GF, Hansen BE. Clinical application of the GLOBE score and UK-PBC score in a real 
world trial cohort of patients with primary biliary cholangitis. Hepatol. Commun. 2018 Apr 
19;2(6):683-692.
POST SCRIPT
12
231
Harms MH, Van Buuren HR, Van der Meer AJ. Improving Prognosis in Primary Biliary 
Cholangitis – therapeutic options and a treatment strategy. Best Pract Res Clin Gastroenterol. 
2018 Jun - Aug;34-35:85-94.
Goet JC, Harms MH, Hansen BE, Carbone M. Risk stratification and Prognostication in 
Primary Biliary Cholangitis. Best Pract Res Clin Gastroenterol. 2018 Jun - Aug;34-35:95-106.
Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, 
Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Pares A, Mason 
AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, Van Buuren HR, Global PBC 
Study Group. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With 
Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. Am J 
Gastroenterol . 2018 Feb;113(2):254-264. 
Van Buuren HR, Lammers WJ, Harms MH, Hansen BE. Surrogate Endpoints for Optimal 
Therapeutic Response to UDCA in Primary Biliary Cholangitis. Dig Dis. 2015;33 Suppl 2:118-
24. 
232 CHAPTER 12
PUBLICATIONS OUTSIDE THE SCOPE OF THIS THESIS
Gatselis NK, Goet JC, Zachou K, Lammers WJ, Janssen HLA, Hirschfield G, Corpechot C, Lindor 
KD, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Lygoura V, Nevens F, Mason 
AL, Kowdley KV, Ponsioen CY, Bruns T, Thorburn D, Verhelst X, Harms MH, van Buuren HR, 
Hansen BE, Dalekos GN; Global PBC Study Group. Factors Associated With Progression and 
Outcomes of Early-stage Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2019 Aug 
13. Epub ahead of print.
Montano-Loza AJ, Hansen BE, Corpechot C, Roccarina D, Thorburn D, Trivedi P, Hirschfield G, 
McDowell P, Poupon R, Dumortier J, Bosch A, Giostria E, Conti F, Parés A, Reig A, Floreani A, 
Russo FP, Goet JC, Harms MH, van Buuren H, Van den Ende N, Nevens F, Verhelst X, Donato 
MF, Malinverno F, Ebadi M, Mason AL; Global PBC Study Group.. Factors Associated With 
Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft 
and Patient Survival. Gastroenterology. 2019 Jan;156(1):96-107.
de Vries EM, de Krijger M, Färkkilä M, Arola J, Schirmacher P, Gotthardt D, Goeppert B, Trivedi 
PJ, Hirschfield GM, Ytting H, Vainer B, Buuren HR, Biermann K, Harms MH, Chazouilleres O, 
Wendum D, Kemgang AD, Chapman RW, Wang LM, Williamson KD, Gouw AS, Paradis V, 
Sempoux C, Beuers U, Hübscher SG, Verheij J, Ponsioen CY. Validation of the prognostic 
value of histologic scoring systems in primary sclerosing cholangitis: An international cohort 
study.  Hepatology. 2017 Mar;65(3):907-919. 
Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, Floreani A, 
Ponsioen CY, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Burroughs AK, Mason AL, Kowdley 
KV, Kumagi T, Harms MH, Trivedi PJ, Poupon R, Cheung A, Lleo A, Caballeria L, Hansen BE, van 
Buuren HR. Development and Validation of a Scoring System to Predict Outcomes of Patients 
With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology. 
2015 Dec;149(7):1804-1812.
de Valk J, Taal EM, Nijhoff MS, Harms MH, Van Lieshout EM, Patka P, Rood PP. Self-referred 
patients at the Emergency Department: patient characteristics, motivations, and willingness 
to make a copayment. Int J Emerg Med. 2015 May 9;8:15. 
*joint first authorship
POST SCRIPT
12
233

CHAPTER 12
CONTRIBUTING AUTHORS
DANKWOORD
BIBLIOGRAPHY
CURRICULUM VITAE
PHD PORTFOLIO
236 CHAPTER 12
POST SCRIPT
12
237
CURRICULUM VITAE
Maren Hermine Harms werd geboren op 28 maart 1990 te Bennebroek. Nadat zij in 2007 
haar VWO-diploma behaalde aan het Hageveld College te Heemstede, startte zij met haar 
studie geneeskunde in Rotterdam. Tijdens de doctoraalfase liep Maren stage op de Intensive 
Care van het Red Cross War Memorial Children’s Hospital in Kaapstad en werkte als student-
assistent op de afdelingen psychiatrie, gynaecologie en op de huisartsenpost. Ze verrichtte 
haar afstudeeronderzoek naar patiëntkarakteristieken en motivatie van zelfverwijzers op de 
afdeling Spoedeisende Hulp Geneeskunde van het Erasmus MC. Na het doorlopen van haar 
coschappen behaalde Maren in 2014 cum laude haar artsexamen. Aansluitend startte ze met 
haar promotieonderzoek naar de prognose en behandeling van primaire biliaire cholangitis, 
onder leiding van prof. dr. H.J. Metselaar, dr. H.R. van Buuren en dr. B.E. Hansen. Tijdens haar 
promotieonderzoek was ze tevens actief binnen Promovendi Netwerk Nederland en was zij 
geruime tijd voorzitter van Promeras, het vertegenwoordigend orgaan van alle promovendi 
binnen het Erasmus MC. In 2018 is ze gestart met de opleiding tot Maag-, Darm- en Leverarts 
(opleider: prof.dr. C.J. van der Woude) en ontving ze de NVH Young Hepatologist Award 
van de Nederlandse Vereniging voor Hepatologie voor het beste klinisch hepatologisch 
wetenschappelijk artikel van Nederlandse bodem in 2018. Momenteel doorloopt zij haar 
tweejarige vooropleiding Interne Geneeskunde in het IJsselland Ziekenhuis in Capelle aan 
de IJssel (opleiders: dr. H.E. van der Wiel en dr. E.L.E. de Bruijne). Maren woont samen met 
Rutger in Rotterdam. 
 
Maren Hermine Harms was born in Bennebroek (The Netherlands) on March 28, 1990. 
After graduating high school, she started studying Medicine in Rotterdam. She took an 
internship at the Intensive Care Unit of the Red Cross War Memorial Children’s Hospital in 
Cape Town and worked as student assistant at the Psychiatry and Gynecology wards and at 
the out of hours General Practitioners Clinic. For her master thesis she researched patient 
characteristics of and reasons for self-referral at the Emergency Department of the Erasmus 
MC. After finishing her rotations in 2014, she graduated with honor. Subsequently, she 
started working on her doctorate thesis regarding the prognosis and treatment of primary 
biliary cholangitis, under the supervision of prof. dr. H.J. Metselaar, dr. H.R. van Buuren and 
dr. B.E. Hansen. During this time, she participated in PhD Network Netherlands and served as 
chairwoman of Promeras, the representing body of all PhD students in the Erasmus Medical 
Center. In 2018 she started her specialization to become a gastroenterologist and received 
the NVH Young Hepatologist Award for the best Dutch clinical hepatology paper in 2018. 
Currently she is working as an Internal Medicine resident at the IJsselland Hospital in Capelle 
aan de IJssel. Together with Rutger, Maren lives in Rotterdam. 
  

CHAPTER 12
CONTRIBUTING AUTHORS
DANKWOORD
BIBLIOGRAPHY
CURRICULUM VITAE
PHD PORTFOLIO
240 CHAPTER 12
PHD PORTFOLIO
PhD student  Maren H. Harms
Department  Gastroenterology and Hepatology
Promotor  Prof.dr. H.J. Metselaar
Copromotors  Dr. H.R. van Buuren & Dr. B.E. Hansen
1. PhD training Year Workload
Methodology and Biostatistics Courses
Journal clubs, department of gastroenterology/hepatology, Erasmus MC, Rotterdam 2014 - 2017 60 hours
Endnote workshop, Erasmus MC library, Rotterdam 2014 6 hours
PubMed workshop, Erasmus MC library, Rotterdam 2014 6 hours
Biostatistics for clinicians, Netherlands institute for Health Sciences (NIHES), Rotterdam 2014 40 hours
Presenting skills for junior researchers, Erasmus Postgraduate School for Molecular 
Medicine (MolMed), Erasmus MC, Rotterdam
2015 12 hours
Biomedical English writing and communication, Erasmus MC, Rotterdam 2015 40 hours
Course Joint Modeling, Erasmus Summer School, Rotterdam 2016 24  hours
Research Integrity Courses
BROK cursus, consultatiecentrum patiëntgebonden onderzoek, Erasmus MC, 
Rotterdam
2014 24 hours
Integrity in scientific research, dept. of Medical Ethics and philosophy, Erasmus MC, 
Rotterdam
2015 36 hours
Oral presentations
Incidence and Impact of Decompensating Events in PBC, Half-yearly Meeting of the 
Dutch Association of Hepatology (NVH), Veldhoven
2015 12 hours
Incidence and Impact of Decompensating Events in Primary Biliary Cholangitis, The 
Liver Meeting, 65th Annual Meeting of the American Association for the Study of 
Liver Diseases (AASLD), Boston, USA
2015 36 hours
Behavioral Patterns of Total Serum Bilirubin Prior to Major Clinical Endpoints in PBC, 
50th International Liver Conference of the European Association for the Study of 
the Liver (EASL), Barcelona, Spain
2016 24 hours
Improvement in Estimated Survival after 1 Year of Obeticholic Acid Treatment, 50th 
International Liver Conference of the EASL, Barcelona, Spain
2016 24 hours
Primary Biliary Cholangitis at a Young Age - Clinical Characteristics and Prognosis, 
Half-yearly Meeting of the Dutch Association of Hepatology, Veldhoven
2016 12 hours
Comparable Beneficial Effects of Beza- and Fenofibrate in Primary Biliary 
Cholangitis, The Liver Meeting, 67th Annual Meeting of the AASLD, Boston, USA
2016 36 hours
Time Trends in Major Hepatic Complications in Primary Biliary Cholangitis: incidence 
and transplant-free survival, Digestive Disease Days, Veldhoven
2017 12 hours
POST SCRIPT
12
241
1. PhD training Year Workload
Time Trends in Major Hepatic Complications in Primary Biliary Cholangitis: incidence 
and transplant-free survival, The Liver Meeting, 68th Annual Meeting of the AASLD, 
Washington, USA
2017 36 hours
Ursodeoxycholic acid is Associated with Prolonged Transplant-free Survival in Primary 
Biliary Cholangitis, 52th International Liver Conference of EASL, Paris, France
2018 36 hours
Poster presentations
Risk Factors for Hepatic Decompensation in Primary Biliary Cirrhosis, 49th 
International Liver Conference of the EASL,  Vienna, Austria
2015 12 hours
Risk Factors for Hepatic Decompensation in Primary Biliary Cirrhosis, Falk 
Symposium 197, Autoimmune Liver Diseases, Lisbon 
2015 12 hours
Primary Biliary Cholangitis at a Young Age - Clinical Characteristics and Prognosis, 
The Liver Meeting, 67th Annual Meeting of the AASLD, Boston, USA
2016 12 hours
Association between UDCA Therapy and Prolonged Transplant-free Survival among 
Patients with Primary Biliary Cholangitis, AASLD, Boston, USA
2016 12 hours
Risk reduction with Obeticholic Acid in patients not achieving the POISE primary 
endpoint, 51th International Liver Conference of the EASL, Amsterdam
2017 12 hours
Effect of Obeticholic Acid Treatment in patients with PBC on categorical shifts in 
GLOBE score, 51th International Liver Conference of the EASL, Amsterdam
2017 12 hours
Risk reduction with Obeticholic Acid in patients not achieving the POISE primary 
endpoint, Monothematic conference, Cholangiocytes in health and disease, EASL, 
Oslo, Norway
2017 12 hours
Attended (inter)national conferences
The Liver Meeting, 65th Annual Meeting of the American AASLD, Boston, USA 2014 28 hours
50th International Liver Conference of the EASL, Vienna, Austria 2015 28 hours
Falk Symposium 197, Autoimmune Liver Diseases, Lisbon, Portugal 2015 20 hours
Half-yearly Meeting of the Dutch Association of Hepatology, Veldhoven 2015 12 hours
The Liver Meeting, 66th Annual Meeting of the AASLD, San Francisco, USA 2015 28 hours
Half-yearly Meeting of the Dutch Association of Gastroenterology, Veldhoven 2016 12 hours
51st International Liver Conference of the EASL, Barcelona, Spain 2016 28 hours
Half-yearly Meeting of the Dutch Association of Hepatology, Veldhoven 2016 12 hours
The Liver Meeting, 67th Annual Meeting of the AASLD, Boston, USA 2016 28 hours
Half-yearly Meeting of the Dutch Association of Gastroenterology, Veldhoven 2017 12 hours
52nd International Liver Conference of EASL, Amsterdam 2017 28 hours
Monothematic conference, Cholangiocytes in health and disease, EASL, Oslo, Norway 2017 20 hours
Half-yearly Meeting of the Dutch Association of Hepatology, Veldhoven 2017 12 hours
The Liver Meeting, 68th Annual Meeting of the AASLD, Washington, USA 2017 28 hours
Half-yearly Meeting of the Dutch Association of Gastroenterology, Veldhoven 2018 12 hours
53rd International Liver Conference of the EASL, Paris, France 2018 28 hours
242 CHAPTER 12
1. PhD training Year Workload
The XXV International Bile Acid Meeting: Bile Acids in Health and Disease, Dublin, 
Ireland
2018 18 hours
Half-yearly Meeting of the Dutch Association of Hepatology, Veldhoven 2018 12 hours
The Liver Meeting, 69th Annual Meeting of the AASLD, San Francisco, USA 2018 28 hours
Awards
Young investigator bursary, International Liver Conference, EASL, Vienna, Austria 2015
Second best poster prize, Falk Symposium 197, Autoimmune Liver Diseases, Lisbon, 
Portugal
2015
International Travel Award, Liver Meeting, AASLD, San Francisco, USA 2015
Poster of Distinction, Liver Meeting, AASLD, Boston, USA 2016
International Travel Award, Liver Meeting, AASLD, Boston, USA 2016
Young investigator bursary, Monothematic Conference, EASL, Oslo, Norway 2017
International Travel Award, Liver Meeting, AASLD, Washington, USA 2017
Young investigator bursary, International Liver Conference, EASL, Paris, France 2018
Young Hepatologist Award for best Dutch hepatology paper, Dutch Association of 
Hepatology, Veldhoven, The Netherlands
2018
Attended seminars and workshops
29th Erasmus Liver Day, Rotterdam 2014 6 hours
12th Post-AASLD symposium, Rotterdam 2014 2 hours
6e Lagerhuidsdebat , Utrecht 2014 3 hours
2nd ‘PBC: past, present and future’ meeting, Amsterdam 2015 6 hours
30th Erasmus Liver Day, Rotterdam 2015 6 hours
13th Post-AASLD symposium, Rotterdam 2015 2 hours
7e Lagerhuidsdebat , Utrecht 2015 3 hours
31th Erasmus Liver Day, Rotterdam 2016 6 hours
Symposium 31th NVH Anniversary, Rotterdam 2017 6 hours
PBC: how to move forward from here – symposium, Amsterdam 2017 8 hours
32th Erasmus Liver Day, Rotterdam 2017 6 hours
2. Teaching Year
Lecturing
Wetenschappelijk onderzoek bij PBC, landelijke bijeenkomst voor patiënten met 
PBC, Nederlandse Leverpatiënten Vereniging, Utrecht
2016
Fibrates in PBC, Early Morning Workshop, International Liver Conference, European 
Association of the Liver
2016
A case with itching, Erasmus Liver Day, Rotterdam 2016
Fibrates: who, what, where; Evening symposium cholestasis, Amsterdam 2017
POST SCRIPT
12
243
Supervision
Supervising graduation project Kiki Janssen, medical student,  trends in liver 
transplantation in primary biliary cholangitis in Europe
2017
3. Extracurricular
Board member Promeras, representing board of all PhD students, Erasmus MC, 
Rotterdam
‘15-‘16
PhD committee, Erasmus MC, Rotterdam ‘15-‘17
Promovendi Network Nederland (PNN) ‘15-‘17
Chair of Promeras, representing board of all PhD students, Erasmus MC, Rotterdam ‘16-‘17

Prognosis and Treatment of
Primary Biliary Cholangitis
a new name, a new era
MAREN HERMINE HARMS
M
aren H. Harm
s
Prognosis and Treat ent of
Pri ary Biliary Cholangitis
a new na e, a new era
MAREN HERMINE HARMS
M
aren H. Harm
s
i    
i  ili  l i i
  ,   
 I  
M
aren H. Harm
s
i
i ili l i i
  ,   
 I  
M
aren H. Harm
s
M
aren H. Harm
s
M
aren H. Harm
s  I  
M
aren H. Harm
s
m
m
m
 I  
M
aren H. Harm
s
M
aren H. Harm
s
   f
  
r
M
aren H. Harm
s
f
r
M
aren H. Harm
s
M
aren H. Harm
s
M
aren H. Harm
s
M
aren H. Harm
s
M
aren H. Harm
s
M
aren H. Harm
s
M
aren H. Harm
s
M
aren H. Harm
s
Uitnodiging
voor het bijwonen van de openbare
verdediging van het proefschrift
PROGNOSIS AND TREATMENT
OF PRIMARY BILIARY CHOLANGITIS
a new name - a new era
door
Maren Hermine Harms
Vrijdag 10 januari 2020
om 13.30 uur
in de Senaatszaal op
Campus Woudstein 
Erasmus Universiteit Rotterdam
Burgemeester Oudlaan 50
3032 PA Rotterdam
Na afloop van de 
plechtigheid bent u van harte 
uitgenodigd voor de receptie
Paranimfen
Sophia van der Wiel
06 45 80 27 86
Els Wieten
06 44 65 66 77
marenpromoveert@gmail.com
Maren H. Harms
Kerkhoflaan 266
3034 TJ Rotterdam
06 17 58 51 76
